





T-cell Checkpoint Pathways Modulate Cell Cycle and 
Steroid Resistance in T-cell Acute Lymphoblastic 
Leukaemia 
Yuzhe Shi 
Student No: 150182377 
 
Thesis submitted to the Faculty of Medical Sciences 
In partial fulfilment of the requirements for the degree of 
Doctor of Philosophy 
2019 
 
Supervisor: Dr. Frederik W van Delft,  
Dr. Anja Krippner-Heidenreich 
Prof. Olaf Heidenreich 
Wolfson Childhood Cancer Research Centre, Northern Institute for 







T-cell Acute Lymphoblastic Leukaemia (T-ALL) results from the malignant 
transformation of immature T cells with hallmarks of differentiation blockage and 
expansive proliferation. The checkpoints during T-cell development are provided by 
the pre-T-Cell Receptor (pTCR) for β-selection and T-Cell Receptor (TCR) for positive 
and negative selection. Recurrent gene lesions in proximity to pTCR/TCR are found in 
T-ALL, such as NOTCH1, FBXW7 and PTEN. Kinases of the pre-B-cell receptor 
signalling have been validated as drug targets in B-ALL. Whether any critical 
components of T-cell checkpoint pathways, such as Lymphocyte-specific non-receptor 
tyrosine Kinase (LCK), play a comparable role in T-ALL remains unclear. A targeted 
shRNA screen against central components of the pTCR/TCR signalling complex in T-
ALL cell lines in vitro and primary cells in vivo identified an essential role for LCK in cell 
proliferation and leukaemia propagation. Knockdown of LCK in the cell lines SUPT1, 
CUTLL1 and MOLT4 revealed a substantial growth defect over time. This was further 
validated in a competitive assay using MOLT4 in vivo, in which control cells 
outcompeted LCK knockdown cells in mouse bone marrow, spleen and liver. 
Phenotypically, knockdown or inhibition of LCK by dasatinib (DAS) impaired cell 
proliferation by inducing G0/G1 arrest in T-ALL cell lines and patient-derived xenografts 
(PDXs) with only trivial induction of apoptosis. The sensitivity of T-ALL cell lines to DAS 
significantly correlated with LCK activation (pY394LCK/LCK). Several cell lines and 
PDXs were glucocorticoid-resistant in vitro. Interestingly, T-ALL cells were re-
sensitised to dexamethasone (DEX) after LCK knockdown. Correspondingly, DAS 
reinforced DEX-induced apoptosis. Drug matrix analyses of ten T-ALL cell lines and 
six PDXs revealed a significant enrichment of DEX/DAS synergy at clinically relevant 
concentrations. A murine phase ‖-like clinical trial of ten T-ALL PDXs confirmed that 
DEX/DAS significantly impaired leukaemia engraftment. Engraftment of human 
leukaemia cells in spleen, bone marrow, and liver was substantially decreased in the 
DEX/DAS group compared with control or single-drug therapy. In addition, DEX/DAS 
significantly reduced CNS infiltration of leukaemia cells. The presented research 
outcomes highlight the crucial role of LCK in T-ALL proliferation and propagation. LCK 
inhibitor DAS, in conjunction with DEX, reverses steroid resistance and significantly 
reduces leukaemia propagation in vivo. The DEX/DAS combination might provide a 
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PI3KAP1 Phosphoinositide-3-kinase adaptor protein 1 
PIP3 phosphatidylinositol-3,4,5-trisphosphate 
PLCγ2 phospholipase C gamma 2 
PRC2 polycomb-repressive complex 2 
pTCR pre T-Cell Receptor 
PTEN phosphatase and tensin homolog 
PTPN11 protein tyrosine phosphatase non-receptor type 11 
PTPN2 protein tyrosine phosphatase non-receptor type 2 
PTPN6 protein tyrosine phosphatase non-receptor type 6 
PTPRC protein tyrosine phosphatase receptor type C 
RAG1/2 recombination activating 1/2 
RUNX1 runt related transcription factor 1 
SAHM1   
SERCA Sarco/endoplasmic reticulum calcium ATPase 
SFKs Src family kinases 
SH2 Src Homology 3 
SH3 Src Homology 2 
SLC Surrogate Light Chain 
SLP76 lymphocyte cytosolic protein 2 
SP single positive 
SRC SRC proto-oncogene, non-receptor tyrosine kinase 




STIL STIL centriolar assembly protein 
SUZ12 SUZ12 polycomb repressive complex 2 subunit 
SYK spleen associated tyrosine kinase 
TAL transaldolase 1 
TAL1 TAL bHLH transcription factor 1, erythroid differentiation factor 
T-ALL T-cell acute lymphoblastic leukaemia 
TCF12 transcription factor 12 
TCF3 transcription factor 3 
TCF3 transcription factor 3 
TCR T cell receptor 
TCRA T cell receptor alpha locus 
TCRB T cell receptor beta locus 
TKI tyrosine kinase inhibitor 
TLX1 T cell leukaemia homeobox 1 
TLX3 T cell leukaemia homeobox 3 
TNFα tumour necrosis factor 
TYK2 tyrosine kinase 2 
UBTF1 upstream binding transcription factor 
VCP valosin-containing protein 
YES YES proto-oncogene 1, Src family tyrosine kinase 
ZAP70 zeta chain of T cell receptor associated protein kinase 70 































1 T-cell Development 
1.1.1 Origins of Thymus-setting Progenitors 
The classic haematopoiesis model proposes that all blood cells arise from 
haematopoietic stem cells (HSC) (Lin-SCA1+KIThiFLT3-) which situate in the bone 
marrow with self-renewal and multipotent ability. A step further in differentiation from 
HSC generates multipotential progenitors (MPP) (Lin-SCA1+KIThiFLT3+) which remain 
multipotent but lack self-renewal capacity. MMP in turn generate common lymphoid 
progenitors (CLPs) (Lin-SCA1lowKITlowIL-7RαhiFLT3hi) and common myeloid 
progenitors (CMPs) (Lin-IL-7Rα-SCA1-KIThiFcγRlowCD34+). In this classic hierarchical 
model, all lymphocytes are derived from CLPs, including T-cell progenitors in the 
thymus (Rothenberg and Taghon, 2005). 
The thymus has been known to be crucially important for T-cell development since 
1967 (Miller and Osoba, 1967). This review concluded leukocytes were produced from 
thymus and migrated to lymph nodes and peripheral blood. However, adult thymus 
cannot support progenitors to self-renew in the long-term. Mice post-irradiation ( 
thymus was shielded from irradiation) receiving a bone marrow transplantation 
showed that equilibration between thymic progenitors and bone marrow chimerism 
only lasted for six to eight weeks (Scollay et al., 1986). Constant supply of T-cell 
progenitors from the bone marrow to the thymus is indispensable for T-cell 
development (Frey et al., 1992). 
However, the precise origin and characterisation of thymus-setting progenitors (TSP) 
remains incomplete. Several studies have provided new evidence that TSPs originate 
from not only CLPs, but also HSCs and MPPs (Bhandoola and Sambandam, 2006) 
(Figure 1). 
CLPs were originally considered as precursors to B-, T- and NK (natural killer) cell 
lineages (Kondo et al., 1997). The understanding of CLPs has increased after 
identification of the crucial role of Notch1 in T-cell development. Notch1 is a cell 
surface transmembrane receptor that controls cell communication and cell fate (Lai, 
2004). Overexpression of constitutively activated Notch1 in mice disrupted B-cell 
development and led to CLPs developing to DP (double positive) thymocytes in the 
bone marrow (Pui et al., 1999). On the contrary, inactivation of Notch1 resulted in a T-




thymus (Radtke et al., 1999). The presence or absence of Notch1 controls CLP 
differentiation towards T-lineage or B-lineage. A subset of pro/pre-B cells has been 
shown to have the differentiation potential towards T cells by efficiently migrating to 
the thymus when placed in the bloodstream. They express B220+CD19-IL-7Rα+KIT-
/low, and are labelled CLP-2 (Martin et al., 2003). With the development of single-cell 
assays, the concept has been challenged that each CLP has equal potential to 
differentiate to the B, T, NK or DC (dendritic cell) lineage. Studies in the murine foetal 
liver have shown lack of evidence of CLPs restrained in lymphoid lineage only 
(Katsura, 2002) and the loss of B-cell lineage potential of CLPs before seeding to the 
thymus (Kawamoto et al., 2000). Therefore, the commitment of progenitors to T cell 
lineage may occur independently of B cell lineage, thus other populations in the bone 
marrow may have the capacity to seed in the thymus and commit to the T cell lineage 
(Figure 1). 
Direct intrathymic injection in mice was used for comparing the efficiency of T-cell 
production by different bone marrow progenitors. DP thymocyte production was 
maintained more than 4 weeks after intrathymic injection of HSCs and MPPs whilst 
thymopoiesis by CLPs only lasted for less than 4 weeks, suggesting HSCs and MPPs 
were more efficient than CLPs (Allman et al., 2003). Another CLP-independent source 
of TSPs are a rare population of circulating progenitors with LSK phenotype (Lin-
SCA1+KIThi) in blood (HSCs and MPPs). On the contrary, CLPs could not be found in 
the blood, suggesting that CLPs might not be the physiological T cell progenitors 









Figure 1. Origins of thymic-setting progenitors. In the bone marrow, 
haematopoietic stem cells (HSC) differentiate into mutipotential progenitors (MPP), 
common lymphoid progenitors (CLP and CLP-2). B-cell development occurs in the 
bone marrow. The cell surface markers of each subset are shown in the diagram; Lin 
(Lineage), SCA1 (stem-cell antigen 1), KIT (CD117, mast/stem cell growth factor 
receptor), FLT3 (fms-related tyrosine kinase 3), IL-7Rα (interleukin 7 receptor α), FcγR 
(fragment C gamma receptor) and CD34 (cluster differentiation 34). In the classic 
haematopoiesis model, CLP and CLP-2 seed in the thymus and become thymus-
settling progenitors (TSP). However, CLP-independent routes to T cells also exist. The 
HSC and MPP cells can circulate in the blood and seed in the thymus. A subset of 
MPPs express RAG1/2 termed as early lymphoid progenitors (ELP). Some MPPs also 
express CC-chemokine receptor 9 (CCR9) and can be the origin of TSP. In the 
thymus, TSP cells undergo differentiation into early T-cell progenitors (ETP) and 
double negative (DN) thymocytes. ETPs are very similar to DN1 (CD25-CD44+) and 
differentiate into DN2 stage (CD25+CD44+). The complete T-cell development 
continues in the thymus and will be discussed in the next section. Dotted/dashed 
arrows represent less well characterised trafficking pathways; solid arrows depict 
clearly defined origins of TSP. The diagram was modified from (Bhandoola and 





Bone marrow LSK progenitors were also investigated to establish if they could seed 
in the thymus. As previously described, HSCs were efficient in thymopoiesis when 
direct injected to the thymus (Allman et al., 2003). However, intravenous transfer of 
HSC subsets into irradiated mice and subsequent re-transplantation of thymic cells in 
secondary recipients demonstrated that only T, NKT, NK and B-lineages, but not 
myeloid-lineage, can be generated in the secondary transplanted mice, suggesting 
that HSCs either failed to self-renewal once settled in the thymus or HSCs could not 
seed in the thymus efficiently (Mori et al., 2001). Characterisation of MMPs in bone 
marrow showed low levels of IL-7Rα (interleukin 7 receptor ) mRNA expression 
(Adolfsson et al., 2005), and a subset of MMPs expressing RAG1/2 (recombination 
activating 1/2) were found as early lymphoid progenitors (ELP) (Igarashi et al., 2002). 
Reported candidate genes expressed by MMPs that might direct progenitors settling 
in the thymus and expansion after thymic seeding are CCR9 (CC-chemokine receptor 
9) (Benz and Bleul, 2005), CCR7 (Krueger et al., 2010), IL-7Rα and FLT3 (fms-related 
tyrosine kinase 3) (Sambandam et al., 2005). 
TSPs settle down in the thymus and develop to early T-cell progenitors (ETP), which 
contain lineage potentials of B-cell, T-cell, NK-cell, myeloid-cell and DC (King et al., 
2002). ETPs are defined minimally as LinlowCD25-KIThi and found to compose 0.01% 
of murine thymus (Bhandoola et al., 2007). The surface protein CD4 was found on 
more than 50% of ETPs. Other lineage markers including CD8 were also found in 
ETPs at low surface expression levels (Michie et al., 1998). 
 
1.1.2 T-cell Development in the Thymus  
In the thymus, ETPs differentiate into CD4 and CD8 double negative (DN) cells, double 
positive (DP) and single-positive (SP) cells. The murine DN cells are divided into four 
stages by differentially expressing CD25 and CD44 (DN1 (CD25- , CD44+), DN2 
(CD25+, CD44+), DN3 (CD25+, CD44-), DN4 (CD25-, CD44-)). Although ETPs express 
CD4 and other lineage surface proteins at certain levels, they are CD25 negative and 
CD44 highly expressing cells, and are considered a fraction of DN1 cells (c-Kithi DN1 






Transcription factors        
The T-cell specification process relies on expression of transcription factors such as 
GATA3 (GATA binding protein 3), TCF-1 (T-cell factor 1, also known as T-cell specific 
transcription factor 7, TCF7) and BCL11B (BAF chromatin remodelling complex 
subunit).  
TCF-1 and GATA3 are rate-limiting factors that regulate early-T cell development (Ting 
et al., 1996; Verbeek et al., 1995). TCF-1 is induced by Notch1 signalling and it 
increases T-cell specification transcription factors such as GATA3, BCL11B and TCR 
(T-cell receptor) components, such as LCK (lymphocyte-specific non-receptor tyrosine 
kinase), LAT (linker for activation of T cells), CD3, and CD3 (Weber et al., 2011). 
GATA3 recruits and regulates different genomic sites depending on T-cell 
development stages (Wei et al., 2011). For example, GATA3 is upregulated in DN1 
stage and occupies binding sites of genes associated with stem cells and progenitors. 
GATA3 dissociates from these sites during T-cell commitment (Zhang et al., 2012). 
GATA3 knockout embryonic stem (ES) cells were used to investigate its function in T-
cell development. Without GATA3,  early thymocyte development was completely 
blocked in contrast to normal development of mature erythroid, myelomonocytic cells 
and B cells (Ting et al., 1996). It seems that GATA3 regulates T-cell development with 
a dose-dependent effect. In the earliest ETP stage, lack of GATA3 showed deficiency 
in development (Hosoya et al., 2009). However, overexpression of GATA3 in bone 
marrow or thymocyte progenitors did not enhance T-cell development but activated 
non-T programs (Taghon et al., 2007). 
Early development arrest at the DN2-DN3 stages was shown after BCL11B 
inactivation (Li et al., 2010a). BCL11B is involved in -selection of  T cells 
(Wakabayashi et al., 2003) but not  T cells. Deletion of BCL11B disabled T-cell 
lineage but switched differentiation to NK-like cells (Li et al., 2010b). During DN2 to 
DN3 transition, multiple genes associated with stem cells or progenitors are 
downregulated whilst genes involved in T-cell commitment are upregulated as 






Signalling pathway        
Notch1 and IL-7 receptor signalling control T cell lineage commitment and 
development in early T-cells (Radtke et al., 1999).  
Notch1 is a cell surface transmembrane receptor that controls cell communication and 
cell fate through mediating cell proliferation, survival, metabolism and differentiation in 
all animal species (Lai, 2004). For T-cell development, the generation of ETPs and 
subsequent differentiation of DN cells requires Notch signalling. An in vitro stromal-
free model showed T-cell commitment can be initiated by Notch1 and cytokines alone 
(Ikawa et al., 2010). Lack of NOTCH1 leads to T-cell development arrest at the DP 
stage (Radtke et al., 1999).  
Four Notch receptors (Notch1/2/3/4) have been described as well as several ligands, 
namely Jagged1/2 (Jag1/2) and Delta 1/3/4 (Dll1/3/4). Studies have shown that Notch 
ligands are provided by the thymus microenvironment, such as Dll1, which is 
expressed in thymic blood vessels, Dll4 is secreted from thymic epithelial cells (TECs) 
in the subcapsular and outer cortical regions and Jag1/2 are limited to thymic medulla 
and inner cortex (Gonzalez-Garcia et al., 2012). The intracellular Notch domain (ICN) 
is cleaved by ADAM (a disintegrin and metalloprotease) and -secretase after ligand 
activation. It translocates to the nucleus and transforms the transcriptional repressor 
CSL (RBPJ, recombining binding protein suppressor of hairless) to become an 
activator by recruiting p300/CBP (E1A binding protein p300/CREBBP, CREB-binding 
protein) and MAML1 (mastermind-like 1) (Kopan and Ilagan, 2009). The bHLH protein 
Hey and Hes, CD25, pTα, c-Myc (myc avian myelocytomatosis viral oncogene 
homolog), cyclin D1, p21Waf and IL7-R are direct targets of Notch (Reizis and Leder, 
2002). 
Notch1 signalling controls T-cell development prominently via enhancing T-cell 
specification and expansion (De Smedt et al., 2002; Garcia-Peydro et al., 2006). In the 
hybrid human-mouse foetal thymus organ culture (FTOC) model, inhibition of Notch1 
signalling by an inhibitor at various concentrations demonstrated that in human 
thymopoiesis, enhancing Notch1 signalling gradually suppresses B, myeloid/DC and 
NK cell lineages (De Smedt et al., 2005). The cellular expansion of T-cell progenitors 
governed by Notch1 signalling is via IL-7R expression (Gonzalez-Garcia et al., 2009). 




oncogene) at the Il7ra promoter in CLP thereby driving the expression of IL-7R 
(Anderson et al., 2002). 
IL-7 and its receptor IL-7R are essential for T-cell development and homoeostasis. IL-
7R is composed of the common cytokine receptor  (c) and the IL-7 specific  chain. 
IL-7 stimulation results in heterodimerisation of IL-7R and c and subsequent IL-7R 
signalling pathway. Through JAK/STAT, PI3K (phosphatidylinositol 3-kinase), and 
MAPK downstream pathways, IL7-R signalling activates Bcl-2, Mcl-1, Ccnd1 (cyclin 
D1) and c-Myc to induce cell proliferation and promote T-cell differentiation (Li et al., 
2006).  
IL-7R expression is dynamically regulated through the process of T-cell development. 
It is up-regulated in ETP stage and grossly increased until DN2 stage. IL-7R is critical 
for DN2 progenitors to survive and undergo expansion in the intrathymic pool (Akashi 
et al., 1998). The TCR lineage T cells are controlled by IL-7R signalling to let the 
TCR locus undergo rearrangement at the DN2 stage (Durum et al., 1998). In 
concordance with this, higher IL-7R expression in DN2 cells results in biased 
differentiation to the TCR T cells (Kang et al., 2001). The expression of IL-7R needs 
to be terminated at the DN3 stage to allow the -selection process which is controlled 
by the pre-T cell Receptor (pTCR). Reduction of IL-7R signalling is also required for 
the upregulation of transcription factor BCL11B which drives the complete  T-cell 
development (Li et al., 2010a). Later, after the SP stage, IL7-R is restored on the cell 
surface to support homeostatic proliferation of matured CD4+ or CD8+ cells in the 






1.1.3 T-cell Checkpoint Pathways in T-cell Development 
In an in vitro human thymopoiesis model, Notch1 and IL-7R signalling termination is 
required for the completion of  T-cell development (Li et al., 2010a). At the DN3 
stage, Notch1 signalling induces pTα expression via the transcriptional activator of 
ICN/CSL/MAML1 binding to the PTCRA enhancer (Reizis and Leder, 2002). pTα 
dimerises with a successfully rearranged TCRβ chain. Together with other CD3 
molecules they form a pTCR (pre-T cell receptor) complex on the cell surface. This 
complex is critical for the β-selection checkpoint at DN3 stage which only allows cells 
with the successful expression of pTCR to proliferate and survive, whereas 
thymocytes without pTCR expression will undergo cell death. After β-selection, cells 
will further differentiate to the DN4 stage (Figure 2).  
The pTCR signalling promotes cell cycle progression, proliferation, survival and allelic 
exclusion of β chain rearrangement. Specifically, the pTCR complex consists of 
disulfide-linked pTα and TCRβ, associated with two heterodimers, CD3ε/CD3γ and 
CD3ε/CD3δ. This complex further associates with CD3ζ (von Boehmer and Fehling, 
1997). All these components, except the pTCRα chain, are shared with the TCR. At 
the DP stage, TCRα is fully rearranged and expressed. This encourages the formation 
of the mature TCR, to replace pTCR on the cell surface, upon which selected cells 
gain proliferative and survival advantages (Aifantis et al., 2008). The TCR complex 
plays a central role in adaptive immunity through signalling processes that dictate T 
cell fate during late development and upon exposure to antigen.  
The only structural difference between TCR and pTCR is the α-chain component, 
TCRα or pTCRα respectively. These two components are encoded by two distinct 
genes. The human PTCRA is located on chromosome 6, has four mRNA isoforms, of 
which three isoforms are predicted to result in pTα protein expression. On the contrary, 
the human TCRα locus is located on chromosome 14q11.2 (including the variable, 





Figure 2. Developmental stages of T-cells in the thymus. The developmental 
stages from HSC, double negative (DN), double positive (DP) to single positive (SP) 
cells are shown. The cell surface markers including pTCR and TCR of each 
development stage of mouse and human are shown on the top and bottom 
respectively. At the DN3 stage, the pTCR (pre-T-cell receptor) is formed with a 
correctly rearranged TCRβ chain, pTα chain, and CD3 molecules. This receptor is 
essential for β-selection in T cell development, which provides the pro-survival and 
differentiation signals to develop into DN3 and DN4 cells. In the DP development 
stage, the rearranged TCRα chain replaces the pTα chain and forms a mature TCR 
(T-cell receptor). Thymocytes are positively selected when the TCR has modest 
affinity for MHC molecules, and negatively selected when the TCR is strongly activated 
by self-MHCs in the thymus. T-cell development is entirely or partially blocked when 
T-cell specification genes are depleted, such as RAG1/2, TCRβ and δ, CD3γ and 
CD3ε, LCK and FYN, ZAP70 and SYK, SLP76 as well as LAT. The diagram was 
modified from (von Boehmer, 2005) and (Gonzalez-Garcia et al., 2012). 
Overexpression of wild-type Lck or a constitutively activated mutant LckY505F induces 





The PTCRA gene encodes for a single-pass transmembrane protein, which is only 
expressed in immature T cells. Previous studies demonstrated that the activation of 
pTCR is ligand independent in contrast to that of TCR (Yamasaki and Saito, 2007). 
The TCR is uniformly distributed on the cell membrane and re-locates to lipid rafts 
upon ligand binding (Schamel and Reth, 2007). However, the pTCR translocates 
autonomously into lipid rafts caused by the palmitoylation of juxtamembraneous 
cysteine residues (Saint-Ruf et al., 2000), where it forms oligomers and induces CD3 
and LCK phosphorylation without any ligand stimulation. pTCR and TCR signalling 
share the same downstream pathways and activate similar transcription factors. Upon 
TCR stimulation, LCK phosphorylates CD3ζ subunits at ITAMs (immunoreceptor 
tyrosine-based activation motifs), where ZAP70 is recruited to the receptor complex 
and phosphorylated by LCK. After ZAP70 activation, it phosphorylates LAT resulting 
in the recruitment of SLP76 (SH2 domain-containing leukocyte protein of 76kDa), 
GADS (GRB2-related adaptor downstream of Shc), GRB2 (growth factor receptor-
bound protein 2), ADAP (adhesion and degranulation promoting adaptor protein) and 
NCK1 (SH2/SH3 adaptor protein). These proteins form a microcluster which recruits 
and activates PLCγ1 (phospholipase Cγ1), ITK (IL-2-inducible T cell kinase) and VAV1 
(vav guanine nucleotide exchange factor 1). PLCγ1 enhances the intracellular calcium 
flux by catalysing PtdIns(4,5)P2 to DAG (diacylglycerol) and InsP3 (inositol (1,4,5)-
trisphosphate) which further activates RAS-RAF-ERK and Calcineurin-NFAT 





Figure 3. A schematic diagram of pTCR/TCR signalling. For the aim of this 
illustration, the pTCR/TCR pathways are drawn in the same cell. However, immature 
thymocytes only express pTCR, which is constitutively activated. Mature T cells 
express TCR on the cell surface. Upon binding with MHC molecules, CD4-associated 
LCK is recruited to the TCR complex, which subsequently activates CD3ζ, ZAP70 and 
downstream signalling. Both pTCR and TCR can activate the PI3K pathway, ERK 
pathway, PLCγ1-NFAT pathway and NF-κB signalling, resulting in gene expression 
which regulates T-cell survival, proliferation, and differentiation. This diagram is 







1.1.4.1 LCK Structure and Regulation 
The crystal structure of LCK was discovered in 1994 (Eck et al., 1994; Sicheri and 
Kuriyan, 1997). LCK is located at chromosome 1 and encodes for a protein of 56 kDa. 
Like other Src family kinases (SFKs) (for example LYN, BLK, FGR, HCK, SRC, FYN, 
and YES), the N-terminal of LCK is myristoylated and palmitoylated allowing its 
localisation in the lipid rafts of the plasma membrane. The SH3 and SH2 domains 
regulate its interaction with other proteins. The kinase domain has an 
autophosphorylation function and the capacity to phosphorylate downstream targets, 
such as CD3ζ and ZAP70. It also contains a regulatory C-terminal tail. Two 
phosphorylation sites were identified to be essential in LCK kinase activity. The 
phosphor-tyrosine 394 moiety represents an active site in the kinase domain. The 
phosphor-tyrosine 505 functions as an inhibitory site for LCK regulation located in the 
C-terminal tail. A structurally closed conformation, that prevents LCK activation, can 
be created by intramolecular (SH2) and intermolecular (SH3) interactions (Figure 4). 
 
 
Figure 4. Schematic protein structure of LCK. The N-terminal of LCK can be 
myristoylated and palmitoylated. The SH3 and SH2 domains are for intramolecular 
and intermolecular interactions. An autophosphorylation site Y394 locates in the 
kinase domain. The C-terminal tail contains the Y505 regulatory site, whose 
phosphorylation is governed by Csk and CD45. The diagram was modified from (Ku 
et al., 2015). 
 
In the absence of TCR stimulation, the Y505 residue of LCK is phosphorylated 
therefore inhibiting LCK activity. In contrast, in the case of pTCR or activated TCR 
signalling and association with CD4 or CD8, LCK is auto-phosphorylated at Y394 
allowing the transmission of downstream signalling (Figure 5). CD45 (PTPRC, protein 




p-LCKY505 (Hermiston et al., 2003), while CSK (C-terminal Src kinase) reduces LCK 
activity as it phosphorylates LCKY505.  
 
Figure 5. Phosphorylation and structure conformation determine LCK activity. 
The closed-inactive form of LCK accounts for 14% of total LCK in the cells, which is 
due to CSK phosphorylating Y505 and intramolecular interactions resulting in a closed 
formation. The primed LCK (48%) has an open confirmation to allow the kinase 
domain being released from intramolecular inhibition. However, it remains 
phosphorylated at Y505. The DPho-active status of LCK, of which both tyrosine sites 
(Y505 and Y394) are phosphorylated, accounts for 21%. The phosphatase CD45 
dephosphorylates Y505 and enforces the full activation of LCK (pY394-activated LCK 
17%). The diagram was modified from (Ku et al., 2015). 
 
New evidence proposes that LCK is constitutively activated in T cells, and this activity 
is controlled both by phosphorylation at Y394 for activation and Y505 for inhibition, as 
well as structure conformation (Figure 5). CSK phosphorylating Y505LCK and the 
intramolecular interactions result in a closed formation of LCK, which accounts for 14% 
of total LCK in the cells. The primed LCK (48%) has an open conformation to allow the 
kinase domain to be released from intramolecular inhibition. However, it remains 
phosphorylated at Y505. LCK autophosphorylates Y394 to activate itself. Therefore, 
after priming, both tyrosine sites are phosphorylated. This is so-called DPho-active 
status (21%). The phosphatase CD45 dephosphorylates Y505 and enforces the full 




CD45 is a plasma-membrane spanning phosphatase estimated to occupy 10% of T-
cell surface (Thomas, 1989). Unlike CD45 in B lymphocytes, there are multiple splicing 
isoforms in T cells. Transgenic expression of a constitutively activated form of LCK 
(LCKY505F) into CD45-/- thymocytes can restore cell differentiation (Seavitt et al., 1999). 
There is also evidence showing that CD45 affects the activating tyrosine 394. In CD45-
/- mice, LCK activity was enhanced and these cells had hyper-responsiveness to TCR 
stimulation. However, no spontaneous autoimmunity or lymphoproliferation was 
observed. This is partially due to activated SFKs recruiting other negative regulatory 
phosphatases to attenuate signalling strength, such as PTPN6 (SHP-1, protein 
tyrosine phosphatase non-receptor type 6), PTPN11 (SHP-2, protein tyrosine 
phosphatase non-receptor type 11), and INPP5D (SHIP-1, Inositol polyphosphate-5-
phosphatase D). As a primary surface phosphatase expressed in nucleated 
hematopoietic cells, CD45 also dephosphorylates other SFKs, JAK1 (Janus kinase 1), 
JAK2, and TYK2 (tyrosine kinase 2) where they play critical roles in BCR (B-cell 
receptor), IL-3, and IFN-α signalling pathways (Huntington and Tarlinton, 2004).  
In T cells, CSK phosphorylates the regulatory tyrosine 505 of LCK. It is constitutively 
associated with p-PAG1 (CBP, phosphoprotein membrane anchor with 
glycosphingolipid microdomains 1), a lipid raft-associated protein, which can be 
disrupted after TCR stimulation. In this case CSK is released from the plasma 





1.1.4.2 LCK Function in Normal T Cells 
It seems that all stages of T-lymphocyte development and function involve LCK.  
The T-cell specific SFK family members are LCK and FYN (FYN proto-oncogene), 
which are not fully redundant despite their structurally and functionally similarities. In 
fact, several unique features of LCK and FYN are observed in T cells, including 
differential expression in different development stages, signalling pathways, 
localisation and specific interaction with proteins. 1) A key feature of SFKs is the 
myristoylation of glycine and palmitoylation of cysteine at N-terminals, which allows 
SFKs to attach to plasma membranes (e.g. Lck) or centrosomal and mitotic structures 
(e.g. Fyn) (Ley et al., 1994). Increasing expression of lipid raft-associated Lck, rather 
than non-raft associated Lck, ameliorates Fyn activation (Filipp et al., 2004).  2) pTCR 
signalling is shown to be only affected in Lck-deficient mice, rather than Fyn-deficient 
mice, resulting in a T-cell differentiation block at the DN3 stage and grossly reduced 
thymic subpopulations (Appleby et al., 1992; Molina et al., 1992; Stein et al., 1992). 
Notably, in Lck-/- mice, it seems that Fyn could substitute Lck to generate DP cells 
before the age of 2 weeks. However, thymocytes failed to undergo expansion and 
failed to correctly create TCRβ rearrangements and CD5 expression in the time of 
more than 2 weeks (Molina et al., 1998). On the contrary, the thymocyte development 
in Fyn-/- mice is relatively healthy, indicating the essentiality of Lck in pTCR signalling. 
The N-terminal domains, rather than the kinase domains, highlight the essential role 
of Lck. This is supported by experiments where artificially expressed Fyn with Lck N-
terminal sequences could restore thymocyte development. This is not the case when 
the N-terminal residue of Lck is replaced with Fyn N-terminal sequences (Lin et al., 
2000). Moreover, a dominant negative (DN) Lck could diminish pTCR signalling, but 
Fyn DN mutants failed to do so (Cooke et al., 1991; Levin et al., 1993). 3) By using an 
Lck-doxycycline-inducible (Lckind) background and Lck-/- and/or Fyn-/- mouse models, 
Seddon and Zamoyska found that both Lck and Fyn are required for the survival of 
peripheral T cells. However, after withdrawing doxycycline which would stop Lckind 
(inducible LCK) expression, the naïve T cells of Lckind x Lck-/- mice (only Fyn expresses) 
failed to proliferate, while naïve T cells from Lckind to Fyn-/- mice (only Lck expresses) 
can undergo homeostatic proliferation as usual. This demonstrates the essentiality of 
Lck in thymocyte survival and proliferation while Fyn failed to restore naïve T cells 




Seddon and Zamoyska, 2002b). Lck has a unique role in regulating T cell 
differentiation and function. 
In mature T-cells, LCK associates with CD4 or CD8 via cysteine-mediated interactions 
(Turner et al., 1990). In terms of DP cells differentiating into SP cells, Lck activity 
regulates positive selection and CD4 or CD8 commitment. Artificial modification of the 
extracellular domain of CD4 into CD8 did not alter CD4 lineage development, even 
though these cells recognise MHC I class (Seong et al., 1992). Transgenic 
manipulation of Lck activity determines CD4 commitment (high Lck activity) or CD8 
commitment (low Lck activity) (Hernandez-Hoyos et al., 2000; Legname et al., 2000). 
In conditional Csk-/- mice, hyperactivated Lck caused all T cells to develop into CD4 
cells regardless of pTCR, TCR or MHC class status (Schmedt et al., 1998). Taken 
together, these studies indicate that Lck controls CD4 versus CD8 lineage 
development. It may be that Lck propagates sustained signalling which is necessary 
to allow thymocytes to commit to the CD4 lineage. However, both Lck and Fyn can 
produce a short duration of signal that is sufficient for CD8 differentiation (Zamoyska 
et al., 2003). 
 
1.1.5 ZAP70 
Another essential tyrosine kinase in pTCR and TCR signalling is ZAP70 (zeta chain of 
T cell receptor associated protein kinase 70). Upon oligomerisation of pTCR and 
activation of TCR, ITAMs of CD3 bind to the SH2 domains of ZAP70, releasing its 
auto-inhibitory status. ZAP70 belongs to the SYK (spleen tyrosine kinase) family and 
has two SH2 domains, two linker regions called interdomain A and B and a kinase 
domain. The phosphorylation sites Y315 and Y319 are considered to be auto-inhibitory 
phosphorylation sites. Y to A mutagenesis of both sites result in higher basal kinase 
activity (Brdicka et al., 2005). Upon activation of TCR, the phosphorylation of Y493 in 
the catalytic domain results in full activation of ZAP70. Both LCK and ZAP70 itself can 
phosphorylate Y493. ZAP70 mutant Y493F can impair the downstream signalling of 
TCR; however, it does not influence the binding of LCK (Mege et al., 1996). In the 
early 90s, patients with ZAP70 deficiency were found to lack CD8+ cells while their 
CD4+ cells fail to respond to antigens. Cell line studies underlined these results. Loss 




cells and a defect in TCR signalling transduction (Williams et al., 1998). It is reported 
that SYK plays redundant roles in pTCR signalling. Double knockout of ZAP70 and 
SYK leads to a complete block in β-selection at the DN3 stage. ZAP70 is critically 
involved in 33% of B-cell derived Chronic Lymphocytic Leukaemia (CLL). ZAP70 
promotes BCR signalling independent of its kinase activity but functions as an adaptor 
protein. Overexpression of ZAP70 SH2 domain enhances the calcium flux in response 
to stimulation of BCR (Chen et al., 2008). 
 
1.1.6 Tonic TCR Signalling 
The resting, naïve, T cells keep circulating in secondary lymphoid tissues, in which the 
tonic TCR signalling governed by SFKs provides survival or maintenance signals. It 
has been shown that Lck constitutively phosphorylates ITAMs of approximately 35% 
of TCR zeta (ζ) motifs in murine thymocytes and lymph node derived T cells (van Oers 
et al., 1993). Also, ZAP-70 has been shown to specifically associate with 
phosphorylated TCRζ (Pitcher et al., 2003; van Oers et al., 1993). One explanation for 
the phosphorylation of TCRζ in resting cells is to prime T cells to facilitate an immediate 
response towards antigens, which is most likely due to the constitutively 
autophosphorylated Lck or Fyn (Stefanova et al., 2002). The long-term survival of 
naïve T-cells is dependent on SFKs, TCR and the co-receptor CD4 as demonstrated 
previously by overexpression of an inducible Lck in Lck-/- and/or Fyn-/- mice (Zamoyska 
et al., 2003). Together, Lck-TCRζ-ZAP70 facilitates T-cell survival through low-level 
signals. 
 
1.1.7 Glucocorticoid Receptor in T-cell Development 
The Glucocorticoid Receptor (GR) belongs to the steroid receptor superfamily which 
includes receptors for thyroid hormone, vitamin D3, retinoic acid, and several orphan 
receptors. The GR resides in the cytosol before the occupation of its ligands – 
glucocorticoids (GC). Dexamethasone (DEX) is a particularly potent synthetic 
glucocorticoid in vitro and in vivo. Upon activation, GR disassociates from its 
cytoplasmic complex and translocates to the nucleus. In the nucleus, GR homodimers 
bind to Glucocorticoid Responsive Elements (GRE) of corresponding genes acting as 




AP-1 (JUN, Jun proto-oncogene) (Yang-Yen et al., 1990), NF-κB (nuclear factor kappa 
B) (Scheinman et al., 1995), CREB (cAMP responsive element binding protein) (Imai 
et al., 1993), STAT3 and STAT5 (Stocklin et al., 1996). As GR interacts with several 
histone acetyltransferases (HATs) such as NCOA1 (nuclear receptor coactivator 1), 
ACTR (NCOA3, nuclear receptor coactivator 3), p300/CBP and P/CAF (KAT2B, lysine 
acetyltransferase), it could enhance gene transcription by chromatin remodelling 
(Shibata et al., 1997). Also, post-translational modification plays a role in GR 
regulation such as phosphorylation by cyclin/CDK (cycline dependent kinase 4) 
complexes and ERK2 (Krstic et al., 1997).  
A significant role of GC has been found in T cell development in the thymus. T-cells 
are generally sensitive to GC associated-apoptosis as well as TCR activation-induced 
programmed cell death. When both stimuli occur simultaneously, T-cells are protected 
from apoptosis as demonstrated by specific lysis assays and DNA fragmentation 
(Sionov et al., 2008). The so-called mutual antagonism model proposes thymocytes 
undergo cell death (death by neglect) when low TCR avidity cannot counteract GC in 
the thymus, whilst increasing TCR avidity can overcome GC-induced apoptosis 
(positive selection) allowing T cells to survive and continue differentiation (Ashwell et 
al., 2000). Thymic epithelial cells (TEC) secrete GC, which might originate from 
thymocyte to epithelial cell contact (Pazirandeh et al., 1999). This model that GC is 
required to antagonise apoptotic signals derived via the pTCR, as well as the mature 
αβ TCR, is supported by several studies (Teh et al., 1988; Vacchio and Ashwell, 1997). 
In an in vivo model, where the immature thymocytes specifically expressed GR-
antisense transcripts, low expression of GR led to decreasing thymus size and the 
number of DP cells suggesting GR signalling is indispensable for thymocyte 
development. This loss of mature T cells was partially through activation-induced cell 





Figure 6. GC antagonises TCR activation induced apoptosis during T-cell 
development. GC inhibits TCR-signalling by displacing LCK and FYN from the TCR 
complex. GC-induced GSK3 attenuates TCR downstream NFAT signalling and 
NOTCH1 function. The GR targeted gene GILZ (glucocorticoid-induced leucine 
zipper) antagonises BIM expression by repressing FoxO3 and inhibits TCR-induced 
apoptosis by preventing FasL and NFκB expression. The diagram was modified from 
(Sionov et al., 2008). 
 
Upon GC-binding with GR, the non-genomic effects of GC rapidly inhibit TCR-
signalling by displacing LCK and FYN from the TCR complex (Lowenberg et al., 2006), 
and GC-induced GSK3 (glycogen synthase kinase 3) attenuates TCR downstream 
NFAT signalling and NOTCH1 function (Woodgett and Ohashi, 2005). The delayed 
response of genomic effects of GC also plays a crucial role in antagonising TCR-
induced cell death. The GR targeted gene GILZ (glucocorticoid-induced leucine 
zipper) antagonises BIM (BCL2 like 11) expression by repressing FoxO3 (forkhead 
box O3) (Asselin-Labat et al., 2004). GILZ also inhibits TCR-induced apoptosis by 





It has been over 65 years since glucocorticoids were first used to treat patients with 
inflammation and autoimmune diseases. Immunosuppression by GC is achieved 
through interference with the expression of a variety of GR-activated genes in T cells, 
such as IL-2 (interleukin 2) (Northrop et al., 1992; Paliogianni et al., 1993), IL-1β 
(interleukin 1 beta) (Zhang et al., 1997), IL-6 (interleukin 6), IL-8 (interleukin 8), TNFα 
(tumour necrosis factor), and GM-CSF (Tobler et al., 1992). Another consequence of 
GC is induction of lymphocyte cell death through activation of the intrinsic apoptotic 
pathway. As a transcriptional regulator, GR-targeted genes directly or indirectly 
regulate cell death. Unlike the activation-induced cell death in T cells which is through 
TCR-FasL/Fas receptor activated Caspase-8, the common path of GR-induced cell 
death is Caspase-9-induced apoptosis (Jamieson and Yamamoto, 2000). Also, the 
fact that a transcriptionally inactive form of the GR could still induce apoptosis 
suggests the existence of an alternative mechanism through which GR affects nuclear 
proteins that are required for cell survival (Helmberg et al., 1995) (Reichardt et al., 
1998). Apart from the genomic function, GCs also suppress immune response 
effectively through GR by rapidly inducing signal transduction. Studies in GR-mutant 
mice, where GR is defective for transcriptional activity, has proven its non-genomic 
actions (Van Laethem et al., 2001).  
 
1.2 T-cell Acute Lymphoblastic Leukaemia 
T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive blood cancer derived 
from the malignant transformation of T cell progenitors, and mainly develops in 
children and adolescents but also arises in adults. T-ALL accounts for 10-15% of 
paediatric and 25% of adult ALL cases. Characteristically T-ALL is more common in 
males than in females (Ferrando et al., 2002). The clinical symptoms are often 
characterised by high peripheral blood cell counts, high circulating numbers of blast 
cells, mediastinal mass and central nervous system (CNS) involvement. In 
UKALL2003, 12% T-ALL patients developed CNS disease while only 5% B-ALL 
patients showed CNS disease. In T-ALL and B-ALL, CNS2 (< 5 white blood cell (WBC) 
in the cerebrospinal fluid (CSF) with blasts) was observed in 8 and 4.7%, and CNS3 
(≥ 5 WBC in the CSF with blasts) in 4.4 and 0.62% respectively (Data obtained in 




The vast improvement in prognosis for T-ALL in children in recent years is achieved 
by intensive therapy, consisting of multi-agent combination chemotherapy, resulting in 
5-year event-free survival (EFS) for paediatric and adult patients of 80% and 50%, 
respectively (Pui et al., 2008). Despite the significant improvements in the treatment 
of T-ALL, approximately 25% of children and 50% to 70% of adults with this disease 
succumb to treatment-resistant illness. Moreover, the high dose treatment can lead to 
severe acute toxicities, and short or long-term side effects are observed in many 
patients. Notably, the outcome for relapsed T-ALL remains extremely poor (Bhojwani 
and Pui, 2013).  
T-ALL are classified in five phenotypic subtypes based on different stages of T-cell 
ontogeny. The ETP-ALL accounts for 15% of T-ALL cases with a poorer prognosis 
compared with typical T-ALL. The characterisation of ETP-ALL is CD3-, CD1a-, CD5-
/low, CD4-, CD8-, but frequently expressing myeloid lineage marker CD33 or stem cell 
markers CD117 and CD34. (Coustan-Smith et al., 2009). The European Group for the 
Immunological characterization of leukaemias (EGIL) proposed T-ALL into pro-T 
(cCD3+, CD7+), pre-T/immature (cCD3+, CD7+ and CD5/CD2+), cortical T-ALL (cCD3+, 
sCD3+/-, CD1a+, CD2+, CD5+, CD7+, CD34-), and mature T-ALL (cCD3+, sCD3+, CD1a-
, CD2+, CD5+, CD7+, CD34-). The cortical T-ALL subgroup has the best prognosis 
(Raetz and Teachey, 2016). 
T-ALL is generally associated with clonal chromosomal translocations and other 
genetic or epigenetic abnormalities, which lead to differentiation arrest, uncontrolled 
growth and clonal expansion. These genetic abnormalities are usually classified as 
Type A and B lesions, with Type A lesions representing the initiating cancer mutation 
and Type B lesions required to lead to full-blown leukaemia in a multistep model.  
 
1.2.1 Type A Oncogenic Gene Lesions in T-ALL 
Genomic and transcriptomic studies have identified major genetic abnormalities in T-
ALL cases that involve promoter and enhancer element of TCR genes and 
transcription factor genes associated with development, including Homeobox genes 
and bHLH genes (Figure 7). Discovery of these oncogenic proteins by using a 
combination of gene analysis strategies such as Giemsa banding (G-banding), 




(aCGH), RNA-sequencing (RNA-Seq) and whole genome sequencing (WGS) are 
crucial for the classification of T-ALL subtypes. 
 
Figure 7. The classification of paediatric T-ALL. 33% of T-ALL cases have TAL1-
associated gene aberrations. The frequency of TLX1 or TLX3 aberrations is 5% and 
20% respectively. LMO2 and LMO1 accounts for 10% of T-ALL cases. The other major 
gene aberrations are HOXA (6%), PICALM-MLLT10 (also known as CALM-AF10, 
5%), KMT2A-MLLT1 (also known as MLL-ENL, 5%), NKX2-1 (5%), NKX2-2 (1%), 
SET-NUP214 (3%), MYB (3%), TAL2 (1%), LYL1 (1%), BHLHB1 (1%), ZEB2 (< 1%) 
and MYC (1%). Data obtained from (Belver and Ferrando, 2016). TAL, T-cell acute 
lymphoblastic leukaemia protein 1; TLX, T-cell leukaemia homeobox; LMO, LIM 
domain only; HOXA, homeobox A; PICALM, phosphatidylinositol-binding clathrin 
assembly protein; KDMT2A, histone-lysine N-methyltransferase 2A; NKX2, NK2 
homeobox; NUP214, nucleoporin 214; LYL1, lymphoblastic leukaemia associated 
haematopoiesis regulator 1; BHLHB1, basic helix-loop-helix protein1; ZEB2, zinc 








The Homeodomain-containing proteins can be divided into two types: class I HOX 
genes and class II orphan HOX genes.  
The class I contains four distinct members, namely HOXA, HOXB, HOXC and HOXD. 
A large-scale gene expression analysis has identified and characterised that only the 
HOXA cluster is associated with T-ALL (Soulier et al., 2005). HOXA9 and HOXA10 
are crucial genes involved in T-ALL pathogenesis (Abate-Shen, 2002). HOXA gene 
expression can be upregulated by translocation with the TCRΒ or TCRG loci in 3% T-
ALL cases. The dysregulated expression of HOXA is also found in T-ALLs with 
translocations of KMT2A-MLLT1 (MLL-ENL) (Rubnitz et al., 1996), PICALM-MLLT10 
(CALM-AF10) (Asnafi et al., 2003), and SET-NUP214 (Van Vlierberghe et al., 2008). 
Members of class II orphan HOX genes are TLX1 (T-Cell Leukaemia Homeobox 1, 
HOX11) and TLX3 (T-Cell Leukaemia Homeobox 3, HOX11L2).The oncogenic role of 
TLX1 in T-ALL is due to the translocation of the strong enhancers of TCRΑ 
(t(10;14)(q24;q11)), TCRB (t(7;10)(q35;q24)) or TCRD (t(10;14)(q24;q11)) leading to 
overexpression of TLX1. Forced TLX1 expression in Notch-activating mouse models 
results in development arrest at the cortical stage (Rakowski et al., 2011). TLX1 
dysregulated expression leads to malignant features such as increased cell 
proliferation, downregulation of anti-apoptotic genes, induction of aneuploidy and 
deletions of tumour suppressor genes such as BCL11B, PTPN2 (Kleppe et al., 2011), 
WT1 (Tosello et al., 2009) and PHF6 (Van Vlierberghe et al., 2010) during T-cell 
transformation (De Keersmaecker et al., 2010). The transcription signatures and 
directly regulated genes of TLX1 and TLX3 are broad overlapping (Della Gatta et al., 
2012). TLX3 high expression can be detected in 20-25% paediatric T-ALL patients 
and 5% in adult T-ALL patients (Belver and Ferrando, 2016). Unlike TLX1, TLX3 is 
frequently translocated to the BCL11B locus (t(5;14)(q35;q32)), which is highly 
expressed during T-cell differentiation (Ballerini et al., 2002). The high level of TLX3 
is associated with relapse of T-ALL, suggesting that monitoring the expression of TLX3 






Class ‖ bHLH proteins 
The third subtype of TALL is characterised by activation of the basic helix-loop-helix 
(bHLH) proteins TAL1 (T-cell acute lymphoblastic leukaemia protein 1, SCL), LYL1 
(lymphoblastic leukaemia-derived sequence 1) and LIM-only (LMO) domain genes. 
The activation of TAL1, through chromosomal translocation t(1;14)(p32;q11), 
t(1;7)(p32;q34) or interstitial deletion of 1p32, is the most common type A lesion in 
childhood T-ALL (Begley and Green, 1999), which accounts for up to 34% of all T-ALL 
cases (Girardi et al., 2017). In only 3% of these cases, this is related to activation by 
the TCR locus, whereas the rest of cases are associated with an interstitial deletion 
that places TAL1 under the control of the STIL (SCL/TAL1 interrupting locus) gene 
promoter. It was recently shown that mutations in TAL1 upstream noncoding sites lead 
to de novo binding sites for MYB (MYB proto-oncogene, transcription factor), recruiting 
CBP, RUNX1, GATA3 and itself to form a super-enhancer promoting TAL1 gene 
expression in a subset of T-ALL patients (5%) (Mansour et al., 2014; Sanda et al., 
2012). A variety of studies have been done to demonstrate the function of TAL1 in the 
transgenic mouse model and whether its expression could lead to leukaemogenesis. 
Firstly, no leukaemia occurs by using a bone marrow mouse model which 
overexpresses TAL1 (Elwood and Begley, 1995). Similarly, transgenic mice with 
expression of TAL1 driven by the CD2 promoter do not develop leukaemia (Curtis et 
al., 1997). Furthermore, overexpression of TAL1-STIL fusion gene cannot induce 
leukaemia in transgenic or knock-in mouse models (Cheng et al., 2007). These results 
indicate that additional genetic abnormalities or signalling pathways are essential for 
the full development of leukaemia. However, it has also been reported that transgenic 
mice which express TAL1 driven by the LCK (LCK proto-oncogene, p56lck) promoter 
develop T-ALL in 80% of these mice (Condorelli et al., 1996). In a study which 
investigated whether TAL1 induced leukaemia through TCF3/TCF12, it was observed 
that leukaemia accelerated in Tal1/Tcf3+/- and Tal1/Tcf12+/- mice, indicating that TAL1 
transformed thymocytes due to the repression of TCF3/TCF12 (O'Neil et al., 2004). 
Also, TRIB2 (tribbles pseudokinase 2) and NKX3-1 which are necessary for T-ALL 
proliferation have been shown to mediate TAL1 oncogenic activity (Kusy et al., 2010; 




LYL1 gene is another member of the class II bHLH transcription factor family. The 
LYL1 gene was discovered in close juxtaposition with the TCRΒ locus as part of the 
t(7;19)(q35;p13) chromosomal translocation causing T-ALL (Mellentin et al., 1989). 
The gene product of LYL1 plays a crucial role in cell proliferation, especially in 
haematopoiesis (Baer, 1993). To illustrate the oncogenic role of LYL1, transgenic mice 
have been created with LYL1 driven by the EEF1A (eukaryotic translation elongation 
factor 1 alpha) promoter. 30% of mice exhibited B-cell and T-cell leukaemia. These 
results indicate that LYL1 has an active role not only in B-cell leukaemia but also in T-
cell leukaemia (Zhong et al., 2007). 
The LIM domain family consists of four DNA-binding proto-oncogenic proteins, such 
as LMO1, LMO2, LMO3 and LMO4. The function of LMO1 and LMO2 in T-ALL is 
studied extensively. LMO1 was found in 1% T-ALL cases with the chromosomal 
translocation t(11;14)(p15;q11) and t(7;11)(q34;p15). LMO2 was upregulated as a 
consequence  of interstitial deletion del(11)(p12p13), t(11;14)(p13;q11) or 
t(7;11)(q35;p13)  accounting for approximately 10% of T-ALL cases (Boehm et al., 
1991). Several transgenic mouse models have been developed to investigate the roles 
of LMO1 and LMO2 in the induction of T-ALL. Both LMO1 and LMO2 transgenic mice 
develop leukaemia with a long latency of 10 months, suggesting these two genes are 
essential but are not sufficient for the leukaemia development (Chervinsky et al., 
1999). LMO proteins are frequently co-expressed with TAL1 or LYL1 in T-ALL 
(Ferrando et al., 2002). Although LMO proteins do not directly interact with DNA, the 
multiprotein complexes including LMO and TAL1/LYL1 disturb downstream gene 
expression through binding to DNA directly and displacing important transcriptional 






Chimaeric fusion proteins 
Fusion proteins found in T-ALL result from chromosomal translocations, involving 
ABL1 associated proteins, KMT2A-MLLT1 (also known as MLL-ENL) (HOXA group) 
and PICALM-MLLT10 (also known as CALM-AF10) (HOXA group) fusion proteins. 
Examples of ABL1 associated fusion proteins are ETV6-ABL1, EML1-ABL1 and 
NUP214-ABL1. ETV6 (ETS variant 6) is located on 12p13 and occurs rearranged due 
to the chromosomal translocation t(9;12)(q34;p13). This translocation occurs with very 
low frequency in patients.  
EML1 (Echinoderm microtubule-associated protein-like 1) is a ABL1 fusion partner in 
EML1-ABL1 resulting from the translocation t(9;14)(q34;q32). The complex 
chromosomal rearrangements with three chromosomal breaks leading to the 
formation of the EML1-ABL1 fusion gene explains the low frequency in patients (Van 
Limbergen et al., 2001). EML1-ABL1 shows increased tyrosine kinase activity and is 
sensitive to imatinib, an ABL1 kinase inhibitor, which provides the possibility to treat 
this type of T-ALL with tyrosine kinase inhibitor (TKI) (De Keersmaecker et al., 2005).  
NUP214 (nucleoporin 214) is located at the nuclear pore complex (NPC) which is 
important for nucleocytoplasmic transport. The NUP214-ABL1 fusion protein can be 
found in 6% of T-ALL. It is also associated with the expression of TLX1 and TLX3 
(Graux et al., 2004), and thought to be subclonal in most cases. Again, it is sensitive 
to imatinib providing a new approach to treat this type of T-ALL by targeting the 
tyrosine kinase. Surprisingly, unlike BCR-ABL1 where the coiled-coil domain of BCR 
facilitates BCR-ABL1 proteins to form a tetramer which is constitutively activated in 
the cytoplasm, it is the nuclear pore localisation function of NUP214, rather than its 
coiled-coil motifs, which is crucial for NUP214-ABL1 to fully induce T-cell leukaemia 
(De Keersmaecker et al., 2008). 
KMT2A is the mixed lineage leukaemia gene located on chromosome 11q23. KMT2A-
MLLT1 fusion occurs upon chromosomal translocation at t(11;19)(q23;p13.3). 
PICALM (clathrin-assembly protein) forms the PICALM-MLLT10 fusion protein as a 
result of the t(10;11)(p12;q21) chromosomal translocation. It is associated with both 
ALL and AML. This protein can be found in approximately 10% of T-ALL patients with 
the malignancy only in the γδ T-cell lineage. The mechanism of induction of T-ALL 




and CALM-AF10 aberrations are also associated with high frequency of corticosteroid 
resistance and dismal survival rates (Ben Abdelali et al., 2013; Ben Abdelali et al., 
2014). 
The cryptic del(9)(q34.11q34.13) deletion was identified in T-ALL patients resulting in 
a fusion protein SET-NUP214. In the GRAALL (French Group for Research on Adult 
Acute Lymphoblastic Leukaemia) 2003 and 2005 trials, 6% of cases (11 patients) 
harboured a SET-NUP214 fusion. Ten out of eleven patients were TCRγδ T-ALLs and 
associated with poor response to corticosteroid (Ben Abdelali et al., 2014). This 
subgroup is characterised by high expression of HOXA genes. Knockdown of this 
fusion gene in a SET-NUP214 positive T-ALL cell line LOUCY significantly impaired 




1.2.2 Type B Genetic Aberrations and Their Role in Oncogenesis 
The type B genetic aberrations are factors cooperating with type A gene lesions in T-
ALL development. Their functions include roles in cell signalling, cell cycle control, 
tumour suppression and chromatin remodelling. Many critical type B genetic 
aberrations contribute to T-ALL development. It is beyond the scope of this thesis to 
discuss all genetic aberrations, but frequently recurring lesions affecting NOTCH1, 
PTEN, IL-7R, and NRAS will be discussed. Dysregulation of these genes is crucial for 
the proliferative and survival advantage of leukemic blast cells and has led to the 




The oncogenic role of NOTCH1 was first discovered as part of the t(7;9)(q34;q34.3) 
chromosomal translocation found in less than 1% of human T-ALL patients (Ellisen et 
al., 1991). However, activating mutations of NOTCH1 occur in more than 60% of T-
ALL cases indicating the crucial role of NOTCH1 in T-ALL development (Weng et al., 
2004). A bone marrow reconstitution assay of cells with forced expression of a nuclear 
form of NOTCH1 (a constitutively active intracellular form of NOTCH1 (ICN)) was 
performed in lethally irradiated BALB/cByJ mice. Rapid T-cell leukaemia progression 
was shown in 50% of transplanted animals indicating NOTCH1 may specifically 
transform T cells (Pear et al., 1996). Notch signalling is activated by DLL4 which is 
expressed by thymic epithelial cells. Ectopic expression of DLL4 in T-cells resulted in 
T-ALL in mouse models (Xiong et al., 2013). 
Two significant regions are mutated in NOTCH1; HD (heterodimerisation domain) and 
PEST domain (polypeptide enriched in proline, glutamate, serine and threonine 
domain). HD mutations are found in exon 26 and 27 which affect NOTCH1 activation 
on the cell surface and the release of ICN. The variations in the HD domain result in 
the increase of S3 cleavage (Figure 8) and the production of ICN. PEST domain 
mutations are found in exon 34 which influence the half-life of ICN. The deletions of 
the PEST domain lead to extended half-life of ICN1 (Gupta-Rossi et al., 2001). In 187 




mutations; 27% had HD mutations, 15% had PEST mutations, and 16% had both HD 
and PEST mutations (Ferrando and Look, 2000).  
 
Figure 8. Schematic diagram of Notch signalling. The Delta-like (DL4) ligand is 
expressed by the thymic stromal cells. After activation by DL4, NOTCH1 undergoes 
S2 cleavage (by ADAM10) and S3 cleavage (by γ-secretase) which releases ICN 
(NOTCH intracellular domain). It can translocate to the nucleus and activate the 
expression of NOTCH target genes. FBXW7 (F-box and WD repeat domain containing 
7) is a negative regulator of NOTCH1. FBXW7 works as an E3 ubiquitin ligase to lead 
to ubiquitin-mediated degradation of ICN. Several effective approaches to block Notch 
signalling are indicated; (1) anti-NOTCH1 antibodies to bind the extracellular domain, 
(2) γ-secretase inhibitors to inhibit the S3 cleavage of NOTCH1, and (3) SAHM1 
(stapled α-helical peptide derived from mastermind-like 1) peptide to disrupt the 






As Notch signalling is pivotal in T-ALL pathogenesis, loss of function of negative 
regulators of NOTCH1 is seen in T-ALL patients. The proteasomal degradation of 
NOTCH1 is mediated by FBXW7 (F-box and WD repeat domain containing 7) (O'Neil 
et al., 2007). Inactivating mutations of FBXW7 resulting in increased level of NOTCH1 
were identified in 8-30% of T-ALL cases (Thompson et al., 2007). 
The induction of Notch-mediated leukaemia is dependent on pTCR signalling, since 
overexpression of ICN fails to induce leukaemia in the absence of pTCR signalling 
(Allman et al., 2001). MYC is a direct target of NOTCH1 and shares many targeted 
genes of NOTCH1. Both NOTCH1 and MYC enhance anabolic pathways of nucleotide 
and amino acid metabolism, protein translation and ribosome biosynthesis (Palomero 
et al., 2006). Another critical downstream transcriptional factor of NOTCH1 in T-ALL 
is HES1 (Hes Family bHLH Transcription Factor 1), which regulates PI3K, NF-κB 
signalling and suppresses pro-apoptotic factor PUMA. Many T-ALL-specific long 
noncoding RNA (lncRNA) were identified to be regulated by NOTCH1. A NOTCH1 
downstream lncRNA LUNAR1 was shown to promote leukaemia growth via enhancing 
IGF1 (insulin-like growth factor 1) signalling (Trimarchi et al., 2014). 
Activated Notch signalling represents a therapeutic target in T-ALL. GSIs (Gamma-
secretase inhibitors) prevent the cleavage of NOTCH by γ-secretase to decrease the 
formation of ICN thereby blocking Notch signalling (Figure 8). However, lack of 
specificity and side-effects are common problems of GSIs (Knoechel et al., 2014). This 
led to the development of other inhibitors to specifically target the Notch pathway for 
the treatment of T-ALL. SAHM1, a stapled peptide, inhibits the Notch1 signalling 
explicitly to halt the progression of leukaemia and also has proved to be effective in a 






PTEN (phosphatase and tensin homolog) is an important negative regulator of the 
PI3K signalling pathway, which is essential for cell proliferation, survival, growth, 
migration and metabolism. Activation of PI3K results in the production of 
phosphatidylinositol triphosphate (PIP3) which activates the key downstream 
molecule AKT (AKT serine/threonine kinase, PKB). AKT is the principal mediator in 
the PI3K pathway which promotes proliferation via the regulation of several factors 
involved in cell cycle control, such as GSK3β, FoxO1 and p27Cip1. The activated AKT 
can induce the phosphorylation of mTOR (mechanistic target of rapamycin) and 
activate anti-apoptosis transcriptional factors (Cantley, 2002).  
The activation of the PI3K/AKT pathway was detected in 15% of T-ALL patients in 
which 13% was accounted for by PTEN deletions or mutations, and 2%  characterised 
by AKT activating mutations (Zuurbier et al., 2012). Moreover, several mouse models 
have shown that mice transplanted with PTEN-deficient or PTEN-mutant HSCs 
develop AML and T-ALL but not B-ALL, suggesting a significant function of PTEN in 
lineage fate determination and leukemogenesis (Zhang et al., 2006). Pten deficiency 
induced leukemogenesis was significantly impaired after the ablation of Raptor which 
is a regulatory-associated component of mTOR complex, suggesting Akt/mTOR 
signalling was the primary oncogenic driver of Pten-loss-evoked leukemogenesis 
(Kalaitzidis et al., 2012). The analysis of primary T-ALL samples illustrates a crucial 
role for PI3K/AKT/mTOR in the progression of T-ALL and provides novel therapeutic 
targets in T-ALL (Gutierrez et al., 2009). The mTOR inhibitor rapamycin induces 
apoptosis in paediatric T-ALL cells and re-sensitises chemo-resistance to doxorubicin 
and dexamethasone (Batista et al., 2011).  
 
IL-7R 
Crosslinking of IL-7 and IL-7R initiates IL-7R signalling through recruitment of JAK1 
and JAK3 and increase of their kinase activity. IL-7R phosphorylates STAT5 (signal 
transducer and activator of transcription 5) which then translocates to the nucleus and 




Recent studies show that Notch signalling can upregulate the PI3K pathway through 
the enhancement of IL7R expression, which is a direct transcriptional target of 
NOTCH1 (Gonzalez-Garcia et al., 2012). IL-7R enhances the PI3K/AKT/mTOR in T-
ALL (Gonzalez-Garcia et al., 2009). A somatic gain-of-function mutation in IL-7R was 
discovered in 10% of T-ALLs resulting in the activation of JAK/STAT signalling (Zenatti 
et al., 2011). The activation mutations of JAK1 and JAK3 were found in 4-18% and 7% 
T-ALL cases respectively (Belver and Ferrando, 2016). Three missense mutations of 
JAK1 (A634D, R724H and R879C) result in oncogenic upregulation of multiple 
downstream pathways such as STAT1, STAT5, AKT and ERK (MAPK, mitogen-
activated protein kinase) (Flex et al., 2008). Another member of the JAK family, TYK2, 
was found to be important in some T-ALL cases through the STAT1 and BCL2 axis. 
Small-molecule inhibitors against TYK2 (JAK inhibitor ǀ and AG490) induced T-ALL 
cell death (Sanda et al., 2013). Loss of PTPN2 was identified in approximately 6% of 
T-ALL cases, resulting in the activation of JAK1 and STAT5 (Kleppe et al., 2011).  
Nowadays, several pieces of data have shown activated IL7R pathway via 
mechanisms other than genetic mutations in IL-7R, JAK or STAT5 genes. In the ETP 
subtype, a point mutation V265G was found in DNM2 resulting in Dynamin 2 loss of 
function and decreased clathrin-mediated IL-7R internalisation. High IL-7R density on 
the surface led to enhanced IL-7 signalling in leukaemic stem cells (Tremblay et al., 
2016). In another ETP-ALL case, a t(2;14)(q22;q23) translocation leading to the 
overexpression of ZEB2 (zinc finger E-box binding homeobox 2) was found to induce 
hyperactivated STAT5. An IL7R-blocking antibody or JAK1/2 inhibitor Ruxolitinib could 
effectively prevent ZEB2 overexpression induced T-ALL in mice (Goossens et al., 
2015). 
These findings indicate that the activation of IL-7R is associated with progression of 
T-ALL and offers a novel therapeutic target. Recent treatments have been developed 
based on chemical inhibition of JAK/STAT5 signalling components, such as the 








The MAPK/ERK pathway, also known as the RAS-RAF-MEK-ERK pathway, is critical 
in the regulation of cell division and growth. Three distinct RAS genes are known; 
KRAS (KRAS proto-oncogene, GTPase), NRAS (Neuroblastoma RAS viral oncogene 
homolog) and HRAS (HRas proto-oncogene, GTPase). Even though RAS activation 
mutations are rare in T-ALL (5-10% of cases), it is shown that constitutive activation 
of ERK1 and ERK2 was found in 38% of cases (Martelli et al., 2012). Upstream of 
MEK/ERK signalling are several pathways, for example IL-7, IL-9 and pTCR/TCR 
signalling (Brownlie and Zamoyska, 2013). It is notable that in a study with a cohort of 
131 ALL patients, highly phosphorylated ERK1 and ERK2 correlated with high white 
blood cell counts and less response to steroids and negatively associated with the 
expression of CD34 antigen (Gregorj et al., 2007). In leukaemia and lymphoma, NRAS 
mutations are two to three times more frequent than mutations in other RAS members. 
Studies have shown that transplantation of NRASG12D bone marrow into recipient mice 
resulted in 100% T-ALL (Wang et al., 2011). A similar outcome was seen for K-
RASG12D. Aggressive T-ALL or T-cell lymphoma was seen in recipient mice after the 
bone marrow transplantation of conditional knock-in K-RASG12D mice. Half of these 
mice with T-ALL-like disease also acquired Notch1 mutations which were 
hypersensitive to γ-secretase inhibitors (Kindler et al., 2008). 
One of the downstream molecules of MAPK/ERK2 is ERG (v-ets avian 
erythroblastosis virus E26 oncogene homolog). The phosphorylation site S283 of ERG 
is regulated by MAPK/ERK2, which is specifically highly phosphorylated in AML and 
T-ALL cells rather than HSPCs (hematopoietic stem and progenitor cells) (Huang et 
al., 2016). Transgenic ERG mice also developed T-ALL, and knockdown of ERG 
inhibited cell proliferation in the human T-ALL cell line MOLT4 (Thoms et al., 2011). 
Adverse outcomes are shown for T-ALL patients with higher ERG expression (overall 







1.2.3 Epigenetic Factors and Non-coding RNAs in T-ALL 
 
Epigenetic factors 
Approximately 56% of paediatric T-ALL cases have epigenetic mutations with the most 
prevalent mutations in PHF6 (the plant homeodomain protein 6) and PRC2 (polycomb-
repressive complex 2) components EZH2 (enhancer of zeste 2 polycomb repressive 
complex 2 subunit), SUZ12 (SUZ12 polycomb repressive complex 2 subunit) and EED 
(embryonic ectoderm development).  
PHF6 inactivation mutations were found in 16% of paediatric T-ALL and 38% of adult 
T-ALL (Belver and Ferrando, 2016). Its epigenetic regulator function involves a wide 
variety of interactions with post-translationally modified histones, double-stranded 
DNA, nucleosome remodelling deacetylase (NuRD) complex, RNA polymerase 1 
(UBTF1), ribosome RNA and DNA, as well as DNA damage checkpoint kinase ATM 
(ataxia telangiectasia mutated) (Girardi et al., 2017).  
Dysregulation of H3K27 (histone 3 lysine 27) methylation caused by defects in PRC2 
is found in 25% of paediatric T-ALL patients resulting from loss-of-function mutations 
and deletions in EZH2, EED and SUZ12 (Belver and Ferrando, 2016). PRC2 acts as 
a tumour suppressor by competing with NOTCH1 to recruit lysine demethylase 
KDM6B (JMJD3, Jumonji D3), which leads to the activation of NOTCH1-targeted 
genes (Ntziachristos et al., 2012). Therefore, loss of PRC2 activity and NOTCH1 
activation mutations are frequently co-occurring.  
Contrary to the oncogenic role of KDM6B, another H3K27me3 histone demethylase 
KDM6A (UTX, ubiquitously transcribed tetratricopepetide repeat X-linked protein) was 
found as a tumour suppressor in T-ALL. Around 5-15% of T-ALL cases have loss-of-
function mutations of KDM6A (Ntziachristos et al., 2014). However, this concept was 
challenged by a study where KDM6A was shown to be hijacked by TAL1 to remove 
H3K27 methylation and activate genes in TAL1+ patients specifically (Benyoucef et 
al., 2016).  
The discovery of alterations in epigenetic regulators in T-ALL paves the way for 





Micro-RNAs and long noncoding RNAs 
The increased understanding of miRNAs (small non-coding RNA molecules of about 
22 nucleotides) and lncRNAs (long noncoding RNAs) allows us to identify and study 
T-ALL pathogenesis-related non-coding sequences.  
The miRNAs miR-19b, miR-20a, miR-26a, miR-92, and miR-223 are pro-tumourigenic 
as they downregulate gene expression of IKZF1, PTEN, BIM, PHF6, NF1 and FBXW7 
(Mavrakis et al., 2011). On the contrary, a tumour suppressive role for miRNA was 
also found, exemplified by miR-193b. The downregulation of miR-193b in T-ALL 
causes MYB and MCL1 overexpression (Mets et al., 2015). Dicer1 (ribonuclease III), 
which cleaves pre-miRNA into miRNA, was found to be essential in Notch-mediated 
T-ALL progression. Dramatic apoptosis of T-ALL cells after the loss of Dicer1 strongly 
indicates Dicer1-processed miRNAs support leukaemia cell survival. The profiling of 
Dicer processed miRNAs identified aberrant expression of miR-21 in T-ALL which 
prevents apoptosis induction of leukaemia cells via suppression of Pdcd4 
(programmed cell death 4) (Junker et al., 2015). 
NOTCH1 regulates many T-ALL-specific long noncoding RNA (lncRNA), such as 
lncRNA LUNAR1, which promotes leukaemia growth via enhancing IGF1 signalling 





1.3 T-cell Checkpoint Pathways in Malignancies 
Although several critical signalling pathways are essential in T-ALL development, 
there is still limited knowledge about the role of individual key signalling components. 
In an RNAi-assisted screen to identify proteins providing survival advantages in T-
ALL, ITK (IL-2 inducible T-cell kinase), ZAP70, LCK and FYN have been found (Sanda 
et al., 2013). These proteins are critical members of the pTCR or TCR signalling 
pathways. The PTCRA gene is highly expressed in more than 50% of T-ALL patients 
(Bene et al., 1995). These findings suggest that pTCR/TCR signalling might have a 
role in T-ALL development and maintenance. However, extensive research in 
elucidating the role of pTCR/TCR signalling in T-ALL has not yet been conducted. 
 
1.3.1 LCK in Leukaemia 
The tumour forming capacity of Lck has been investigated in genetically modified 
mouse models. Overexpression of wild-type Lck or a constitutively activated mutant 
LckY505F in DBA/2 x C57BL6/J F2 murine zygotes led to a specific high expression of 
Lck in thymus and grossly increased the total phosphotyrosine levels. The 
physiological Lck mRNA levels in thymocytes are approximately 12 pg/μg total RNA. 
A two-fold increase of Lck mRNA in LckY505F mice resulted in large thymic lymphoid 
tumours with an immature phenotype (CD3-, CD4-, CD8-/low). This was in line with the 
fact that LckY505F could transform NIH 3T3 fibroblasts in vitro (Marth et al., 1988). 
Wildtype Lck is also capable of transforming thymocytes with a 6-fold increase in 
mRNA levels. This time, more mature T cells (CD3low, CD4-/low, CD8low) were observed 
compared with LckY505F transgenic mice. The cells derived from both transgenic mouse 
models can continue to grow in vitro without the addition of growth factors. Overall, 
Lck overexpression induces tumorigenesis in mouse models (Abraham et al., 1991). 
Notably, LCK plays a significant oncogenic role in a human T-ALL cell line HSB-2 cells. 
HSB-2 cells are double negative T-cells with a t(1; 7)(p34; q34) translocation, placing 
LCK under the control of the TCRB promoter. Moreover, LCK carries four mutations; 
(1) the V28L point mutation, which is located within the CD4/CD8 binding domain. This 
only creates a weak LCK oncogenic ability in fibroblast cells, but could be important in 
T-cells since it may affect the binding of CD4/CD8, (2) the second mutation was 




between the SH2 and C-terminal catalytic domains. The inhibitory function of the SH2 
domain relies on its binding with phosphorylated Y505 of the kinase domain. This QKP 
insert might stabilise the alignment of the phosphorylated Y505 residue and the SH2 
domain, which disrupts the negative regulation of phosphorylated Y505 and produces 
a constitutively active LCK. Last but not least, two-point mutations (3) A353V and (4) 
P447L with unknown function can synergise with the QKP insert to promote fibroblast 
transformation. Together these mutations result in a 10-fold higher activity of LCK 
compared to other T-ALL cells. In normal T cells, LCK is down-regulated at the 
transcriptional level after T cell activation. However, when translocated under the 
control of TCRB in the t(1;7)(p34;q34) translocation, the high expression of LCK in 
HSB-2 cells counteracts the repression of LCK transcription leading to constitutive 
activation (Wright et al., 1994).  
Recent studies report that NOTCH1 can activate AKT through LCK to upregulate anti-
apoptotic genes in T cells. This suggests cooperation between NOTCH1 and LCK in 
leukaemogenesis (Sade et al., 2004). Another research study has shown that CCND3 
can cooperate with NOTCH1 through the pTCR-LCK axis (Sicinska et al., 2003).  
Moreover, LCK was shown to be crucial in BCR signalling in CLL. Firstly, varied levels 
of LCK expression in 39 CLL primary samples were identified. When stimulating CLL 
cells with IgM, LCK high-expressing cells showed more activation of CD79a, ERK, 
AKT and IKK phosphorylation, which could be reversed by siLCK or a specific LCK 
inhibitor (Pyrrolo(2,3-d)pyrimidine substituent) when used in excess of 1 μM 
concentration (Talab et al., 2013). 
 
1.3.2 Other SFKs in Haematological Malignancies 
An ever-increasing body of evidence highlights the role and influence of SFKs in 
haematological malignancies. For example, in CML (Chronic Myeloid Leukaemia), the 
dysregulated expression or activation of HCK, LYN and FYN has been shown; 1) the 
phosphorylation of several cellular proteins such as WAS (WASP actin nucleation 
promoting factor), BTK, HSP90, PKCδ (protein kinase C delta) and CSK in Ph+ 
(Philadelphia-positive) CML leukaemic cells is mediated by SFKs (Rubbi et al., 2011); 
2) LYN and HCK directly phosphorylate BCR-ABL1, after their activation by BCR-




BCR-ABL1 and STAT5 resulting in cell survival (Ban et al., 2008); 4) overexpression 
of HCK and LYN correlated with therapy resistance (Mahon et al., 2008; Pene-
Dumitrescu and Smithgall, 2010). Inhibition of SFKs induced apoptosis in imatinib or 
nilotinib resistant CML (Gamas et al., 2009; Gioia et al., 2011). Similar to their role in 
CML, LYN, HCK and FGR appear to be involved in BCR-ABL1+ B-ALL. The activation 
of HCK is shown to be induced by BCR-ABL1 in malignant B cells (Hu et al., 2004). 
The SFK LYN is predominantly expressed in B-cells and has also been implicated in 
CLL. An aberrant LYN-HSP90 cytosolic complex causes the constitutive activity of 
LYN in CLL cells. Disruption of this LYN-HSP90 interaction by the HSP90 inhibitor 
geldanamycin was toxic to CLL cells (Trentin et al., 2008). STAT3 and MCL-1 
expression can be upregulated by LYN, as well as the activation of CD40 signalling 
through LYN to increase anti-apoptotic mediators, such as NF-κB, BCL2 and MCL-1 
(Contri et al., 2005; Tibaldi et al., 2011). 
Oncogenic transformation of myeloid cells to AML requires the activity of SFKs, such 
as LYN, HCK and FGR (Duong et al., 2013). SFKs have been shown to promote AML 
progenitor proliferation and survival via MAPK and PI3K/AKT pathways as well as 
increased expression of anti-apoptotic proteins. Hyper-activated LYN is found in 76% 
of primary AML cells (Roginskaya et al., 1999), in which LYN strongly binds to FLT3-
ITD and links it to STAT5 to activate anti-apoptotic targets, such as BCL2 and BCL-xL 
(Okamoto et al., 2007). In CBL (Cbl proto-oncogene, E3 Ubiquitin-Protein Ligase) 
mutated AMLs, the ubiquitin-mediated degradation of FYN was hindered resulting in 
overactivity (Bandi et al., 2009; Dos Santos et al., 2013). 
CSK, the negative regulator of LCK, constitutively binds to PAG1. Upon TCR activation, 
PAG1 is released from the plasma membrane together with CSK allowing the full 
activation of LCK (Torgersen et al., 2001). In a study of high-resolution genome 
profiling of 40 childhood ALLs, a case of a microdeletion (8q21.13) affecting PAG1 
was found. About 10% of near-haploid ALL has PAG1 homozygous deletions 






1.3.3 LCK Inhibitor - Dasatinib 
Dasatinib (DAS) is a potent dual kinase inhibitor targeting ABL1 and SFKs. Dasatinib 
was approved by US FDA and EU in 2009 for CML and Ph+ ALL patients with 
chemotherapy or imatinib resistance (Squibb, 2009). Although it was initially designed 
to target the oncogenic fusion protein BCR-ABL1, it was also found to inhibit activated 
SFKs, such as LCK and FYN, as well as block anti-CD3 induced tyrosine 
phosphorylation (Schade et al., 2008). In MRC compound-screening, at 0.1 μM, DAS 
inhibited 100% activity of ABL1, 99% activity of Src and Lck; at 1 μM, DAS treatment 
led to 0% activity of ABL1, DDR2, and 1% activity of Lck (obtained from Kinase 
Profiling Inhibitor Database, MRC PPU international Centre for Kinase Profiling). 
Though both dasatinib and imatinib are potent BCR-ABL1 inhibitors, the chemical 
structures are very different. Imatinib can only bind with the inactive conformation of 
BCR-ABL1. The activation loop in the imatinib-bound ABL1 folds back to the ATP-
binding site leading to an inhibitory conformation. In this form, Phe382 in the DFG (Asp-
Phe-Gly) motif point toward ATP-binding site. On the contrary, both the active and 
inactive conformations of BCR-ABL1 were found to be inhibited by dasatinib. The 
Phe382 of dasatinib-bound ABL1 is buried in a hydrophobic pocket which is not 
accessible by ATP. This is typically found in activated kinases (Tokarski et al., 2006). 
Using a dose of 60-120 mg/m2 once daily, the Cmax (maximum plasma concentration) 
of dasatinib in patients was reached within 0.5 - 6 hours, and the half-life of dasatinib 
is around 2 to 5 hours in paediatric Ph+ CML patients (Zwaan et al., 2013). In a study 
of patients who received 140 mg once or 70 mg twice daily, around 5 - 28% of dasatinib 
was shown to cross the blood brain barrier to penetrate the CNS (Porkka et al., 2008).  
Since several SFKs have been demonstrated to play a role in many types of 
leukaemia, dasatinib has been explored for its efficacy in CML, JMML (Juvenile 
MyeloMonocytic Leukaemia), AML, and CLL. When examining a Nilotinib-resistant 
CML cell line K562NR, dasatinib was shown to effectively inhibit Lyn and induce 
apoptosis (Okabe et al., 2011). JMML harbouring CBL mutations is associated with 
hypersensitivity of monocytic cells to GM-CSF (granulocyte macrophage-colony 
stimulating factor), which is driven by Src and Lyn. Dasatinib treatment in JMML 
patient samples decreased GM-CSF induced growth, demonstrating its efficacy in 




progenitor cells by inhibition of LYN, HCK and FGR. The secondary engraftment 
capacity of dasatinib-treated AML stem cells is dramatically decreased (Dos Santos 
et al., 2013).  
 
1.4 pBCR Signalling and Its Role in BCP-ALL 
The pre-B cell receptor (pBCR) is essential for B cell development in providing a 
checkpoint in the bone marrow (Figure 9). The composition of pBCR is a correctly 
rearranged Igμ, SLC (Surrogate Light Chain; VpreB and λ5), CD79A (Igα) and CD79B 
(Igβ). Knock-out studies showed that SLC knockout mice, either VpreB or λ5, have a 
differentiation block and an accumulation of pro-B cells.  
 
Figure 9. A diagram depicting pBCR signalling. The pre-B cell receptor (pBCR) is 
composed of VpreB, λ5, Igµ, Igα (CD79a) and Igβ (CD79b). The pBCR activates the 
Lyn-Syk-SLP65 axis to regulate NF-κB signalling, MAPK signalling and Ca2+ pathway. 




Whether the pBCR is ligand-dependent or aggregates autonomously on the plasma 
membrane initiating the signalling pathway is still not clear. The non-immunoglobulin 
part of SLC λ5 is positively charged and facilitates pBCR aggregation and interaction 
with various proteins. Clustered pBCR complexes facilitate the phosphorylation of 
CD79A-CD79B (Igα - Igβ) by SFKs. This further recruits and phosphorylates SYK to 
amplify the signal since it can phosphorylate neighbouring pBCR as a positive 
feedback mechanism (Hendriks and Middendorp, 2004).  
The pBCR itself functions as a tumour suppressor gene. Evidence comes from studies 
in Ph+ B-ALL, in which BCR-ABL1 suppresses pBCR expression (Trageser et al., 
2009). Re-introduction of a functional rearranged Igμ reduces cancer cell growth in 
ALL with a non-functional Igμ (Klein et al., 2004). SYK can be phosphorylated by SFKs 
or autophosphorylated. It has been shown that SYK plays an oncogenic role in pBCR 
signalling since overexpression of SYK leads to pre-B cell proliferation and 
rearrangement of IgL (Wossning et al., 2006). Overexpression of SYK results in 
leukaemic transformation in vivo (Wossning et al., 2006). SFKs and SYK also activate 
PI3K signalling by phosphorylating CD19 and PI3KAP1 (Phosphoinositide-3-kinase 
adaptor protein 1). The downstream molecule of SYK is BLNK (B cell linker, also called 
SLP65), which activates PLCγ2, BTK (Bruton tyrosine kinase) and ERK signalling 
pathway. The BLINK-BTK-PLCγ2 axis downregulates λ5 by activating Aiolos (IKZF3) 
to terminate pBCR function and promote Igκ (the κ chain of IgL) rearrangement by 
inducing the expression of IRF4 (interferon regulatory factor 4). BLNK seems to 
suppress leukaemia progress since the deficiency of BLNK promotes B-ALL cell 
growth by elevating the autocrine IL-7 and JAK3-STAT5 pathways. Another possible 
mechanism of BLNK suppressing leukemic transformation is the fact that it inhibits 
AKT to release FOXO1 and upregulate FOXO1-targeted genes, which switches cell 
proliferation to cell differentiation (Flemming et al., 2003). FOXO proteins are rapidly 
degraded in the cytoplasm as a result of AKT phosphorylation, which inhibits FOXO 
to import into the nucleus. As a transcription factor, FOXO slows down cell cycle 
progression and induces RAG1/2 expression to promote pre-B cells to differentiate. A 
truncated form of BLNK is found in BCR-ABL1 ALL. This leads to a reduction in pBCR 
gene expression. Studies have demonstrated that inactivation of FOXO1 reduces its 
inhibition of CCND2 and MYC. In this way, BLNK antagonises proliferation and 




zinc finger 1). Overexpression of the Ik6 isoform (a dominant negative mutant form of 
IKZF1) in B-ALL cells leads to BLNK phosphorylation (Y36) and drives leukaemic cells 
to undergo cell cycle arrest (Trageser et al., 2009).  
In summary, the downstream functions of pBCR include: (1) BLNK-BTK independent 
pathway to activate RAS-RAF-MEK-ERK signalling to promote cell proliferation; (2) 
BLNK-BTK dependent pathway to negatively regulate λ5 expression to terminate 
pBCR signalling, facilitate allelic exclusion of Igμ and promote IgL rearrangement by 
mediating the expression of RAG1/2 (Figure 9).  
It has been reported that the aberrant activation of pBCR signalling facilitates B cell 
transformation. Gene expression studies demonstrate that 13% of B-cell precursor 
ALL (BCP-ALL) are pBCR+ (Geng et al., 2015). The well-known target genes of pBCR 
signalling are CDKN2A (cyclin-dependent kinase inhibitor 2A) and p53. The pro-
survival signals originating from the pBCR pathway promote BCL6 expression, and it 
competes with BACH2 (BTB domain and CNC homolog 2) to alter p53 and CDKN2A 
function, antagonising cell death. Further evidence related to the oncogenic role of 
pBCR signalling is provided by studies of BTK. In BCR-ABL1 ALL, a BTK mutant which 
lacks kinase activity, works as a scaffold protein to facilitate BCR-ABL1 mimicking 
pBCR signalling to provide continual pro-survival signals to leukaemic cells (Trageser 
et al., 2009).  
A dual role for SYK has been found by the Markus Mϋchen group in 2015. The intrinsic 
mechanism of B cell negative selection also exists in B-ALL. The activation of BCR 
signalling caused by BCR-ABL1 is tightly regulated by inhibitory receptors PECAM1 
(platelet and endothelial cell adhesion molecule 1), CD300A and LAIR1 (leukocyte-
associated immunoglobulin-like receptor 1), which recruit phosphatases PTPN6 and 
INPP5D to negatively regulate BCR signalling. Hyperactivation of SYK is toxic to Ph+ 
ALL cells due to mimicking auto-reactive BCR signalling, which forces the leukemic 
cells to undergo cell death. This provides a new perspective in the treatment of B-ALL 
by enhancing the BCR pathway to simulate the auto-reactive BCR signalling (Chen et 
al., 2015). 
Several drugs targeting pBCR signalling provides novel treatments for B-ALL, 




diminishes SYK activity and blocks oncogenic pBCR signalling, 2) inhibitors against 
INPP5D such as 3AC (3-α-aminocholestane) resulting in SYK hyperactivation (Chen 
et al., 2015). Other drug targets such as Ibrutinib and Idelalisib are used to target BTK 
and PI3K respectively in BCP-ALL (Rickert, 2013). 
 
1.5 Glucocorticoid Resistance and Underlying Mechanisms 
The synthetic GCs, dexamethasone and prednisone, are essential as first-line 
chemotherapy in treating ALL. However, glucocorticoid-resistance (GC-resistance) 
remains a considerable issue in the clinic (Inaba and Pui, 2010). The inadequate 
response to GCs after seven days of initial therapy significantly associates with 
therapy failure and high-risk of relapse (Dordelmann et al., 1999). The molecular 
mechanisms of GC-induced cell death can be influenced at multiple levels, such as 
GR isoforms and its stability, GR interacting chaperone proteins, signalling pathways 
proximal to the GR, GR downstream apoptotic-related proteins, transcription factors, 
as well as epigenetic regulations. 
 
1.5.1 GR Isoforms and GR-interacting Proteins 
Two decades ago, a study (Leung et al., 1997) reported glucocorticoid resistance 
resulting from aberrant expression of GR isoforms. The human GR is composed of a 
classic α isoform and a transcriptionally inactive β isoform (Bamberger et al., 1995). 
GRβ differs from GRα in the C-terminal residues by alternative using of Exon 9β rather 
than 9α, which lacks the ability to bind GCs. Both isoforms are expressed in the cells. 
However, GRβ resides in the nucleus constitutively. Overexpression of GRβ inhibits 
GR transcription activity in a dominant negative fashion. One example of this is 
patients with GC-resistant asthma, who have more GRβ expressed in peripheral blood 
mononuclear cells (Leung et al., 1997). However, this association was debated by 
several groups, when they demonstrated that instead of a specific GR isoform, it was 
the low expression of total GR which was associated with steroid resistance (Haarman 
et al., 2004; Lauten et al., 2003; Tissing et al., 2005a). 
Two independent studies tried to evaluate the components of the GR-multiprotein 




as Hsp90 (heat shock protein 90), Hsp70, Hsp40, BAG-1 (BCL2 associated 
athanogene, also called RAP46), HOP (HOP homeobox), FKBP-51, and FKBP52 
were measured and suggested that these proteins were of minor importance for GC 
resistance (Lauten et al., 2003; Tissing et al., 2005b).  
 
1.5.2 Signalling Pathways Involved in Steroid Resistance 
Overexpression of ICN (NOTCH) induces GC resistance in DP thymocytes (Deftos et 
al., 1998). The Notch signalling inhibitor (γ-secretase inhibitor) reverses GC-
resistance in CUTLL1, a cell line characterised by an activating NOTCH1 
translocation. In addition, it restored NR3C1 (GR, nuclear receptor subfamily 3 group 
C member 1) and BCL2L11 gene expression after DEX treatment (Real et al., 2009). 
The transcriptional repressor HES1 is controlled by NOTCH1 and binds to the 
promoter of NR3C1 and negatively regulates its expression in T-ALL. Knockdown of 
HES1 increased NR3C1 protein level and sensitised dexamethasone response (Real 
et al., 2009). 
It has been extensively studied that inhibition of IL-7 signalling sensitises DEX 
response in T-ALL. Steroid resistance-related mutations in JAK1 and KRAS were 
identified by targeted sequencing of paired diagnostic and remission patient samples. 
This study showed that hyperactivated IL-7 signalling upregulates expression of the 
anti-apoptotic proteins MCL1 and BCL-xL, and inhibits GSK3β and BIM through its 
downstream ERK and AKT pathways (Li et al., 2016).  
In T-ALL, AKT has been shown to directly phosphorylate the serine 134 residue of 
GR, retaining its localisation in the cytoplasm, therefore blocking the activation and 
translocation of GR after ligand stimulation. Consistent with this finding, 
dexamethasone in combination with MK2206 (an AKT inhibitor) facilitates GR 
translocation, induces a greater degree of apoptosis, and reduces leukaemia 
engraftment in vivo (Piovan et al., 2013). Recently, a study has shown that the Akt 
inhibitor (Akt inhibitor IV) in vivo causes severe hepatotoxicity. Furthermore it was 
shown that Akt2, rather than Akt1, actively phosphorylated FoxO3a inhibiting Bim 




The first association of RAS mutations with GC resistance was published in 2013, 
where the authors identified infants with RAS mutations were less sensitive to 
prednisone in a cohort of 109 infant ALLs (Driessen et al., 2013). KRAS mutations 
have been identified at a low level in subpopulations of diagnostic samples, which may 
confer steroid-resistant relapse (Irving et al., 2014). The combination of 
dexamethasone and Selumetinib (MEK inhibitor) has been shown to synergise in RAS 
pathway mutated ALL (Matheson et al., 2019). This combination is currently tested in 
an early phase clinical trial SeluDex (UK, 2018). 
 
1.5.3 Mechanism of TCR Signalling on GC-induced Apoptosis  
During T-cell development, TCR signalling antagonises GC-induced apoptosis via 
multiple mechanisms, but mainly via ERK, AKT and Calcineurin/NFAT pathways. GC-
induced apoptosis relies on GSK3 activation and BIM expression (Kfir-Erenfeld et al., 
2010). 
TCR signalling activates ERK signalling pathway after stimulation which antagonises 
GC-induced apoptosis (Figure 10). On one hand, ERK phosphorylates GSK3β at 
Thr43, which facilitates RSK1 (ribosomal protein S6 kinase A1) inactivation of GSK3β 
by phosphorylating Ser9GSK3β (Ding et al., 2005). On the other hand, ERK promotes 
BIM degradation via proteasome pathway by phosphorylation of BIMEL (Ley et al., 
2003). The murine Fas-negative cell line 2B4.11 was used for the investigation of how 
TCR signalling rescues cells from GC-induced apoptosis. The downstream 
Ras/MEK/ERK cascade, rather than PI3K/AKT cascade, was shown to be essential in 
preventing GC-induced cell death (Jamieson and Yamamoto, 2000).  
GR translocation and GR-targeted genes were investigated under conditions of TCR 
activation alone or in presence of DEX. T-cell activation did not directly influence 
intracellular localisation of GR and transcription of GR-targeted genes (Zacharchuk et 
al., 1990). The Calcineurin/NFAT pathway is activated by TCR stimulation. Inhibitionof 
Calcineurin by Cyclosporin A (CsA) effectively blocked the activation of NFAT 
signalling pathway, therefore reducing the antagonism between TCR activation-
induced and DEX-induced apoptosis. The mechanism of by which Calcineurin 




genes (Zhao et al., 1995). TCR antagonises GC-induced apoptosis also through AKT 
signalling, which often inhibits GSK3 function by phosphorylation (Sade et al., 2004). 
 
Figure 10. Known mechanisms of how TCR signalling antagonises GC-induced 
apoptosis in normal T cells. GC-induced apoptosis relies on BIM and GSK3. TCR 
signalling activates ERK, which then inhibits BIM via phosphorylation and GSK3 
function. AKT, another downstream molecule of TCR signalling, phosphorylates GSK 
resulting in GSK inactivation. The TCR activated Calcineurin-NFAT pathway also 
antagonises GC-induced apoptosis. NOTCH1 can be upregulated by TCR signalling, 
which promotes AKT inhibition of GSK3. Taken together, TCR signalling antagonises 
GC-induced apoptosis. The diagram was modified from (Sionov et al., 2008). 
 
The full activation of a T-cell requires interactions of TCR-MHC as well as 
costimulatory molecules (CD28/CTLA4 and B7-1 and/or B7-2). The majority of 
thymocytes undergo apoptosis during T-cell development due to physiological levels 
of GCs. However, this can be blocked by the interaction of CD28 and B7 (Wagner et 
al., 1996). The blockade of GC-induced apoptosis by TCR activation allows 




One microarray study of a murine T lymphoma cell line (DEX-sensitive) demonstrated 
that Lck expression was downregulated by DEX (Harr et al., 2010). Further 
investigation indicated that DEX affected Lck phosphorylation, protein expression and 
its downstream calcineurin pathway. Knockdown of Lck by shRNA or inhibition of Lck 
by dasatinib synergised with DEX to inhibit TCR signalling. Reduction in ZAP70, LAT, 
SLP-76, and p-MEK1/2, as well as an increase in Annexin V+ cells and caspase-3 
activity were seen after Lck inhibition (Harr et al., 2010). As LCK is highly expressed 
in CLL, this study was expanded to include primary CLL cells. DEX did not affect LCK 
protein or phosphorylation levels due to the fact that these CLL cells were resistant to 
DEX. However, GC sensitivity and apoptosis were enhanced by concurrent use of 
dasatinib (Harr et al., 2010). 
 
1.5.4 GR Downstream Apoptotic-related Proteins 
Bcl-2 expression negatively correlates with GC sensitivity during T cell development. 
DP cells are more sensitive to GC compared with SP cells, which have higher 
expression of Bcl-2 (Cohen and Duke, 1984) (Hockenbery et al., 1991). In GC-
sensitive ALL PDXs, GR inhibits MYB resulting in the downregulation of BCL2 
expression. However, in GC-resistant samples, BCL2 is highly expressed due to 
sustained MYB activity (Jing et al., 2015). Rapamycin (mTOR inhibitor) was shown to 
increase prednisolone sensitivity via MCL1 inhibition. The AKT-MCL1 axis, but not the 
AKT-BCL2/BCL-xL pathway, was inhibited by rapamycin, and it restored BIM function 
in B-ALL cells (Wei et al., 2006).  
The gene BAG-1 was the first GR-interacting protein to be cloned from a cDNA 
expression library in 1995 (Zeiner and Gehring, 1995). It binds to GR at the hinge 
region and inhibits GR in its trans-activation of apoptosis-related genes. Mouse S49.1 
cells became resistant to GC-induced apoptosis after BAG-1 overexpression, while 
sensitivity to GC was restored after rapamycin treatment which downregulated BAG-
1 (Kullmann et al., 1998). 
By correlating prednisolone sensitivity in vitro with gene expression microarrays in a 
cohort of 444 patients, researchers from St. Jude Children’s Research Hospital 




resistance was induced by overexpression of CASP1. GR was cleaved at the 
transactivation domain by CASP1, which can be reversed by RNA interference of 
CASP1 (Paugh et al., 2015). 
 
1.5.5 Transcription Factors and Epigenetic Regulations 
In BCP-ALL patients, mutations in CREBBP (CREB binding protein) resulting in a 
defective histone acetyltransferase domain have been identified in patients who 
experienced induction-treatment failure. Notably, the dysregulated targets of CREBBP 
include many GC-regulated genes. In vitro testing of vorinostat demonstrated GC-
resistant T-ALL cell lines were sensitive to HDAC inhibition, providing a potential new 
therapy for GC-resistant ALL (Mullighan et al., 2011). More recently, by comparing 
open chromatin domains of lymphocytes and non-lymphoid cell types, as well as GC-
associated transcriptome and epigenome, lymphocyte-specific open chromatin 
domains (LSOs) were identified. In GC-sensitive cells, DNA regions such as promoters 
and enhancers with lymphocyte-specific chromatin access were unmethylated 
(enhancers) and bound to CTCF (CCCTC-Binding Factor). Subsequently, after GC 
stimulation, the GR translocated to the nucleus and bound adjacent to CTCF at 
enhancer regions facilitating the formation of an active and accessible loop to initiate 
transcription of specific genes, such as BCL2L11. On the contrary, the same regions 
were highly methylated in GC-resistant cells similar to non-lymphoid cell types. 
Without lymphocyte-specific chromatin access, the association of CTCF and DNA 
looping after GR incorporation was inhibited which caused silencing of GR-targeted 




1.6 Hypothesis and Aims 
T-ALL represents approximately 15% of paediatric ALL. Although the prognosis is 
generally good, cure is achieved by intensive chemotherapy often accompanied by 
acute and chronic side effects. The prognosis for relapsed T-ALL remains extremely 
poor (Bhojwani and Pui, 2013). These patients represent an unmet medical need and 
urgently require an improved understanding of the mechanisms underlying T-ALL drug 
resistance and novel targeted therapies.  
The checkpoints during T-cell development are provided by the pTCR during β-
selection and TCR in positive/negative selection (Li and Rudensky, 2016). According 
to their established roles in normal thymocyte development, namely to govern life-
death decisions and promote survival and proliferation, it seems reasonable to suggest 
that aberrant pTCR and TCR signalling might be critically involved in transforming 
thymocytes into cancer cells and/or remain involved in T-ALL progression. Currently 
known gene lesions in T-ALL such as NOTCH1, FBXW7/CBL, PTPRC, PI3K/AKT, 
RAS and NF1, are situated proximally, distally or around the pTCR and TCR signalling 
complex, and might affect pTCR/TCR signalling activity.  
The oncogenic role of pBCR signalling in BCP-ALL has been established and has 
been validated as a valid drug target to treat leukaemia (Rickert, 2013). pTCR/TCR 
signalling is similar to pBCR-signalling, as they share multiple downstream signalling 
pathways. Moreover, their functions in lymphocyte development are highly analogous 
(Reth and Brummer, 2004). 
The T-cell specific SFK, namely LCK, is a central molecule in pTCR/TCR signalling 
transduction. A critical role for LCK has already been shown in Chronic Lymphoblastic 
Leukaemia in enhancing the oncogenic role of BCR signalling (Harr et al., 2010). The 





My hypothesis is that the pTCR/TCR signalling pathway, or components thereof, 
provide proliferative and survival advantage to malignant T-cells and, thus, might 
represent a novel drug target.  
My aims are to explore the functional role of pTCR/TCR pathway elements in T-ALL 
cellular behaviour and drug resistance, as well as to investigate their value as novel 
drug targets. To accomplish this several main approaches are used: (1) shRNA 
screening to investigate the role of different components of the pTCR/TCR signalling 
complex in the maintenance of T-ALL, (2) The top hit of the shRNA screen, i.e. LCK, 
was further studied for its dependency of the proliferation/survival of T-ALL cells after  
gene modulation of LCK or use of dasatinib to study, (3) Development of a novel and 
highly-efficient drug combinations for T-ALL by using drug matrixes in a panel of T-
ALL cell lines and primary cells, (4) Translation of findings into immunocompromised 
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2.1 Patient Samples 
2.1.1 Patient Samples 
The patient-derived material was collected as part of diagnostic investigations of 
patients at the Great North Children’s Hospital, Department of Paediatric Haematology 
and Oncology, Newcastle upon Tyne, United Kingdom. The material was collected 
and stored with informed consent obtained from all subjects in accordance with the 
Declaration of Helsinki. Samples with explicit written consent for in vivo studies were 
requested from the Newcastle Biomedicine Biobank, Newcastle University, United 
Kingdom and used according to approvals given by the Newcastle Biomedicine 
Biobank (NHB application NHB-008) and the local institutional review board Newcastle 










TAL1 CASP8AP2 T-ALL14 46, XY, del(6)(q13q23) 































T-ALL3 46, XX  
biallelic loss 14q11.2 14q32.33  
an interstitial deletion of TCRA 
or unbalanced TCRA rearrangement 

























T-ALL32 46, XY 
t(11;19)(q23;p13.3) 
KMT2A-MLLT1 
Table 1. Details of patient samples used in this project to generate PDXs. The 
unique patient number (UPN), (PDX T-ALL ID used in this study), gender and disease 
status, characterised oncogenes and deletions and cytogenetics are shown. 
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2.1.2 Generation of Patient-Derived Xenograft 
Patient-derived xenografts (PDX) were harvested from the NOD.Cg-
PrkdcscidIl2rgtm1wjl/SzJ (NSG) mice after the engraftment of patient samples. In this 
study, patient samples (usually 1x106 or 2 x106 cells per mouse) were intrafemoral 
injected into NSG mice. Peripheral blood samples may be taken by tail bleeding used 
for leukaemia engraftment staining. Mice were weighed weekly and monitored daily. 
Once they showed signs of illness, enlarged spleens (can be seen as a darker area 
through the skin when scruff handling of mice), or weight loss >15% for three 
consecutive days, they were humanely killed by a schedule 1 method (dislocation of 
the neck). Bone marrow and spleen samples were collected. Spleen samples were 
homogenized through a cell strainer and bone marrow samples were harvested by 
flushing the lumens with PBS or crushing bones with a pestle and mortar with PBS. 
 
2.2 Tissue Culture 
2.2.1 T-ALL Cell Lines 
SUPT1, CUTLL1, MOLT4, Jurkat, HPB-ALL and CCRF-CEM were cultured in 
RPMI1640 (Roswell Park Memorial Institute 1640, Sigma Aldrich#R8758, Dorset UK) 
with 10% FBS (ThermoFisher#10500-064, Paisley UK). HSB-2, KOPT-K1, ALLSIL, 
DU528 and MOLT16 were cultured in RPMI1640 with 20% FBS (Table 2). All cell line 
were cultured in a 5% CO2 and humidified atmosphere at 37°C. All T-ALL cell lines 
used in this study were authenticated by STR (Short Tandem Repeat) profiling 
analysis (NewGene, Newcastle upon Tyne, UK).  
2.2.2 Other Cell Lines 
Human embryonic kidney 293T cells (293T) are cultured in DMEM (Dulbecco’s 
modified Eagle’s medium, Sigma Aldrich#D6171, Dorset UK) with 10% FBS, 2 mM L-
Glutamine (Sigma Aldrich#G7513, Dorset UK) and 1 mM Sodium Pyruvate (Sigma 
Aldrich#S8636, Dorset UK). The murine stroma cell line OP9-DL1 used in these 
studies was kindly provided by Professor Sophie Hambleton, Newcastle University, 
United Kingdom and is subject to a Material Transfer Agreement between Sunnybrook 
Health Sciences Centre, Toronto, Canada and Newcastle University, United Kingdom. 
OP9-DL1 cells were cultured in MEMα (Minimum Essential Medium α, 
ThermoFisher#12561056, Paisley UK) with 20% FBS.  
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TCRαβ-   CDKN2A t(11;14)(p13;q11) 
LMO2/TTG2-TRD  













































Table 2. Details of T-ALL cell line used in this study. The origin of cell lines are 
listed (age, gender, diagnosis/relapse, ATCC or DSMZ ID, diseases). Characteristics 
of cell lines showed as TCR expression, gene mutation, deletion and cytogenetics. 
Abbreviations: T-LBL (T-cell lymphoblastic lymphoma), T-NHL (T-cell non-Hodgkin 
Lymphoma), LS (lymphosarcoma). 
Materials and Methods 
58 
 
2.2.3 The Co-culture of PDX Cells 
PDXs were co-cultured in vitro with OP9-DL1 in StemSpan Serum-Free Expansion 
Medium II (STEMCELL#09655 Cambridge UK) medium supplemented with 20% FBS, 
human IL-7 (interleukin 7, 10 μg/ml) (PeproTech#200-07, London UK) and SCF (stem 
cell factor, 100 μg/ml) (PeproTech#300-07, London UK). The feeder cell line OP9-DL1 
was seeded in 12-well plates (0.45 x 104 cells/well) (Corning#3513, NY USA) one day 
before seeding PDX cells. Cell counts and viability were checked under the 
microscope by Trypan blue solution (Sigma Aldrich, Dorset UK) for both PDXs and 
feeder cells. The proliferation of PDXs was estimated by cell counts and/or cell cycle 
staining (see Ch2.10.2) once a week. 
 
2.3 Plasmids and Cloning 
The shRNA plasmids were based on the pLKO5d.SFFV.eGFP backbone (kindly 
provided by Jan-Henning Klusmann, MHH Hannover (Schwarzer et al., 2017)). 
Oligonucleotides encoding for the shRNA were designed by myself, synthesised by 
Sigma Aldrich, phosphorylated by T4 PNK (Polynucleotide kinase, Thermo Scientific, 
Paisley UK), annealed at a 95°C heat block slowly cooling down to room temperature. 
The pLKO5d.SFFV.eGFP vector was digested using BsmB1 (Esp3I ThermoFisher, 
Paisley UK) and purified by agarose gel and Qiagen Gel Extraction Kit (ID 28706, 
Valencia CA). Ligation of the annealed oligonucleotides with the digested vector 
results in a new construct that will target the respective gene products (Figure 11). 




Figure 11. The schematic diagram of pLKO5d.SFFV.eGFP plasmid. RRE, Rev 
response element enhances titre by increasing packaging efficiency of full-length viral 
genome; 5’ LTR, 5’ long terminal repeat; 3’ SIN LTR, 3’ self-inactivating LTR for 
increased lentivirus safety; SFFV promoter, spleen focus-forming virus promoter; 
eGFP, enhanced Green fluorescent protein. 
 
2.4 Lentivirus Production and Cell Transduction 
2.4.1 Lentivirus Production 
Lentivirus was generated in 293T cells. One day before co-transfection with a second-
generation lentiviral vector pMD2.G and pCMV ΔR8.91 (Bomken, Buechler et al. 
2013), 1 x 106 293T cells were seeded per 10 cm plate (Corning, USA). For co-
transfection, 5 μg pMD2.G, 15 μg pCMVR Δ8.91 and 20 μg of the lentiviral vector were 
mixed to a final volume of 500 μl containing 0.25 M CaCl2. This solution was slowly 
mixed with 500 μl 2xHeBS (0.28 M NaCl, 0.05 M HEPES, 1.5mM Na2HPO4, pH 7.0) 
drop by drop. After thorough mixing, the mixture was left for 30-40 mins at room 
temperature. The 1 ml transfection mix was gently dropped onto a 293T monolayer of 
25-35% confluency. On the 3rd day, the cells were carefully washed once with PBS, 
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and fresh cell culture medium was added. After culturing the cells for 72 hours, the 
supernatant containing lentivirus was harvested and filtered through a 0.45 μM 
Syringe Filter (StarLab, UK). 
The filtered lentivirus was either added directly to T-ALL cells or concentrated to 
improve the transduction efficiency. Lentivirus was centrifuged by ultra-centrifuge 
centrifugation (Beckman Coulter Optima XE-100, IN, USA) of 26,500 x g at 4°C for 
two hours and re-suspended in an appropriate volume of 100 μl – 500 μl cell culture 
medium. 
 
2.4.2 Transduction of T-ALL Cells 
T-ALL cells were seeded in 48-well plates with 1 – 2 x 106 cells per well and transduced 
in the presence of 0.1% polybrene (8 µg/ml final) by spinfection at 900 x g for 50 mins. 
After spinfection the cells were cultured, and the next day the majority of the lentiviral 
and polybrene containing supernatant was removed from the cells, before the addition 
of fresh RPMI1640 and transfer of cells to a 24-well plate. The transduction efficiency 
was measured by flow cytometry 6 days post-transduction. 
 
2.5 Targeted shRNA Screening 
2.5.1 Library Preparation 
A library of short hairpin RNA (shRNA) targeting PTCRA, LCK, FYN, ZAP70, CD3E 
and LAT was generated (Table 3). Positive and negative controls comprising 18 
shRNAs were selected based on in-house RNAi screens in different types of cancers. 
All shRNAs cloned into pLKO5d.SFFV.eGFP vectors were verified using Sanger 
sequencing (Source Bioscience, Nottingham UK). 
  




Gene Oligo Sequences  5’ → 3’ 




















































































22F shRPS29#2 AGCGACGGCACGGTCTGATCCGGAAATAGTGAAGCCACAGATGTATTTCCGGATCAGACCGTGCCGG 






























































Table 3. Oligonucleotide sequences of the targeted shRNA screen library 
comprising of 36 shRNAs. Both forward (5’→ 3’ starting with AGCG) and reverse 
(5’→ 3’ starting with GGCA) sequences are shown. Three shRNAs per gene targeting 
FYN, LCK, PTCRA, ZAP70, LAT and CD3E as well as PTEN have been used. 
 
All plasmids were equally pooled together before generating lentiviral shRNA library. 
The non-concentrated virus was titrated on T-ALL cell lines (50 - 500 μl) and the 
transduction was performed as described above (Chapter 2.4.2). Transduction 
efficiency was estimated by GFP expression analysed by flow cytometry using a BD 
FACS Calibur (BD Biosciences, Wokingham UK). Cells transduced by approximately 
20 - 30% were selected to reduce the risk of multiple integrations (Fehse et al., 2004). 
Samples were collected at baseline, day 16, 30 and 40 for the in vitro screen.  
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T-ALL PDXs (L963, LK203 and LK080) were transduced with concentrated lentivirus 
(2 x 106 cells were transduced with virus that were concentrated from 30 ml 
supernatant). Baseline samples (2 days after transduction) were taken before PDXs 
were injected into NSG mice (2 x 106 cells per mouse). Mice were kept until they began 
to exhibit clinical signs which necessitated humane killing. Spleen and bone marrow 
samples were harvested by homogenising material through a cell strainer with PBS or 
by flushing the lumens with PBS, respectively.  
Genomic DNA (gDNA) was extracted using a DNeasy Blood&Tissue Kit 
(Qiagen#69504, Manchester UK). In general, cell pellets were suspended in 180 μl 
ATL buffer. After mixing with 20 μl proteinase K, samples were incubated at 56°C for 
1h with occasionally vortexing to disperse the sample. Later add 200 μl Buffer AL and 
vortex again. 200 μl ethanol (96-100%) was added and mixed thoroughly to yield a 
homogeneous solution. The mixture was transferred into the DNeasy Mini spin 
column. After centrifugation (8000 g for 2 mins), Buffer AW1 was added to the column 
with a new collection tube. Finally, gDNAs were eluted in distilled water.  
The gDNA was quantified by Nanodrop ND-1000 (Thermo Scientific, Paisley UK). 
Library amplification was performed using 1xPhusion GC-rich buffer, 200 μM of each 
dNTPs, 0.5 μM NGS-F3 primer, 0.5 μM reversed indexed primer, 0.04U/μl Phusion 
Hot Start II DNA polymerase (ThermoFisher#F549L, Paisley UK) and 825 ng gDNA 
per reaction (50 µl per reaction). The resulting amplicons were analysed by agarose 
gel (agarose, Sigma; O’RangeRuler Ladders and GeneRuler 1kb DNA Ladder, 
ThermoFisher) and purified by QIAGEN Gel Extraction Kits (ID 28706, Valencia CA). 
Pooled amplicons were sequenced by next-generation sequencing (NGS) (Illumina 
MiSeq) at Newcastle University Genome Core Facility. 
 
2.5.2 NGS Bioinformatics Analysis 
The NGS bioinformatics analysis were done by Sirintra Nakjang from Bioinformatics 
Support Unit (Newcastle University). Raw sequencing reads were trimmed at both 
ends up to the locations of barcode sequence before aligning to the reference shRNA 
barcodes using Bowtie2 (Langmead and Salzberg, 2012) with a zero mismatch 
tolerance. An in-house script was used to extract read counts from aligned sequence 
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files. Differential representation analyses of aligned read counts from different screen 
datasets were performed as described in Dai et al. using edgeR (Dai et al., 2014; 
Robinson et al., 2010). In brief, read counts were normalised to adjust for library size 
differences across samples. The likelihood ratio test method based on generalised 
linear models (GLM) framework in edgeR was used to test for differential 
representation of shRNA barcodes.  
For screen data from cell lines, time-course differential representation analysis with 
replicates was performed to identify shRNAs with changes in their abundance over 
time (days 0, 16, 30 and 40). The analysis was performed for each cell line 
independently. Depletion of shRNAs over time was allocated a negative slope of the 
regression line, whereas enrichment of shRNAs was allocated a positive slope. 
For the primograft LK203 in vitro screen dataset, we treated samples from different 
time points (day 16 and day 30 with/without mesenchymal stem cell) as non-baseline 
samples and tested for differential representation between the baseline samples and 
non-baseline samples.  
To control for unwanted variation (e.g. biological, technical) between samples derived 
from the in vivo screen dataset, the RUVg approach was employed to estimate factors 
of unwanted variation under the assumption that our negative controls (i.e. non 
targeted control (NTC) and shRNA targeting RUNX1/ETO) had constant 
representation across samples (Risso et al., 2014). 
To adjust for this unwanted bias, the estimated factors of unwanted variation as well 
as the covariate of interest were both included in the model for differential 
representation analysis which was performed on upper-quartile normalised counts 
using the GLM approach from edgeR as described above. In this dataset, we tested 
for differential representation between baseline samples and samples either from 
spleen or bone marrow separately. 
 
2.6 RNA Extraction and Quantitative Real-Time PCR 
RNA was extracted from 5 x 106 cells by using the RNeasy Mini Kit (Qiagen#74106, 
Manchester UK) and working after the manufactory recommendations. Briefly, cells 
were collected at 500 g for 3 mins and lysed in RLT buffer with 1% β-mercaptoethanol. 
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The cell lysates were transferred to the QIAshredder column and centrifuged at 8000 
g for 2 mins. The flow-through was mixed with 70% Ethanol and moved to the RNeasy 
mini-spin column. After the centrifugation, the flow-through was discarded, and the 
column was washed twice with RW1 and RPE buffer respectively. Finally, the column 
was dried off by centrifugation at maximum speed for 2 mins. The RNA was dissolved 
in RNase-free water and eluted from the column by centrifugation at 8000 g for 2 mins. 
The cDNA was synthesised using RevertAid H Minus First Strand cDNA Synthesis Kit 
(Thermo scientific#1631, Paisley UK). Briefly, 200 - 1000 ng of RNA was mixed with 
1 μl of the random hexamer. RNase-free water was used to make a total volume of 12 
μl. They were incubated at 70°C for 5 mins and cooled down to 4°C using the Applied 
Biosystems thermocycler (GeneAmp PCR system 2700, ThermoFisher, Paisley UK). 
A master mix which contained 4 μl MMLV buffer (5x), 2 μl dNTP, 1 μl RNase inhibitor 
and 1 μl MMLV RT enzyme for each sample was prepared. Eight μl of the master was 
mixed with each sample and PCR tubes were incubated in the thermocycler at 42°C 
for 60 mins followed by an incubation at 70°C for 10 mins.  
For quantitative real-time PCR (qRT-PCR), the Applied Biosystems ViiA 7 
(ThermoFisher, Paisley UK) was used. The template cDNA (20 μl of the cDNA 
synthesis reaction) was diluted in 80 μl ddH2O. The primers for qRT-PCR (Table 4) 
were ordered from Sigma Aldrich (Dorset UK). Relative mRNA expression was 
expressed as 2-DCt (Livak and Schmittgen, 2001). 











Table 4. The qRT-PCR primers used in this study. The primer sequences were 
designed by myself using NCBI (National Centre for Biotechnology Information) 
Primer-BLAST specifically for LCK, PTCRA, ZAP70, FYN and GILZ. 
 
Materials and Methods 
66 
 
2.7 Protein Assays 
2.7.1 SDS-PAGE and Western Blot 
5 x 106 cells were harvested, and the pellets were resuspended in Laemmli buffer 
(32.9 mM Tris-HCl pH 6.8, 13.15% glycerol, 1.05% SDS, 0.005% bromophenol blue, 
5% β-mercaptoethanol). After sonication (QSonica#Q125, CT, USA), protein samples 
(20-30 μg per lane) were loaded and electrophoresed in 8% PAGE gel to run for 90-
120 mins at 100 V. Proteins were transferred on to methanol activated Polyvinylidene 
difluoride (PVDF) membrane (Merck Millipore#IPVH00010, Watford, UK). After the 
transfer, the membrane was blocked with 5% milk or BSA (Fisher 
Bioreagents#BP9702, Loughborough, UK). The membrane was incubated with 
primary antibodies overnight at concentrations recommended by the antibody 
datasheets. The following primary antibodies were used: LCK (#2984, clone D88), p-
SRC (Tyr416) (#6943, clone D49G4), p-LCK (Tyr505) (#2751), p-PLCγ1 (Tyr783) 
(#2821), PLCγ1 (#5690, clone D9H10) (all purchased from Cell Signalling), GAPDH 
(Cat#5G4, clone 6C5, Hytest, Finland) and Clathrin (BD Biosciences, Wokingham, 
UK). On the 2nd day, blots were washed and incubated with respective secondary 
antibodies from Dako (CA, USA) for 1 hour: Goat Anti-Mouse IgG HRP (P0447), Goat 
Anti-Rabbit IgG (P0448). For developing blots, Immobilon Western Chemiluminescent 
HRP Substrate (Millipore#WBKLS0500, Watford, UK) and ChemiDoc MP Imaging 
System with Image Lab Software (Bio-Rad, Watford, UK) have been used. 
 
2.7.2 Reverse Phase Protein Array 
The Reverse Phase Protein Array (RPPA) protocol was obtained from Edinburgh 
University. CUTLL1, MOLT4 and SUPT1 cells (1 x 107 cells) were pelleted (300xg, 5 
mins), washed once with ice cold PBS and resuspended in 700 μl Lysis buffer (1% 
Triton X-100, 50 mM HEPES, pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 100 
mM NaF, 10 mM sodium pyrophosphate, 10% glycerol, containing freshly added 1 
mM Na3VO4, protease and phosphatase inhibitors from Roche. A homogenous lyses 
of the cells was ensured by pipetting the lysates up and down and vortexing of the 
samples for 15 seconds followed by an incubation on ice for 30 mins and repeated 
vortexing. The cell lysate was centrifuged at 15,000 rpm for 10 mins at 4°C. The 
supernatant was carefully collected, 10 μl was used for protein quantification; 100 μl 
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was used for total cell lysate; the rest of samples were shipped on dry ice to the 
Protein/Antibody Microarray Facility of Edinburgh University. 
For protein quantification Protein Assay (5x) (Cat#500-0006, Bio-Rad, Watford, UK) 
was used. Briefly, dilute one part 5x assay buffer with four parts of distilled water. 
Samples for a standard curve was generated using 2 mg/ml BSA dilutions (0, 0.05, 
0.1, 0.15, 0.2, 0.3, 0.4 mg/ml) in 100 μl PBS each. Cell lysates were diluted in PBS 
(1:10 or 1:20) to a final volume of 100 μl, and 1 ml of 1x Protein Assay Buffer was 
added to each sample. Samples were loaded in a 96-well plate in quadruplicates and 
the absorbance readings at 595 nm were acquired by the POLARstar Omega plate 
reader (BMG LABTECH, Bucks, UK). Data was analysed in Mircosoft Excel and 
protein concentrations were calculated from the BSA standard curve. 
 
2.8 Competitive Assay 
2.8.1 In vitro Competitive Assay in T-ALL Cell Lines 
In vitro T-ALL cells (1 x 106) were transduced with shRNA lentiviral supernatant (500 
μl). Transduction efficiencies as demonstrated by GFP expression were determined 
by flow cytometry at day 6. On the same day, 5 x 106 cells were mixed with parental 
cells to generate approximately 50% GFP expression. The exact percentage was 
determined again after mixing by flow cytometry. These cells were cultured for 4 - 6 
weeks and the GFP expression was assessed every three days. A relative GFP 
expression of 1 denotes a mixture of 50% GFP+ cells with 50% parental cells (ratio 
1:1). Graphs were generated by using GraphPad Prism (version 6, CA, USA). 
 
2.8.2 Competitive Assay of MOLT4 and Jurkat Engraftment in vivo 
MOLT4 cells were transduced with either pLKO5d.SFFV.RFP657-shNTC (kindly 
provided by O Heidenreich) or pLKO5d.SFFV.eGFP-shLCK#3. After six days, the GFP 
and RFP expression were determined by flow cytometry, and cells were mixed to give 
a 1:1 ratio of RFP:GFP. In total, 1 x 107 cells were injected intrafemorally into five NSG 
mice. Twenty-six days post-injection mice showed signs of ill health and were 
humanely euthanised. Samples were collected from bone marrow, spleen and liver. 
Fluorescence expression levels were determined by using flow cytometry. The 
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RFP:GFP ratio was calculated to assess cell composition after leukaemia propagation 
in vivo. 
The in vivo competitive assay of Jurkat cells was performed with pLKO5d.SFFV.eGFP 
empty vector transduced cells. Approximately 95% of these cells were GFP+, thus 
GFP positivity was used as a marker for the presence of Jurkat cells derived from 
mouse samples. To compare the LCK effects on leukaemia propagation in vivo, cells 
were transduced with pLKO5d.SFFV.RFP657-shNTC and pLKO5d.SFFV.dTomato-
shLCK#3. Similar to MOLT4, cells were mixed and had an equal distribution of RFP 
and dTomato before injection into five NSG mice. All five mice were harvested 22 days 
after injection due to 11-19% of weight loss. Spleen and bone marrow samples were 
collected as described above and assessed by flow cytometry. 
 
2.9 siRNA to Knockdown LCK in PDXs 
The siRNAs against LCK were adapted from the core sequences of shLCK#3 and 
purchased from Sigma Aldrich (Dorset, UK). Lyophilsed sense and antisense siLCK 
strand were reconstituted in hybridisation buffer (25 mM HEPES, 100 mM NaCl, pH 
7.5) at a final concentration of 100 μM, mixed 1:1 equal molar quantity of and 
hybridised by initial incubation at 95°C followed by a slow cooling down to room 
temperature. 
Oligo  Length Sequence (5'-3') 
siLCK 21 CCAUCUACAUCAUCACUGA[dT][dT] 
siLCK_as 21 UCAGUGAUGAUGUAGAUGG[dT][dT] 
Table 5. siLCK sequences. The lengths of both LCK siRNAs are 21 nucleotides with 
19-base core sequences and 3’ dTdT (deoxyribonucleotides) to confer nuclease 
resistance. 
 
On the day of electroporation, PDX cells were counted and resuspended at 2 x 107 
(for the 1st electroporation) or 1x107 (for the 2nd and 3rd electroporation) density in 4 
mm gap width electroporation cuvettes (Cat#450135, BTX Molecular Delivery 
SystemsTM). Cells were electroporated sequentially three times with siLCK and siCtrl 
(siRUNX1/ETO provided by O Heidenreich) at 350V and 10 ms with 2 pauses. Cell 
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cycle analysis was performed on day 3, 6 and 9. LCK knockdown levels were 
measured by flow cytometry after the intracellular staining of LCK and p-SRC. 
 
2.10 Flow Cytometry 
2.10.1 Intracellular PhosFlow Staining 
For each sample, 3 x 106 cells were harvested for intracellular staining of LCK and 
pSRC and transferred into three FACS tubes (BD#352054, Wokingham, UK). Cells 
were washed once with cold PBA (PBS, 1% BSA and 0.05% NaN3), fixed in Cytofix 
Fixation Buffer (BD Biosciences#554655, Wokingham, UK) for 15 mins at 37 degree, 
washed and permeabilised in PermBuffer III (BD Biosciences#558050, Wokingham, 
UK) for 30 mins on ice. Cells were left unstained (i) no stain control (mouse serum 
(Sigma Aldrich#M5905, Dorset, UK)) or were stained with (ii) control IgGs (mouse 
serum, PE-IgG1 control (R&D#IC200P, Abingdon, UK), Alexa Fluor 647-IgG control 
(Biolegend#400130, London, UK)) or (iii) LCK/pLCK specific stain (mouse serum, 
Alexa Fluor 647-LCK (0.38 µl/sample) (BioLegend#628303, London, UK), PE-Src 
(Y418, 7.5 µl/sample) (BD Biosciences#560094, Wokingham, UK) in a final volume of 
50 µl PBA for 45 min on ice in the dark. Cells were washed twice in PBA and fixed in 
2% PFA (Paraformaldehyde in PBS (pH=7.4) prepared in-house) and analysed on BD 
FACSCantoTM II (BD Biosciences, Wokingham, UK). 
 
2.10.2 Cell Cycle Assay 
Cell cycle analysis was performed using Propidium iodide (PI, Sigma Aldrich#P4170, 
Dorset, UK) or Hoechst 33342 (Sigma Aldrich#14533, Dorset, UK) on the BD Calibur 
or BD FACSCantoTM II. For PI staining, 1 x 106 cells were resuspended in 200 μl citrate 
buffer (0.25 M sucrose, 40 mM sodium citrate, pH 7.6). Subsequently 800 μl staining 
solution (20 μg/ml PI, 0.5% NP40, 0.5 mM EDTA in PBS, pH 7.2) and 2 μl RNase A 
(50 mg/ml) were added to the cells. Cells were analysed by flow cytometry 
immediately. For Hoechst 33342 staining, 1 x 106 cells were washed and resuspended 
in 1 ml cell culture medium containing 10 μl Hoechst 33342 (stock concentration 10 
mg/ml). After 15 mins incubation, cells were analysed on the FACSCantoTM II. 
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2.10.3 Apoptosis Assay 
Apoptosis assays were performed using PE-Annexin V and 7-AAD (BD 
Biosciences#559763, Wokingham, UK) as per manufacturer’s instructions or APC-
Annexin V (Biolegend#640920, London, UK) and LIVE/DEAD Fixable Aqua 
(ThermoFisher#L34966, Paisley, UK) on the BD LSRFortessaTM X-20 or Attune NxT 
(ThermoFisher Invitrogen, Paisley, UK). Briefly, 1 x 106 cells were washed twice with 
cold PBS and resuspended in 1mL 1 x Binding buffer of which 100 μl of sample was 
transferred to a new tube with the addition of 5 μl Annexin V and 5 μl 7-AAD (or 0.5 μl 
LIVE/DEAD Fixable Aqua). After 15 mins incubation at room temperature in the dark, 
samples were taken for flow cytometry analysis. 
 
2.10.4 Mouse Peripheral Blood Staining 
For the determination of murine peripheral blood engraftment with human T-ALL 
blasts, 20 µl of mouse blood samples were incubated with APC-huCD45 (HI30, 10 
µl/sample) (BD Biosciences#555485, Wokingham, UK), PE-huCD7 (M-T701, 10 
µl/sample) (BD Biosciences#555361, Wokingham, UK) and BV421-mCD45 (30-F11, 
2 µl/sample) (BD Biosciences#563890, Wokingham, UK) for 20 mins at room 
temperature in the dark. Red cells were lysed by using freshly prepared lysis buffer 
(155 mM NH4Cl, 12 mM NaHCO3, 0.1 mM EDTA) for 10 mins. Thereafter, LIVE/DEAD 
Fixable Aqua (ThermoFisher Paisley UK) was added to cells followed by 10 mins 
incubation in the dark. Finally, the samples were fixed in 2% (PFA) (Paraformaldehyde 
in PBS (pH=7.4) prepared in-house) and analysed on the BD FACSCantoTM II. The 
raw data were analysed and visualised using FlowJo (FlowJo_v10, Oregon, USA). 
 
2.10.5 Cell Trace Violet Proliferation Assay 
2 x 107 L963 cells were incubated with 5 μM Cell Trace Violet (CTV) 
(ThermoFisher#C34571, Paisley UK) for 20 mins at 37°C. To stop the reaction, FBS 
was used at the final concentration of 10%. Cells were washed in PBS and reseeded 
in SFEM II medium with OP9-DL1 cells. Two weeks later, cells were separated from 
feeder cells by multiple transferring of non-adherent cells over a time period of 4 - 6 
hours. BD FACSCantoTM II was used to assess CTV distribution at the excitation / 
emission of 405/450 nm. Data were interpreted by using FlowJo. 
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2.11 Drug Matrix Assays 
T-ALL cell lines were seeded at 4 x 104 and 90 µl per well in 96-well plates 
(Corning#3598, NY, USA). Dasatinib (0 – 30 μM) (DC Chemicals#302962-49-8, 
Shanghai, China), Dexamethasone (0 – 15 μM) (Sigma Aldrich, Dorset, UK), MK2206 
(0 – 50 μM) (Cat#CAY11593, Cambridge Biosciences, Cambridge, UK), SCH772984 
(0 – 50 μM) (Cat#CAY19166, Cambridge Biosciences, Cambridge, UK) were titrated 
and added to T-ALL cells in a 10 µl volume, and cultured for 72 h in a 37°C cell 
incubator. Assays were performed in triplicates. Cell proliferation and cytotoxicity were 
assessed after three days using Cell Counting Kit 8 (CCK-8, NBS Biologicals, 
Cambridgeshire, UK). The tetrazolium-based substrate was added to each well and 
the absorbance was measured at OD450 nm in a POLARstar Omega plate reader 
(BMG LABTECH, Bucks, UK). IC50 (half-maximal inhibitory concentration) or GI50 
(growth inhibition of 50%) values were determined by using the GraphPad Prism 
software. 
To investigate the combined effect of dasatinib and dexamethasone, drug matrix 
assays were performed using T-ALL cell lines and PDX cells. Cells (4 x 104 cells per 
well for T-ALL cell lines and 8 x 104 cells per well for PDX cells in a volume of 80 µl 
were seeded in 96-well plates. PDXs were expanded ex vivo by co-cultured with OP9-
DL1 cells for 1-2 weeks. To seed PDX cells for the drug matrix assays, PDXs and 
feeder cells were harvested by trypsinisation. PDX cells were separated from OP9-
DL1 cells by multiple transferals of the non-adherent cells into a new plate as 1-2 hours 
was sufficient for OP9-DL1 cells to adhere to the plate. Dasatinib (80 nM – 50 μM) and 
Dexamethasone (0.09 nM – 600 nM) were titrated and added to cells (10 µl each) in 
2-dimensions to create a 6 x 10 matrix. After 72 h culturing of the cells, the plates were 
developed with CCK-8 and read by an Omega plate reader. Cell viability data were 
analysed for drug-combination synergy by using Combenefit software (v2.021) (Di 
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2.12 Mouse Work 
Mice used in this project were bred and housed in the Newcastle University 
Comparative Biology Centre under specific pathogen-free conditions. A flow hood 
(FASTER S.r.l, Cornaredo (MI), Italy) was used for sterilised manipulations or 
experiments. All mouse work was approved and followed Home Office Project License 
PPL60/4552 and carried out by researchers with Home Office Personal License under 
the Animal (Scientific Procedures) Act 1986. All mice were humanely killed by a 
schedule 1 method when they exhibited endpoints as specified by the license. 
 
2.12.1 Toxicitiy Study 
A pilot toxicity study in a small number of NSG mice was carried out to explore the 
maximal tolerant dose of dasatinib in combination with 1 mg/kg dexamethasone. Six 
healthy mice (three males and three females) were dosed daily (Monday to Friday) 
with a combined administration of 1 mg/kg dexamethasone and dasatinib by 
intraperitoneal (IP) injection. Mice were examined and weighed daily upon drug 
administration. The starting dose of dasatinib was 5 mg/kg. This was increased weekly 
to 10 mg/kg, 20 mg/kg and 35 mg/kg (set as the highest dose) of dasatinib in 
combination with 1 mg/kg dexamethasone. At the 3rd week of treatment at 1 mg/kg 
dexamethasone and 35 mg/kg dasatinib, all six mice lost 10-15% of weights indicating 
that they could not tolerate this dose. Dosing was stopped, and weights were 
monitored continuously for ten days.  
 
2.12.2 The Murine Phase II-like Clinical Trial 
The power analysis of this in vivo study was based on the ‘resource equation’ 
approach (Arifin and Zahiruddin, 2017): 
n = DF/k + 1 
In this equation, k = number of treatment groups, and n = number of mice per group. 
The acceptable range of DF (degrees of freedom) is between 10 to 20 (R. Mead, 
2012). In this study, we have used a paired T-test. In this case, k is set equal to 2. 
Therefore, minimum n = 10/2 + 1 = 6; maximum n = 20/2 + 1 = 11. Taken together, 
the total sample size of this in vivo study should be 24 – 44 mice in order to compare 
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the control vehicle, dasatinib-treated, dexamethasone-treated and drug combination-
treated group. 
Acute leukaemia PDXs that mimic human randomised clinical trials can characterise 
drug efficacy and generate potential biomarkers in both treatment-naïve and 
relapsed/refractory disease (Townsend et al., 2016). Ten PDXs were used for the 
phase II-like trial in vivo. All 10 PDXs were generated from NSG mice which were 
injected with primary patient samples previously. For each PDX sample, 2 x 106 cells 
were intrafemorally injected into 4 NSG mice each (40 mice in total). The 4 NSG mice 
derived from one PDX sample were matched for gender and age. Human T-ALL 
engraftment in mouse peripheral blood was monitored weekly by tail vein bleeds (20 
μl blood/mouse) using hCD7/CD45 and mCD45 as marker proteins. The four mice of 
each PDX were randomised to receive the vehicle, dasatinib alone, dexamethasone 
alone or combination treatment by intraperitoneal (IP) injection upon engraftment of ≥ 
0.5% peripheral blood hCD45+/hCD7+ cells. Treatment was given for two or three 
weeks depending on the clinical status of the mice. When any of the four mice 
displayed signs of ill health or weight loss, all four mice derived from one PDX were 
sacrificed at the same time to assess leukaemia engraftment in bone marrow, spleen, 
liver and CNS. Spleen and liver samples were collected by homogenising material 
through a cell strainer with PBS. Bone marrow samples were collected by flushing the 
lumens or crushing bones with a pestle and mortar with PBS. Flow cytometry was 
performed on the BD FACSCantoTM II, and data were analysed by FlowJo. GraphPad 
Prism was used to visualise the data and statistic was achieved by using RStudio (MA, 
USA) with a linear mix model. Murine heads were stripped of soft tissues and 
decalcified in Hilleman and Lee EDTA solution (5.5% EDTA in 10% formalin) for 3 
weeks, then trimmed and put in fresh EDTA for 4 days. Samples were processed on 
a Tissue-Tek VIP processor using a routine overnight 17.5 hour cycle. Following 
paraffin wax embedding, 2.5µm sections were cut onto Poly-L-silane coated slides. 
Sections were then stained with Gill’s haematoxylin and Putt’s eosin (both made in 
house). Quantification of CNS infiltration was performed using a Hamamatsu 
Nanozoomer Digital Pathology slide scanner with digital slide management/image 































The RNAi screens in T-ALL cells were used for identification of leukaemia 
vulnerabilities and drug resistance in several studies. In Notch1-induced T-ALL, miR-
19 facilitates leukaemia progression in vivo. A genome-wide screen comprising of 
12,000 shRNAs was performed to identify the targeted genes of miR-19 in murine cell 
line FL5-12 (Foetal Liver clone 5-12). Several PI3K regulators such as Prkaa1, Pten 
and PP2A were determined to be suppressed by miR-19. Thus, a novel oncogenic 
function of miR-19 was identified in T-ALL (Mavrakis et al., 2010). A shRNA knockdown 
screen was performed in T-ALL cell line DND41 to investigate GSI (γ-secretase 
inhibitors) resistance. The readout was an array format of cell viability dye. In this 
screen, they identified the chromatin regulator BRD4 leading to resistance to GSI. The 
BRD4 inhibitor JQ1 enhanced apoptosis, and the drug combination of GSI-JQ1 
effectively reduced primary leukaemias in vivo (Knoechel et al., 2014). TYK2 was 
identified as a critical gene regulating T-ALL survival in a tetracycline-induced shRNA 
screen targeting 1740 genes in Jurkat, CCRF-CEM and SKW-3 cells. After labelling 
shRNA-induced cells with Cy3 and un-induced cells with Cy5 and amplification and 
barcoding gDNA, amplicons were hybridised onto the microarray chip for analysing 
relative abundances of each population. After identification of TYK2, they also found 
that the TYK2-STAT1-BCL2 pathway promotes T-ALL survival. TYK2 mutations were 
discovered in 4 cell lines, and in the other TYK2 dependent cell lines IL-10/IL-10R 
activated TYK2 (Sanda et al., 2013). 
However, these shRNA screens were performed in murine or human T-ALL cell lines 
in vitro. To explore the importance of the pTCR/TCR complex for T-ALL proliferation 
or survival, targeted shRNA screens were performed not only in four T-ALL cell lines 
but also in three PDX samples in vivo. The shRNA abundance in our study was 
determined by the state-of-the-art next-generation sequencing, which increases the 





3.2 Targeted shRNA Screens in T-ALL Cells 
3.2.1 Generation of pLKO shRNA Library 
To explore the critical genes of pTCR/TCR signalling for T-ALL cell proliferation or 
survival, a library targeting six essential components of pTCR/TCR signalling complex: 
PTCRA, CD3E, LCK, FYN, ZAP70 and LAT were designed. The shRNA library (Figure 
12) also contained positive controls (shRNAs targeting RPL9 and RPS29 were 
expected to be lost because cells without ribosome genes could not survive, and 
shRNAs targeting PTEN were supposed to be enriched because PTEN is a tumour 
suppressor in T-ALL) and several negative controls (shRNAs expected to have no 
change). The negative controls were selected from in-house RNAi screens in various 
leukaemia subtypes. The core sequences of shRNAs were obtained from Dharmacon 
(http://dharmacon.horizondiscovery.com). Oligos were cloned into the shRNA 
expression vector pLKO5d-SFFV-eGFP. 
 
Figure 12. The composition of targeted shRNA screen library. The shRNA library 
was composed of 36 constructs including three shRNAs per gene for pTCR/TCR 
complex genes PTCRA, LCK, FYN, ZAP70, LAT and CD3E; two shRNAs per gene for 
depletion positive controls RPL9 and RPS29; eleven shRNAs targeting genes that 
were unlikely to change as indicated in in-house RNAi screens; and three shRNAs 






All shRNA sequences were confirmed by Sanger sequencing. Two sequences 
targeting the gene LCK (namely shLCK#1 and shLCK#3) are shown in Figure 13. 
The results confirmed the sequences originally ordered. All 36 constructs were 
confirmed to be successfully generated. 
 
Figure 13. Sanger sequencing results of shLCK#1 and shLCK#3. The 
chromatogram plots demonstrate the sequence of shLCK#1 and shLCK#3 cloned into 
the pLKO5d-SFFV-eGFP vector. Top line sequences corresponds to the designed 
shRNA sequences. Green: Adenine (A); Red: Thymine (T); Blue: Cytosine (C); Black: 







3.2.2 Primer Design and PCR Condition Optimisation for Genomic DNA 
Amplification 
Previously, our lab has performed shRNA screens using pTRIPZ and pGIPZ 
backbones. However, T-ALL cell lines are generally difficult to transduce when using 
pTRIPZ and pGIPZ. Thus, the pLKO5d-SFFV-eGFP backbone was chosen aiming for 
higher transduction efficiencies for T-ALL cell lines. The amplification primers were 
designed as follows: the forward primer fitted to the Illumina P5 sequence required for 
the attachment of the library fragment to the flow cell surface, with an additional 
sequence needed for binding of the standard Illumina sequencing primer, and a 
pLKO5d-SFFV-eGFP vector specific binding sequence; the reverse primer included 
the Illumina P3 sequence, the index sequence, and a vector specific binding sequence 
(Figure 14). After alignment those two primers which were previously used in the group 
to the pLKO5d-SFFV-eGFP vector, only the reverse primer could be used to amplify 
the shRNA region of pLKO5d-SFFV-eGFP.  The full list of reverse primers with 89 
barcodes is shown in Appendix 1. Three additional forward amplification primers were 
designed by myself accordingly. 
 
Figure 14. Primer design for shRNA library amplification. The forward primer 
(newly designed) contains Illumina P5 sequence (red), standard Illumina sequencing 
binding site (blue), stagger sequences (black) and pLKO5d-SFFV specific binding site 
(green). The reverse primer contains Illumina P3 sequence (upper case in black), index 







To design a forward primer specific for the pLKO5d-SFFV-eGFP vector, the vector 
sequences were blasted against the human genome (NCBI BLAST Genome 
(GRCh38.p12 reference, Annotation Release 109)). Primers were created 5’ of the 
shRNA cloning site within the GFP sequence. This was necessary when using the 
pLKO5d-SFFV-eGFP vector, as there were 153 bp (5’) before shRNA hairpin structure 
overlapping with Homo sapiens chromosome 6. Initially, three primer binding sites 
were selected and tested for their amplification efficiency. Full primer sequences are 
shown in Appendix 1. NGS-F1 BS (binding site) and NGS-F3 BS were overlapping and 
situated closer to the shRNA sequence while NGS-F2 BS was further upstream from 
the shRNA sequence which would generate a predicted amplification fragment of 863 
bp (Figure 15). 
 
Figure 15. Design of three primer binding sites for specifical amplification of the 
pLKO5d-SFFV-eGFP shRNA region. About 150 bp nucleotides 5’ of the shRNA 
region (red) corresponds to a sequence found in Homo sapiens chromosome 6 (black). 
NGS-F1 BS (red italic, underlined) and NGS-F2 BS (red italic, not underlined) binding 
sites were closer to the shRNA sequences compared to the NGS-F2 binding site. Final 
primers used for library amplification are highlighted in yellow (NGS-F3 BS and reverse 




The three primer sets (forward primer NGS-F1, NGS-F2, NGS-F3 and the reverse 
primer) were tested for library amplification efficiency. For this, genomic DNA (gDNA) 
of CUTLL1 wildtype (WT) cells, CUTLL1-shNTC and MOLT4-shNTC cells was used 
as PCR template. In the meantime, PCR efficiency under different buffer conditions 
was also considered. The standard buffer from Phusion High-Fidelity PCR kit was 
compared with/without the addition of MgCl2 and GC-rich buffer. Overall, all three sets 
of primers gave specific amplification (expected size of NGS-F1/R 436bp; NGS-F2/R 
863bp; NGS-F3/R 433bp) of shRNA integration sites since there was no amplification 
band in CUTLL1 WT cells. The NGS-F3 gave rise to a brighter DNA amplicon, and 
GC-rich buffer generated the maximum amount of PCR products (Figure 16). Using 
the NGS-F2 primer, a PCR fragment was generated which turned out to be too long 
for MiSeq analysis. This primer was thus not used in further experiments. Thus, the 
NGS-F3 primer and the GC-rich buffer were used for the library amplification of the 
targeted shRNA screen. 
 
Figure 16. The optimisation of primer sets and PCR buffer conditions. Three 
newly in-house designed forward primers and a reverse primer were tested. gDNA 
from CUTLL1 WT, CUTLL1 shNTC and MOLT4 shNTC was used as PCR template. 
The standard buffer with/without MgCl2 and GC-rich buffer were also tested to compare 
the amplification efficiency. The amplicons were separated on an agarose gel (2%). 
Amplicon size NGS-F1/R 436bp; NGS-F2/R 863bp; NGS-F3/R 433bp. Marker, 




Next, the effect of the number of PCR cycles on library amplification was tested. As 
expected, more thermocycles gave more abundant PCR products (Figure 17). Twenty-
three cycles was recommended by the protocol of Thermo Scientific Decode Pooled 
Lentiviral shRNA Screening Libraries, however, the yield after gel purification was not 
sufficient for NGS sequencing which requires at least 10 nM (2.6 ng/μl) of the amplicon. 
Using 27 or 31 PCR cycles, no non-specific amplification of the gDNA was observed. 
Thus, the library amplification was performed using 31 PCR cycles (Figure 17). After 
the library amplification, PCR products were purified from the agarose gel. Qubit 
Fluorometric Quantification was used to assess the yield of DNA fragments after PCR 
amplification (Appendix 2). 
 
Figure 17. Optimised PCR conditions. The PCR cycles of 23, 27 and 31 were tested 
with gDNA of CUTLL1 shNTC. A 433bp fragment was generated by the primer set of 
NGS-F3 and a reverse indexed primer. The fragments were visualised on a 2% 
agarose gel. PCR conditions are listed in the table. Marker, GeneRuler 1kb DNA 
Ladder. 
 
3.2.3 Transduction Efficiency of T-ALL Cell Lines in Targeted Screens 
Once the 36 shRNA constructs were generated, equal amounts of individual shRNAs 
were pooled together and lentiviral shRNA libraries were generated. For the targeted 
screen in T-ALL cell lines (SUPT1, MOLT4, CUTLL1 and HPB-ALL), two independent 
batches of lentiviral shRNA libraries were produced. Virus titration was performed to 
optimise for transduction efficiency (Figure 18). High transduction efficiency may result 
in multiple copies of shRNA in one cell, while low efficiency may cause low library 
complexity or non-sufficient sequencing depth. Therefore, a range of 20 - 30% 




approximately one shRNA integration site per cell (Fehse et al., 2004). Overall, library 
2 transduced HPB-ALL and MOLT4 (22.2% - 65%) better than library 1 (10.2% - 
54.8%). Higher transduction efficiencies, as demonstrated by GFP expression, were 
observed with higher virus concentrations (Figure 18). Finally, HPB-ALL with 50 μl 
library 1 (20.9%) and 20 μl library 2 (26.2%), and MOLT with 50 μl library 1 (18.1%) 
and 20 μl library 2 (22.2%) were selected and expanded to proceed with the screening. 
A similar strategy was used for SUPT1 and CUTLL1 cells. Transduced cells with 20 - 
30% efficiency were chosen to continue the targeted shRNA screen. 
 
 
Figure 18. Verification of transduction efficiencies using lentiviral library 1 and 
2. HPB-ALL and MOLT4 were transduced with library 1 and 2 using different amounts 
of non-concentrated virus supernatant (20, 50, 100 and 200 μl). The first column 
correspond to non-transduced cells. After forward/sideward scatter gating for alive 
cells, flow cytometry plots were generated showing GFP expression (X-axis); Y-axis, 




3.2.4 A Targeted Screen in T-ALL Cell Lines Demonstrates the Importance of TCR 
Components. 
The pTCR/TCR complex is composed of pTCRα / TCRα, TCRβ, CD3ε, CD3δ, CD3γ 
and CD3ζ chains. The TCRα chains undergoes somatic recombination from V(D)J 
rearrangement after the TCRβ chain. However, the pTCRα is a nonpolymorphic gene 
that is translated from the PTCRA gene. It is reported that PTCRA transcript is 
expressed in 57% of the TCRαβ lineage and 40% of TCRγδ T-ALLs (2003 Blood). 
Since the pTCR complex, encompassing PTCRA, provides proliferative and survival 
advantage during normal T-cell development presumably without ligand binding, we 
focused our intention first on PTCRA as a potentially critical gene in T-ALL. After 
performing qPCR of twelve T-ALL cell lines (Figure 19), four T-ALL cell lines (SUPT1, 
CUTLL1, MOLT4 and HPB-ALL) with high PTCRA expression were chosen to conduct 
targeted shRNA screens. Karpas 45 was not chosen due to its more demanding nature 







































































Figure 19. The transcription level of PTCRA in a panel of T-ALL cells. PTCRA 
expression was normalised relative to the housekeeping gene GAPDH. In T-ALL cell 
lines, SUPT1, CUTLL1, Karpas 45, HPB-ALL, Jurkat and MOLT4 express high mRNA 
levels of PTCRA. Primary patient samples of L963, LK203, LK080, L970, L903, L809, 
L907 and L214 were also examined for PTCRA expression. 
 
The selected four T-ALL cell lines (SUPT1, CUTLL1, MOLT4 and HPB-ALL) were 
transduced with lentiviral library. Two independent lentiviral shRNA libraries were 
prepared, one of them for repetition experiments. Baseline samples were harvested 




replaced by fresh medium every three days. To track shRNA depletion or enrichment 
over time, samples at day 16, 30 and 40 were harvested. Overall, each cell line had 
eight samples (two independent samples each at baseline, day 16, day 30 and day 
40), with a total sample number of 32. After extraction of gDNA, each sample was 
barcoded and amplified with different reverse primers (Appendix 1). Each barcoded 
sample was quantified by Qubit Fluorometer and pooled together accurately to 
generate the library. This sequencing library included 82 barcoded samples (both T-
ALL cell line samples and PDX samples) (Figure 20). The sequencing library was 
composed of an equimolar pool of 82 samples (2.6 ng/μl, 10nM each). NGS was 
performed at the Genomic Core Facility in Newcastle University (NCL) and generated 
25,000,000 reads which was sufficient for 8000 x coverage. The sequencing reads 
underwent bioinformatic analyses to determine the accumulation or loss of cell clones. 
Briefly, raw sequencing reads were trimmed at both ends up to the locations of barcode 
sequence before aligning to the reference shRNA barcodes. Read counts were 
extracted from aligned sequence files. Differential representation analyses of aligned 
read counts from different screen datasets were performed. 
 
Figure 20. In vitro shRNA screen workflow. T-ALL cell lines SUPT1, MOLT4, 
CUTLL1 and HPB-ALL were transduced with the lentiviral library containing 36 
shRNAs and cultured in vitro. The gDNA samples were collected at baseline (day 6), 
day 16, day 30 and day 40. NGS was used to determine shRNA enrichment and 
depletion. 
 
The analysis in T-ALL cell lines took different time points into consideration, therefore 
slope was used for the magnitude of the relative change in shRNA abundance over 
time (16, 30 and 40 days) after in vitro propagation. In SUPT1 cells, shRPL9#1, 
shRPL9#2 and shRPS29#2 targeting ribosome genes were depleted (slope: -0.56, -
0.18 and -0.53; p-value: 2 x 10-16, 0.00034 and 2.7 x 10-17) while all 3 shRNAs of PTEN 
were enriched significantly (slope, p-value: shPTEN#1 0.29, 4.8 x 10-6 shPTEN#2 0.28, 
3.25 x 10-9 shPTEN#3 0.42, 1.06 x 10-8), suggesting this screen was successfully 




loss of PTEN is expected to cause cell proliferation, thus, resulting in an enrichment of 
cells expressing shPTEN. Secondly, cells expressing shRNAs targeting one of four 
specific components of the pTCR/TCR complex were significantly depleted: two 
shRNAs targeting LCK (slope, p-value: shLCK#1 -0.35, 4.5 x 10-7 shLCK#3 -0.62, 5.1 
x 10-13), two PTCRA targeting shRNAs  (slope, p-value: shPTCRA#2 -0.54, 1.08 x 10-
11 shPTCRA#3 -0.36, 0.000489), one ZAP70 shRNA  (slope -0.37; p-value 2.55 x 10-
8) and two CD3E shRNAs  (slope, p-value: shCD3E#1 -0.24, 9.3 x 10-6 shCD3E#2 -
0.14, 0.009456) (Figure 21). 
 
Figure 21. Volcano plots of the targeted shRNA screens in SUPT1 and MOLT4. 
The magnitude of the relative shRNA change in shRNA abundance over time of SUPT1 
(left) and MOLT4 (right) is represented. Depleted (negative slope) and enriched 
(positive slope) shRNAs from two independent experiments are shown on the X-axis. 
The Y-axis represents log10 transformed p values. Dots above the line show 
significance (p < 0.05). Red dots indicate significantly depleted shRNAs targeting the 
pTCR/TCR complex. Purple, positive controls. Raw data are shown in Appendix 3. 
 
The degree of shRNA depletion and enrichment in MOLT4 cells was less pronounced 
compared with SUPT1 cells. The positive control shRPS29#1 was significantly lost 
(slope -0.32; p-value 0.0003114). MOLT4 carries a PTEN deletion, therefore no 
significant enrichment was seen of shPTEN#1 and shPTEN#3. Importantly the 
depletion of shLCK#1 (slope -0.13; p-value 0.04), shLCK#3 (slope -0.49; p-value 8.6 x 
10-10), and shPTCRA#2 (slope -0.19; p-value 0.0069573) were significant, suggesting 
an essential role of LCK and pTCRα for cell proliferation or survival in MOLT4 cells 
(Figure 21). 
In CUTLL1 cells, all three PTEN shRNAs showed significantly enrichment (slope, p-
value: shPTEN#1 0.23, 2.4 x 10-17 shPTEN#2 0.11, 4.7 x 10-4 shPTEN#3 0.27, 3.17 x 
10-21) while the positive control for depletion shRPL9#2 was lost (slope -0.07; p-value 




1.27 x 10-30) and shZAP70#1 (slope -0.14; p-value 9.67 x 106) were lost (Figure 22). 
The shLCK#1 was also lost (slope -0.055), however, not yet statistical significant 
(p=0.059). 
A more pronounced difference was observed in HPB-ALL cells. Similar with SUPT1, 
three shRNAs targeting PTEN (slope, p-value: shPTEN#1 0.19, 1.25 x 10-6 shPTEN#2 
0.36, 8.99 x 10-15 shPTEN#3 0.32, 1.14 x 10-16) were enriched and shRPL9#1 (slope -
1.21; p-value 4.08 x 10-22), shRPL9#2 (slope -0.55; p-value 2.77 x 10-14) and 
shRPS29#1 (slope -0.16; p-value 5.1 x 10-4) were depleted significantly. All three 
shRNAs against LCK were lost (slope, p-value: shLCK#1 -0.12, 9.76 x 10-4 shLCK#2 -
0.17, 4.79 x 10-6 shLCK#3 -0.31, 2.41 x 10-17). However, the effect of shRNAs targeting 
ZAP70 and PTCRA were inconsistent. shZAP70#1 was lost (slope -0.15; p-value 4.9 
x 10-4) and shZAP70#3 (slope 0.30; p-value 2.1 x 10-10) was enriched; shPTCRA#2 
was lost (slope -0.09; p-value 0.019) and shPTCRA#1 (slope 1.16; p-value 6.5 x 10-23) 
was enriched. Intriguingly, two shRNAs targeting FYN (slope, p-value: shFYN#1 -0.11, 
0.003 shFYN#2 -0.15, 0.001) were identified to be lost only in HPB-ALL cells (Figure 
22). 
 
Figure 22. Targeted screen in T-ALL cell lines CUTLL1 and MOLT4. Volcano plots 
show significantly lost and enriched shRNAs during cell propagation. Depleted 
(negative slope) and enriched (positive slope) shRNAs are shown on the x-axis. The 
y-axis represents log10 transformed p values. ShRNAs above the line show 
significance (p < 0.05). Red dots indicate significantly depleted shRNAs targeting the 





Figure 23. The heatmap summaries shRNAs depletion and enrichment in all four 
cell lines. Heatmap on the left depicting gains (red; > 0 - (+1) positive slope) or losses 
(blue < 0 - (-1) negative slope) of shRNA constructs after in vitro culture of four cell 
lines. The right heatmap shows the significance of each shRNA in all four T-ALL cell 
lines; significant enrichment (p < 0.05 red), significant depletion (p < 0.05 green), not 
significant (p > 0.05 white). 
 
The targeted shRNA screens in T-ALL cell lines highlighted the significance of 
pTCR/TCR components in T-ALL cell maintenance. Overall, the screen itself worked 
well as positive controls behaving precisely as what we expected such as shRNAs 
shRPL9#1, shRPL9#2 and shRPS29#1 targeting ribosome genes were depleted. 
SUPT1, CUTLL1, and HPB-ALL cells are PTEN wildtype in which all three shRNAs 
targeting PTEN were significantly enriched. Consistently, in PTEN null MOLT4 cells, 
shPTEN#1 and shPTEN#3 were not enriched. The shPTEN#2 was significantly 
enriched with a slope of 0.1. Designed negative controls such as shRUNX1/ETO, 




Across all four cell lines, the most significant change is observed for LCK whose 
shRNA#3 and #1 showed top 1 and top 2 depletion, suggesting that LCK is essential 
for cell propagation in T-ALL cell lines (Figure 23).  
Some discrepancies could be observed when comparing four cells. They might be 
explained by (i) insufficient knockdown, e.g. shLCK#2 only showed significant 
depletion in HPB-ALL cells, but not the other three cell lines. Verification of LCK 
knockdown of all three shRNAs in CUTLL1 and MOLT4 revealed barely any 
knockdown of LCK mRNA when using shLCK#2 in CUTLL1 and MOLT4 (Figure 30) 
suggesting this shRNA is less efficient than the other two shRNAs. The depletion of 
shLCK#2 in HPB-ALL cells might mean that LCK expression was affected in this 
particular cell line, however, this requires further validation. Moreover, shZAP70#1 was 
significantly lost in SUPT1, CUTLL1 and HPB-ALL cells, but no substantial effect was 
observed by shZAP70#2 and #3. Validation ZAP70 KD in vitro in CUTLL1 and MOLT4 
cells indicated that only shZAP70#1 reduced ZAP70 on the transcriptional level (Figure 
30). The slope of shZAP70#1 in MOLT4 cells was -0.069, indicating it was lost during 
the screen. However, the p-value fell just short of statistical significance. This might be 
due to lower transduction levels in MOLT4 compared with the other three cell lines. In 
further in vitro validation experiments, it was confirmed that knockdown of ZAP70 by 
shRNA#1 indeed impaired cell proliferation of MOLT4 (Figure 30).  
(ii) Differential expression patterns of pTCRα. The shRNAs targeting PTCRA showed 
different patterns in four T-ALL cell lines. According to our analyses of these T-ALL cell 
lines, SUPT1 and MOLT4 cells are cells that only express pTCR while CUTLL1 and 
HPB-ALL express both pTCR and TCR. This might explain why SUPT1 and MOLT4 
cells showed depletion of shPTCRA#2 and #3, since they are more dependent on the 
pTCR signalling complex. On the contrary, CUTLL1 and HPB-ALL might overcome 
pTCR depletion by compensating through TCR signalling.  
(iii) Lack of on-target effect. Two shRNAs each to target ribosome proteins RPL9 and 
RPS29 as positive controls for this screen were used. Anti-sense sequences were 
obtained from other gene-editing screens in our lab. As expected, shRPL9#1 and #2 
were depleted in all four T-ALL cell lines indicating the essential role of ribosome 
protein RPL9 in T-ALL cells. However, shRPS29#1 was depleted in HPB-ALL, SUPT1 
and MOLT4 while shRPS29#2 was enriched in HPB-ALL, CUTLL1 and SUPT1. This 
raises the possibility that either shRPS29#2 lack of on-target effects or both shRNAs 




(iv) Differences in T cell biology. Several shRNA sequences were obtained from other 
group members’ screens in leukeamic cells, in which knockdown did not affect the 
leukeamic cell proliferation/engraftment. However, some of these did not behave as 
proper negative controls in our screens, such as shTRPM7#1 and #2, shSESN2, 
shERGIC3 and shKLHL7. This is most likely due to differences in T-ALL cell biology 
compared with other types of leukaemia.  
Together, among the six components of the pTCR/TCR complex included in this 
shRNA screen, depletion of the kinases LCK and ZAP70 indicated a significant and 
essential role in T-ALL cell maintenance in all four cell lines. In contrast FYN, CD3ε 
and LAT does not seem to be essential in general as shCD3E was lost only in SUPT1 
cells, whilst shFYN showed depletion only in HPB-ALL. Two of LAT shRNAs were not 
depleted or enriched, whereas the third shRNA of LAT showed enrichment in SUPT1 
and HPB-ALL. Overall, it suggests that these three genes are less important for cell 





3.2.5 Targeted Screens in Patient-Derived Xenografts (PDXs) 
The same targeted screen which was performed in T-ALL cell lines (Chapter 3.2.4) 
was performed in three PDXs L963, LK080 and LK203 as they express higher levels 
of PTCRA at the mRNA level among eight PDXs that I have tested (Figure 19). They 
were transduced with highly concentrated lentivirus generated from the same library 
mentioned previously. Transduction efficiencies of L963, LK080 and LK203 were 3%, 
5% and 7.5% respectively as demonstrated by GFP positivity. Two days after 
transduction, baseline samples were harvested in triplicates, cells were washed 
several times and injected into six NSG mice per PDX. Mice were weighed and 
monitored twice a week. When leukaemia symptoms were observed, the six mice 
derived from one patient sample were harvested around the same time. Mice injected 
with LK203 were harvested 54/56 days after injection and enlarged spleens were 
observed weighing between 0.55 - 0.74g. Mice with the relapse sample LK080 were 
harvested 67/68/69 days after injection. The spleen weight was 0.88 - 1.27g for five 
mice, with one mouse displaying a smaller spleen (0.45g). The patient sample L963 
took the longest time to full leukaemia engraftment in vivo with a 77/81 day lifespan. 
The spleens derived from these mice were enlarged with a weight of 0.70 - 1.05g. Bone 
marrow samples from femurs and tibias were collected and used in NGS analysis. In 
parallel, PDX LK080 and LK203 were also kept in vitro for 30 days. Two samples (day 
16 and day 30) were harvested for LK080, and three samples (day 16, day 30 with 
MSC, and day 30 without MSC) were collected for LK203 after long-term culture. All 
gDNA was extracted and amplified with barcode primers. The purified amplicons were 
sequenced in house using NGS. 
 
3.2.5.1 The Targeted shRNA Screen in LK080 
Unfortunately the NGS analysis of LK080 both in vivo and in vitro failed. For the in vivo 
screening of LK080, a large number of shRNAs was represented by very low read 
counts (< 10), which means many shRNAs in these samples were under sampled due 
to a few dominant clones in the library (shRNAs with extremely high counts). For 
example, in mouse 1 and mouse 6, the frequency of shRUNX1/ETO reads was 90.2%, 
99.6%, 85.5%, and 98.3% in the spleen and bone marrow cells; mouse 3 had dominant 
clones containing shZAP70#2, shCD19#1 and shRUNX1/ETO with a total percentage 
of 87.9% in the spleen and 99.9% in the bone marrow. Similar results were observed 




amplification, which might be indicative of clonal engraftment of non-transduced cells. 
Overall, these results suggest that LK080 cells might undergo clonal expansion in vivo, 
rendering this sample non-informative in our analysis. 
 
Figure 24. Dominant clones of LK080 in vivo screening. Mouse ID, sample origin, 
barcode index and the abundance of some dominant clones in percent (shFYN#1, 
shZAP70#2, shLAT#3, shCD19#1, shTRPM7#2, shRUNX1/ETO, shPTEN#1) are 
shown. The abundance of total dominant clones was calculated and listed in the last 
column. 
 
On the contrary, LK080 in vitro screening samples did not show any clonal expansion. 
All 36 shRNAs were presented in samples from day 16 and day 30, without significant 
loss of LCK shRNAs in LK080 in vitro screening. There was significant depletion of 
ribosome shRNAs and enrichment of shPTEN shRNAs; however, the fold change 
(log2(FC)) was much less compared with LK203 in vitro screening (-0.79 - 0.47 in 
LK080 while -1.3 - 1.05 in LK203 sample), suggesting that LK080 might have less 
doublings in vitro compared with LK203. In addition, the viability of ex vivo growing 
LK080 cells was around 50% only, compared with ≥ 75% for LK203. In summary, the 
in vitro culture of LK080 was not as successful as LK203 in detecting differential shRNA 





3.2.5.2 The Targeted shRNA Screen in LK203 
The samples derived from in vivo screening of L963 and LK203 were analysed for their 
shRNA representation. An intended output of shRNA screens would be an equal 
distribution and a full presentation of all shRNAs in the baseline samples while 
depletion of shRNAs targeting gene essentiality of T-ALL cells and enrichment of 
shRNAs of tumour suppressor genes during leukaemia propagation. First, similar to T-
ALL cell lines, the baseline samples of L963 and LK203 showed an equal and 




Figure 25. The composition of shRNAs of PDX L963 and LK203 at baselines. 
There are 36 shRNAs in the targeted shRNA library. Reads from three baseline 
samples taken 2 days after lentiviral transduction of L963 and LK203 are plotted in pie 
charts. The distribution of each of the 36 shRNAs is indicated in different colours as 





For the ex vivo screen of LK203, after transduction of lentiviral library, LK203 was kept 
on MSC cells. One sample was collected at day 16, and two more samples were 
collected at day 30. They were considered as triplicates in the final bioinformatics 
analysis to perform significance tests. The significantly enriched shRNAs included two 
shRNAs targeting PTEN (shPTEN#2 Log2(FC) = 0.5773, p = 0.0322 and shPTEN#3 
Log2(FC) = 0.9738, p = 9 x 10-5). The positive controls targeting ribosome genes which 
were supposed to be lost, such as shRPL9#1, #2 and shRPS29#1, were significantly 
depleted in LK203. Intriguingly, three shRNAs targeting LCK were all significantly 
depleted (shLCK#1 Log2(FC) = -0.771, p = 0.0012; shLCK#2 Log2(FC) = -0.679, p = 
0.0061; shLCK#3 Log2(FC) = -0.655, p = 0.0159) in LK203 indicating the importance 
of LCK for LK203 proliferation in vitro. Two shRNAs targeting LAT were significantly 
lost (shLAT#1 Log2(FC) = -0.793, p = 0.0015; shLAT#3 Log2(FC) = -0.815, p = 0.0063) 
(Figure 26). shZAP70#1 and shPTCRA#2, #3 showed negative slopes, however did 
not reach significance. 
 
Figure 26. The volcano plot of PDX LK203 ex vivo shRNA screen. The Log2(fold 
change) is shown on the X-axis while log10(p-value) is shown on the Y-axis. Each dot 
represents a shRNA. Any shRNAs above the line are significantly enriched or depleted. 
Red colour demonstrates shLCK#1, shLCK#2 and shLCK#3. Purple, positive controls. 
Raw data are shown in Appendix 3. 
 
Transduced LK203 was injected into six NSG mice. Bone marrow and spleen samples 
were collected for NGS analysis. However, in the LK203 in vivo shRNA screen, only a 
few shRNAs showed significant depletion. These shRNAs were ribosome shRNAs 
(shRPL9#1, #2 and shRPS29#1, #2). No shRNAs showed significant enrichment 
including PTEN shRNAs. Also, no other shRNAs targeting TCR components were 




significance (p=0.0149). Overall, the in vivo shRNA screen of LK203 seems to have 
less pronounced differences compared to the in vitro shRNA screen of LK203. Several 
aspects were considered in understanding these data: 1) The baseline samples of the 
LK203 in vivo screen had equal shRNA distribution and they were the same baselines 
as used in the LK203 in vitro screen. 2) The LK203 samples derived from the mice 
showed all 36 shRNAs in all bone marrow and spleen samples, suggesting this PDX 
did not undergo clonal expansion in vivo. All six mice had confirmed leukaemic bone 
marrow and enlarged spleens (0.55 - 0.74g). There was thus no problem with 
leukaemia engraftment of this PDX sample. 3) The final reads of the LK203 in vivo 
screen were similar to all other barcoded samples. The average number of reads of 6 
mice spleen and bone marrow samples was 283,561, with 312,697 reads for the 
baseline samples and 293,269 for the in vitro screen samples indicating all barcoded 
samples were equally sequenced. 4) It might be the case that LK203 was dependent 
on LCK in vitro but not in vivo. However, with overall less pronounced shRNA fold 
change and less positive controls behaving as expected such as shPTEN, the 
conclusion that LCK is dispensable for LK203 in vivo does not appear convincing. 5) 
Last but not least, the in vivo shRNA screen analysis was much more challenging as 
the biological coefficient of variation was over 100%, demonstrating huge variations 
between samples from different mice. The bioinformatics analysis was performed with 
the assumption that shNTC and shRUNX1/ETO would have constant representation 
across all LK203 samples. However, this assumption might not be true for all of the 
samples. To further investigate this, more thorough bioinformatics analyses are 





3.2.5.3 The Targeted shRNA Screen in L963 in vivo 
The in vivo shRNA screen was also performed in PDX L963. After thawing (day 0), 
L963 was transduced with highly concentrated lentiviral shRNA library. Two days later, 
baseline samples were taken, and remaining cells (1.2 x 107 cells) were used to inject 
into six NSG mice (2 x 106 cells per mouse). These mice were harvested due to obvious 
leukaemia engraftment after 77 days and 81 days. All six spleens were enlarged 
weighing between 0.7g and 1.05g. After gDNA extraction and amplification, an 
expected 433 bp band was generated as seen in samples from mouse bone marrow 
and spleen (Figure 27). 
 
Figure 27. Representative results of gDNA amplification in targeted shRNA 
screens. gDNA was isolated, amplified with NSG-F3 and reverse barcoded primer. 
The amplicon was loaded onto agarose gels (2%). The gels show an approx. 400bp 
band (theoretical size 433bp). These amplicons obtained from L963 samples including 
three baselines (gDNA of L963 cells before injection into NSG mice), bone marrow 
samples (BM) from mouse 1, 2 and 3, and bone marrow samples from mouse 4, 5 and 
6. M (NEB 100bp DNA Ladder)  
 
In the bone marrow and spleen samples of L963 cells, the positive control shRPL9#1 
was significantly depleted (Log2(FC) = -6.49, p = -0.0017 and Log2(FC) = -6.10, p = 
0.0013 respectively). There was no enrichment of any PTEN shRNAs. However, the 
dependence of L963 on PTEN is not known at this point. Notably, across all six mice 
engrafted with L963, shLCK#3 was significantly lost in bone marrow (Log2(FC) = -8.57, 
p = 3.01x10-7) and spleen (Log2(FC) = -8.03, p=2.17 x 10-8) of each individual mouse. 
However, shLCK#1 only showed a substantial loss in mouse 2, 4 and 5, but not the 






Figure 28. The targeted screen in L963 demonstrates the essential role of LCK 
in vivo.(Top) The in vivo screen was performed using L963 as shown in the schematic 
diagram (n = 1). L963 was transduced with lentiviral shRNA libraries, and intrafemorally 
injected into 6 NSG mice. Mice were euthanised after 11 weeks due to leukaemia 
symptoms. Bone marrow and spleen samples were collected. (Middle) Volcano plots 
are representing the magnitude of the fold change (Log2) in shRNA abundance derived 
from bone marrow and spleen of L963 on the x-axis. The y-axis represents log10 
transformed p values. Dots above the line represent significant shRNAs (p < 0.05). The 
red dot shows shLCK#3. (Bottom) Bar plots of shLCK#3 and shLCK#1 expression in 
L963 mice. The x-axis shows sample annotations (baseline samples in green columns; 
bone marrow in orange columns; and spleen samples in blue columns). The y-axis 
shows the normalised sequencing reads (Log2). Raw data are shown in Appendix 3. 
 
Taken together, similar to the results obtained of T-ALL cell lines, screening data 
obtained on PDX samples (L963 in vivo; LK203 in vitro), indicate that LCK is 




3.3 LCK Deficiency Leads to a Growth Defect Characterised by G0/G1 Arrest 
3.3.1 Knockdown of LCK, ZAP70 or PTCRA Leads to a Proliferation Defect in T-
ALL Cell Lines 
To validate the results from the targeted shRNA screens, I performed shRNA 
knockdown individually targeting LCK, ZAP70, PTCRA and FYN in T-ALL cells. 
Several negative control shRNAs such as shNTC, shRUNX1/ETO, and shFLG were 
also included. Cells were transduced with individual shRNA (GFP+) and mixed with 
parental GFP negative cells on day 6 to generate approximately 50% GFP expression. 
They were kept in culture for up to 40 days. The GFP expression was measured every 
three days to assess the competition of wildtype cells and transduced cells.  
All three shRNAs from the targeted library of LCK, ZAP70, PTCRA, and FYN were 
used in MOLT4 and CUTLL1. The negative control shRNAs (shFLG, shRUNX1/ETO, 
and shNTC) retained their GFP expression for up to 40 days. Knockdown of FYN by 
three shRNAs did not influence cell growth in both CUTLL1 (maximal 50% KD) and 
MOLT4 (maximal 40% KD) (Figure 29). These results were consistent with the targeted 
shRNA screen results. 
 
Figure 29. Knockdown of FYN does not affect cell growth in CUTLL1 and 
MOLT4.Three shRNAs were used to target FYN expression (square shFYN#1; triangle 
shFYN#2; and circle shFYN#3). Transduced cells were seeded in a 1:1 ratio with non-
transduced parental cells (relative GFP expression equals 1.0). Cells were cultured 
and analysed repetitively for the presence of GFP+ cells over a time of 40 days for 
CUTLL1 and MOLT4, respectively. A relative GFP expression of 1 denotes a mixture 
of 50% GFP+ cells with 50% parental GFP- cells (ratio 1:1). The x-axis represents the 
time (day). The y-axis represents the relative GFP expression of the control shRNA 
transduced cells (black) and shFYN cells (pink). Knockdown levels of FYN on mRNA 
level are shown in bar charts. 
 
CUTLL1 did not respond to PTCRA knockdown while all three shRNAs of PTCRA led 




remarkably similar effects for the same LCK and ZAP70 shRNAs. There was no effect 
after shLCK#2, shZAP70#2 and shZAP70#3 knockdown which can be explained by 
no reduction of LCK or ZAP70 at transcriptional level. This also explains why these 
three shRNAs were not significantly depleted in any of the targeted shRNA screen, 
while other shRNA designed for the same target showed significant depletion. Both 
shLCK#1 and shLCK#3 reduced LCK expression levels in CUTLL1 and MOLT4, with 
a more pronounced knockdown of shLCK#3. The growth defects could be correlated 
with LCK knockdown levels, as shLCK#3 resulted in more growth defect than shLCK#1 
(Figure 30). The targeted shRNA screen showed significant depletion of shZAP70#1 
in CUTLL1 but not MOLT4 cells. However, shZAP70#1 led to a growth defect in both 
CUTLL1 and MOLT4 cells in the competitive assay (Figure 30). 
 
 
Figure 30. Competitive in vitro assays in CUTLL1 and MOLT4 cells. T-ALL cell 
lines CUTLL1 and MOLT4 were transduced with three shRNAs per gene targeting 
LCK, ZAP70 and PTCRA and three negative shRNAs. The knockdown levels were 
determined six days after the transduction by pLKO5d-eGFP constructs. Cells were 
mixed with parental cells in a 1:1 ratio according to their GFP expression. The GFP 




control shRNAs) was measured repetitively and plotted over time (square, shRNA#1; 
triangle shRNA#2; and circle shRNA#3). The x-axis represents time (days) and the y-
axis the relative GFP expression. A relative GFP expression of 1 denotes a mixture of 
50% GFP+ cells with 50% parental cells (ratio 1:1). Knockdown levels of targeted 
genes are shown in bar charts to the right of the competitive assays. 
The summarised data of MOLT4 and CUTLL1 are included in (Figure 31). Four more 
T-ALL cell lines (SUPT1, RPMI8402, HPB-ALL and Jurkat) were tested. Knockdown 
of LCK (shLCK#3), PTCRA (shPTCRA#1), or ZAP70 (shZAP70#1) all led to 
proliferation defects in SUPT1 and RPMI8402, but not HPB-ALL cells (Figure 31). 
The HPB-ALL results were not consistent with the targeted shRNA screen as LCK was 
shown to be crucial in HPB-ALL cells in the previous screen. However, shNTC cells 
lost GFP expression at a similar speed as shLCK knockdown cells. The results are 
difficult interpret (see discussion). 
The competitive assay in Jurkat cells was performed in a different way. Jurkat was 
transduced with RFP657-shNTC and GFP-shLCK#3. After 6 days after transduction, 
the fluorescent protein expression was measured. GFP-shLCK#3 cells were seeded 
in a 1:1 ratio with RFP657-shNTC cells. Mixed cells were cultured and analysed 
repetitively for the presence of GFP+ and RFP657+ cells over a time of 10 days. 
Notably, RFP657-shNTC cells outcompeted GFP-shLCK#3 cells, suggesting that 
knockdown of LCK affected cell proliferation also in Jurkat (Figure 31). Overall, these 
data suggest that the protein kinase LCK plays a universal role for cell proliferation 





Figure 31. Summary of competitive assays in six T-ALL cell lines. MOLT4, 
CUTLL1, SUPT1, RPMI8402, and HPB-ALL were transduced with GFP-shRNAs and 
mixed equally with parental cells. Representative experiments are shown in this figure. 
The x-axis represents time (days since mixture) and the y-axis shows relative GFP 
expression. Over a period of 40 days, GFP expression was monitored and plotted after 
normalisation. shLCK#1, blue square; shLCK#3, blue circle dot; shPTCRA#1, red 
square; shZAP70#1, purple square; shNTC, black square. For Jurkat cells, after 
lentiviral transduction, RFP657-shNTC cells were mixed with GFP-shLCK#3 cells in 
equal numbers. The RFP657 and GFP expression were monitored by flow cytometry 
and indicated as percentage. The mean of three independent experiments is shown in 





3.3.2 Verification of LCK as a Critical Factor for the Maintenance of T-ALL Cells 
in vivo 
To further evaluate LCK function in leukaemia progression, in vivo competitive assays 
with MOLT4 and Jurkat cells were performed. For this cells were transduced with 
RFP657-shNTC and GFP-shLCK (or dTomato-LCK) separately. After six days of 
transduction, these cells were mixed to generate RFP657:GFP (or dTomato) in a 1:1 
ratio. On the same day, five NSG mice per cell line received mixed samples by 
intrafemoral injection. When mice showed disease-related symptoms or weight loss 
they were euthanised, and samples were collected to analyse GFP (dTomato) and 
RFP657 expression (Figure 32). 
 
Figure 32. Schematic of in vivo competitive assays. MOLT4 cells were lentivirally 
transduced with either RFP657-shNTC or GFP-LCK. After 6 days of transduction, cells 
were mixed to generate a mixed sample with RFP657:GFP in a 1:1 ratio. These cells 
were injected into 5 NSG mice. After leukaemia engraftment and expansion in vivo, 
samples from mice spleen, liver and bone marrow were isolated and used to analyse 
GFP and RFP657 expression by flow cytometry. 
 
Since transduced MOLT4 cells were not 100% positive for RFP657 or GFP, it was not 
possible to obtain mixed samples of exactly 50% GFP and 50% RFP657. In this 
experiment shNTC cells (RFP) and shLCK (GFP) cells represented 41.7% and 39.2% 
respectively. The remainder 18.7% of cells refers to the non-transduced population. 
Mice receiving MOLT4 cells lived for 26 days before showing disease-related 
symptoms such as pale colour, loss of muscle tone or weight loss. MOLT4 cells engraft 
in the liver, spleen and bone marrow. Spleens were enlarged weighing from 0.14 g to 
0.21 g with approximately 3 - 5% of cells being MOLT4. Flow cytometry analysis 
revealed shNTC cells represented 50.2%, 47.7%, 59.8%, 49.0% and 55.9%, while 
shLCK cells accounted for 14.9%, 16.6%, 19.4%, 18.0% and 20.6% respectively 
demonstrating knockdown of LCK leads to population loss when in competition with 




in mouse 1 and mouse 2, however, the engraftment rates for the other three mice were 
11 - 15% in the liver and 1.7 - 22% in the bone marrow. Overall, the representation of 
RFP657-expressing control cells was 56% (mean obtained from mouse 3-5) and 
clearly outcompeted GFP-shLCK cells with a mean of 22% in all liver derived samples. 
The bone marrow samples were more heterogeneous as the RFP657 vs GFP ratios 
and ranged from 58.2% vs 8.5% to 35.4% vs 20.8% (Figure 33). 
 
Figure 33. In vivo competitive assay with MOLT4 in NSG mice. Expression of GFP 
and RFP657 was determined on day 0 before injection (cells were mixed after six days 
post-transduction) and on day 26 after harvesting spleen (n = 5), bone marrow (n = 3) 
and liver (n = 3) samples from the mice. Y-axis: RFP657; X-axis: GFP. Numbers in up 
left square and bottom right square represent RFP657 and GFP expression 




In summary, these data show that the RFP657-shNTC MOLT4 cell population 
outcompeted the GFP-shLCK transduced cell population in all five mice. After cleaning 
the data for non-transduced cells and comparing RFP657 and GFP expressions to 
those determined at the injection day (day 0), a significant advantage to engraft and 
propagate in vivo of control shRNA cells compared to LCK knockdown cells in all 
tissues analysed, the spleen (p < 0.0001), BM (p = 0.0276) and liver (p = 0.0003), can 
be observed (Figure 34). 
 
Figure 34. In vivo competitive assay with MOLT4 cells. Non-transduced cells were 
excluded from the analysis. The proportion of shNTC (RFP657) cells and shLCK (GFP) 
cells is shown in red and green, respectively. Statistical analyses were performed on 
the proportions of shLCK cells (spleen (n = 5), BM (n = 3), liver (n = 3)) using student 
t-tests (spleen (p < 0.0001), BM (p = 0.0276) and liver (p = 0.0003)). 
 
The in vivo competitive assay using Jurkat cells was performed with pLKO5d-SFFV-
eGFP-transduced Jurkat cells. Approximately 95% of these cells express GFP, which 
was used as a marker for Jurkat cells derived from in vivo samples. To compare the 
LCK effects on leukaemia propagation in vivo, cells were transduced with RFP657-
shNTC or dTomato-shLCK. They were mixed and had an equal distribution of RFP657 
and dTomato before intrafemoral injection into NSG mice. Five NSG mice were used 
for this experiment, and weight loss, compared with the highest weight, was observed 
in all five mice (11% - 19%) after 22 days. At that time, spleen and bone marrow 
samples were collected, although the weights of the spleens were only 0.04 g to 0.08 
g.  
The engraftment of Jurkat cells in all five NSG mice (LN, RN, BN, NN, 2LN) was 
generally very poor, with only two mice (BN and 2LN) demonstrating spleen 




marrow engraftment. When examining RFP657 and dTomato expression, the leg 
tumour showed RFP657-shNTC population outcompeting the dTomato-shLCK 
population (shNTC 42.4% vs shLCK 34.8%). Surprisingly, the spleen and bone marrow 
samples showed different results as LCK knockdown cells were more abundant than 
control cells (15.9 - 17.2% RFP-shNTC cells; 58.6 - 59.6% dTomato-shLCK cells). At 
this point, the results were not clear enough to draw any conclusion (Figure 35). 
To further elaborate on the question whether shNTC cells outcompete shLCK cells, 
Jurkat cells from the leg tumour, spleen and bone marrow were kept in vitro for five 
days, as T-ALL cell line Jurkat should proliferate better in vitro and quickly become the 
dominant population in these samples. Flow cytometric analysis was performed and 
indicated that the GFP populations in the leg tumour and spleen represented 95.4%, 
95% and 93.9% of total cells. However, no GFP was detected in the BM sample, 
suggesting that at least the GFP signal on the harvested day was not a true GFP signal 
of Jurkat cells, and possibly derived from auto-fluorescent mouse BM cells. Therefore, 
it is most likely, that none of the five mice showed BM engraftment. Of interest is, that 
although leukaemia cells had been injected in the femur, they did not engraft in the 
bone marrow, at least not in the bone marrow derived from femur and tibia that were 
harvested. To date, the reason for the lost in weight is not clear. 
After five days in vitro culture, the leg tumour sample was obviously losing the LCK 
knockdown cell population (shNTC 41.8% vs shLCK 25.3%). In the spleen samples 
however, there were more shLCK cells than shNTC cells indicating the results from 
the day of harvest were likely true data. When compared with the composition on 
harvest day and five days later in vitro, the shLCK population started to be 
outcompeted by control population (59.6% to 56.8 in BN spleen, 58.6% to 52.5% in 
2LN spleen) (Figure 35). It is currently not understood how the splenic 
microenvironment affects LCK knockdown or control cells differently with regards to 
nutritional requirement and subsequent cell survival. In the tumour sample, shNTC 
outcompeted shLCK in a similar fashion as in the in vitro result. As only one mouse 
developed a leg tumour, a conclusion can unfortunately not be drawn at this point. 
Studies of Jurkat in mouse models often use the intrahepatic or subcutaneous 
injection, and Jurkat cells form solid tumours growing in the abdominal cavity or under 
the skin (El Zawily et al., 2017). Using this route of tumour cell application, it is likely 




outcompeted shLCK cells. However, this solid tumour-like orthotropic mouse model 
does not represent the generally accepted mode of leukaemia modelling. 
 
Figure 35. The in vivo competitive assay with Jurkat cells.Tissues that showed 
engraftment of Jurkat (one leg tumour (left), two spleen samples (middle) and one bone 
marrow sample (right)) were analyse for GFP-expressed Jurkat cells (top). The GFP 
percentage was used to determine pLKO5d-SFFV-eGFP transduced Jurkat cells. The 
shNTC (RFP657) and shLCK (dTomato) expression of Jurkat cells are shown in the 
bottom (competitive assay analysis). Y-axis showed RFP657 expression (shNTC 
transduced cells in Q1) while X-axis showed dTomato expression (LCK knockdown 
cells in Q3).The proportion on the day of harvest is shown on row 1 and row 3, while 




3.3.3 Knockdown of LCK Induces G0/G1 Arrest in T-ALL Cell Lines 
To investigate the effects of LCK knockdown in T-ALL cells, cell cycle and apoptosis 
assays were performed. The apoptosis assay was performed in MOLT4, SUPT1, 
CUTLL1 and Jurkat using PE-Annexin V and 7-AAD. A mild effect of increasing early 
apoptosis (Annexin V+/7-AAD-) was observed in MOLT4 after LCK knockdown 
(shNTC, 9%; shLCK 17%); however, this was not shown in CUTLL1, SUPT1 and 













































CUTLL1 MOLT4 SUPT1 Jurkat  
Figure 36. Analysis of cell death induction in T-ALL cell lines after LCK 
knockdown. Apoptosis assay was performed after six days of transduction with 
shNTC (black) and shLCK#3 (white) in CUTLL1 (n = 2), MOLT4 (n = 2), SUPT1 (n = 
1) and Jurkat (n = 1). Annexin V positivity (%) was shown on the Y-axis referring to the 





Analysis of DNA content revealed that knockdown of LCK using two shRNAs in Jurkat 
and MOLT4 cells increased the G0/G1 phase and decreased S and G2/M phase 
compared with shCtrl cells. This was mirrored in SUPT1 cells where LCK loss induces 
cell cycle arrest (45.5% G0/G1 in shCtrl increased to 53.3% in shLCK#3) suggesting 
that LCK plays a critical role in the G1/S checkpoint (Figure 37). Overall, these data 
indicate that LCK promotes T-ALL cell cycle progression since knockdown of LCK 
leads to a significant increase in the G0/G1 phase in all three T-ALL cell lines. 
 
Figure 37. Knockdown of LCK leads to cell cycle arrest. T-ALL cell lines Jurkat and 
MOLT4 were transduced with shLCK#1 and #3. After 6 days of transduction, the cell 
cycle was assessed after Hoechst staining by flow cytometry. Both shRNAs targeting 
LCK (blue) induced G0/G1 cell cycle arrest compared with shCtrl (red). SUPT1 cells 
were transduced with shCtrl and shLCK#3. DNA content was stained with Hoechst and 
cell cycle analysis was performed in FlowJo. Three independent experiments (n = 3) 
were summarised in the bar plots with the y-axis representing the cell cycle distribution. 







3.3.4 Knockdown of LCK in PDXs Leads to Cell Cycle Arrest 
3.3.4.1 Knockdown of LCK by shRNA in L963 Leads to the Reduction of Proliferation 
in vitro 
The observation that LCK knockdown induced G0/G1 arrest in T-ALL cell lines was 
studied further in T-ALL PDX cells. L963 cells from the spleen were thawed and co-
cultured in vitro with mouse OP9-DL1. 1 x 107 cells were transduced with highly 
concentrated lentivirus containing shCtrl or shLCK#3. After six days, GFP expression 
was assessed by flow cytometry to determine the transduction efficiency, which was 
8.0% for shCtrl and 6.4% for shLCK#3 (Figure 38). Cell cycle analysis was performed 
on GFP positive cells using Hoechst 33342 on day 7, day 13 and day 17 by flow 
cytometry and manual gating of G0/G1, S and G2/M phases. All LCK knockdown T-ALL 
cells showed a decrease in S phase over time (Figure 38). To assess LCK knockdown 
levels, PhosFlow was used to determine p-Y394LCK and total LCK on day 8 and day 
13. A substantial knockdown of LCK was seen; namely 45% KD at total LCK protein 
level and 71% KD at p-Y394LCK level. 
Having confirmed that a successful knockdown of LCK in PDX L963 caused cell cycle 
arrest, a cell proliferation assay using Cell Trace Violet (CTV) was performed. CTV is 
a cell permeable, stable and well-retained proliferation dye binding to intracellular 
amines. Upon cell division the dye is divided equally onto the daughter cells, i.e. the 
intensity of CTV is diluted by half after one cell division. Thus, more cell divisions will 
lead to peaks of less CTV intensity, which can be assessed by flow cytometry. In this 
experiment, 2 x 107 L963 cells were labelled with 5 μM CTV and split into two wells to 
receive shCtrl virus and shLCK virus respectively. In total, seven CTV peaks were 
observed in both samples. However, LCK knockdown cells had fewer cells in later 
divisions (5 and 6) and more cells in early divisions (1, 2 and 3) compared with shCtrl 
cells. (shCtrl and shLCK percentages in 0 - 6 divisions: 3.7% vs 3.7%; 6.8% vs 8.0%; 
14.7% vs 18.5%; 17.5% vs 20.0%; 17.3% vs 17.9%, 17.4% vs 13.3%; and 8.8% vs 
4.0%) (Figure 38). These data demonstrate that LCK is crucial for cell cycle 






Figure 38. Knockdown of LCK by shRNA in PDX L963 results in proliferation 
defects. PDX L939 were lentivirally transduced with shCtrl and shLCK#3 expression 
constructs coexpressing GFP to allow for the assessment of transduction efficiencies 
(x-axis, GFP expression, y-axis, side scatter height SSC-H). Cell cycle analysis on 
GFP positive cells was performed on day 7, 13 and 17 after transduction and Hoechst 
stain by flow cytometry. The S phase of shLCK (orange) was compared with S phase 
in shCtrl (blue) cells over time. PhosFlow determined LCK knockdown levels and 
activating p-Y394LCK reduction on day 8. As negative control an isotype control 
antibody (IgG) was used. Cell Trace Violet (CTV) labelling was used to assess cell 
proliferation of L963 (n = 1). Cells were labelled with CTV, transduced with shLCK or 
shCtrl and grown for another two weeks on OP9-DL1 feeder cells. Flow cytometric 
analysis of the CTV incorporation in GFP positive cells, shLCK (blue) and shCtrl (red), 







3.3.4.2 Knockdown of LCK by siRNA in PDX Leads to the Reduction of S Phase 
In addition to shRNA lentiviral transduction, siRNA oligonucleotides were designed 
against LCK allowing for transient knockdown of LCK in T-ALL PDX. LK203 and L963 
were electroporated consecutively every three days with 100 nM siRNA under 300 V 
for 5 ms (3 times). They were kept in vitro supported by OP9-DL1 feeder cells. LCK 
knockdown levels were assessed by flow cytometry on day 4 and day 9 with more 
pronounced knockdown of LCK observed at the latter time point. A 67% KD of p-
Y394LCK and 43% KD of total LCK protein were observed in LK203. L963 had a similar 
knockdown efficiency to LK203 (Figure 39). Moreover, LK203 proliferated much better 
in vitro with a substantial S phase while the majority of the population of L963 was at 
G0/G1 phase. After three electroporation, PI or Hoechst 33342 were used to determine 
cell cycle phases. A significant G0/G1 arrest was observed in LK203 (p = 0.004). A 
similar effect was shown in L963, however, as L963 initially had a substantial number 
of cells in G0/G1 phase, the increase in cell cycle arrest after LCK knockdown did not 
reach significance (p = 0.2039) (Figure 39). 
 
Figure 39. Successful LCK knockdown by siLCK in LK203 and L963 leads to 
G0/G1 arrest. Three consecutively siRNA electroporation were performed in PDX 
LK203 and L963 to knockdown LCK. As a control siRUNX1/ETO (siCtrl) was used. 
Total LCK and p-Y394LCK levels were examined by flow cytometry. Cell cycle 
distributions were determined on day 3, day 6 and day 9. Data were summarised and 
plotted in bar plots. Statistical analysis were performed on G0/G1 phase (n = 3, LK203 













Pharmacological Inhibition of LCK by Dasatinib Induces 











The kinase activity of LCK is controlled by pY394LCK at the kinase domain for positive 
regulation and pY505LCK at the cytoplasmic tail for inhibitory effects. In the latest report 
(Wan et al., 2019) where a FRET-based (Fluorescence resonance energy transfer-
based) biosensor for LCK was used in live cells demonstrated that a 60% portion of 
LCK was pre-activated with phosphorylated Y394 in T-ALL cell line Jurkat. Impairment 
of this phosphorylation site by the mutation of Y394F led to low levels of LCK 
aggregation at the plasma membrane and complete abolishment of the basal-level 
LCK activation (Wan et al., 2019). Activated LCK phosphorylates and activates CD3ζ 
(ITAMs), ZAP70 (pY493) and PLCγ (pY783), resulting in pTCR/TCR signalling 
cascades. 
Dasatinib (DAS) is a very potent dual ABL/SRC family kinase inhibitor in clinical trials 
of Philadelphia positive ALL and CML. In MRC (Medical Research Council) 
compound-screening, DAS effectively inhibits 100% activity of ABL1 and 99% activity 
of LCK at 0.1 μM and 1 μM. Inhibiting other SFKs (LYN, HCK or FGR) by dasatinib 
has been shown the efficacy in treating several types of leukaemia, such as JMML, 
CLL, and AML. In this study, DAS was selected to target LCK clinically.  
In healthy T cells (PBMCs, peripheral blood mononuclear cells), dasatinib has been 
shown to specifically block anti-CD3 induced activation of TCR signalling as 
demonstrated by reduced pAKT, pERK and CD69 expression (Schade et al., 2008). 
The successful application of chimeric antigen receptor (CAR) – engineered T cells in 
advanced malignancies has opened a new era for immunotherapy. However, the side 
effect -- cytokine release syndrome (CRS) remains a significant clinical challenge 
(Mestermann et al., 2019). Recently, dasatinib has been shown to act as a 
pharmacological on/off switch for CAR T cells to minimise CRS. The underlying 
mechanism is treatment with dasatinib inhibits LCK activation as well as impairs 
cytokine production and cell proliferation of CAR T cells. Moreover, this inhibitory effect 
can be fully reversed as dasatinib only halts cell proliferation of CAR T cells without 





4.2 DAS Abolishes LCK Activation in T-ALL Cell Lines and PDXs 
To access the effects of DAS on LCK, western blotting of phospho-LCK was performed 
on T-ALL cell lines and PDXs treated with control vehicle or DAS for 24 hours. 2 μM 
DAS was more or less the average IC50 values of SUPT1, Jurkat and CUTLL, therefore 
this concentration was used for T-ALL cell lines. The phosphorylation of both the 
activation site Y394 and inhibitory site Y505 of LCK was abolished entirely by DAS (2 
μM) in SUPT1, MOLT4 and CUTLL1 cell lines. Since LCK activates ZAP70 and PLCγ1 
by phosphorylation of Y493 and Y783 respectively (Brownlie and Zamoyska, 2013), 
the activation status of the LCK downstream targets PLCγ1 and ZAP70 were 
investigated. Treating cells with DAS led to reduction in p-Y783PLCγ1 and p-Y493ZAP70 
levels in T-ALL cell lines (Figure 40) indicating that DAS diminishes LCK kinase 
activity. The mode actions of DAS were also explored in T-ALL PDXs. Consistent with 
T-ALL cell line data, DAS (1 μM) inhibited p-Y394LCK and p-Y505LCK in all PDX tested 
(LK203, L963, L970, L907, L809 and LK080). In line with cell line data, activating 
phosphorylation of the downstream lipase PLCγ1 was abolished in PDX LK203, L963, 
L970 and L907 (Figure 40). Overall, this data indicates that LCK kinase activity is 






Figure 40. DAS abrogates LCK kinase activity in T-ALL cells. T-ALL cell lines (n = 
3) and PDXs (n = 2) were treated with 2 μM and 1 μM DAS respectively for 24 hours. 
Whole cell lysates were generated and applied to Western Blot analysis. LCK 
activation (p-Y394) and inhibition (p-Y505), PLCγ activation (p-Y783), ZAP70 
activation (p-Y493) and expression was examined using phosphor-specific antibodies. 
GAPDH or Clathrin served as housekeeping proteins. 
 
The effect of DAS on LCK was also assessed in L963 by PhosFlow. After 24 hour 
treatment of 1 μM DAS, p-Y394LCK reduced 85%, and total LCK decreased 67% 
(Figure 41). A decrease of LCK total protein was also observed in other samples by 
western blotting but not in this PDX (Figure 40) (Disucssion in Chapter 6.2.2.2). 
 
Figure 41. DAS inhibits LCK activation in T-ALL PDX L963. PhosFlow determined 
LCK activation and protein level in L963 after DAS treatment (1 μM for 24 hours, n = 
1) (x-axis represents the distribution of p-Y394LCK (PE) and LCK (Alexa Fluor 647), y-
axis shows events (cell counts)). The bar graph displays the median of p-Y394LCK 
(orange bars) and LCK (blue bars) (x-axis shows control and dasatinib treatment, y-




4.3 DAS Induces Cell Cycle Arrest in T-ALL 
4.3.1 DAS Induces G0/G1 Cell Cycle Arrest in T-ALLs 
T-ALL cell lines were treated with DAS for 24 hours and cell cycle analyses were 
performed after staining cells with Hoechst 33342 or PI. Treatment of DAS (2 µM) 
resulted in a significant G0/G1 arrest in MOLT4, SUPT1, and Jurkat. A similar effect 
was observed in HSB2 and KOPTK1 cells in which 100 nM DAS induced substantial 
G0/G1 cell cycle arrest. MOLT16 showed no significant difference in cell cycle profile 
after DAS treatment which is consistent with its resistance to DAS compared to other 
T-ALL cells (Figure 44). Similar studies were expanded to T-ALL PDXs. With 24-hour 
treatment of DAS (1 μM), LK203, L963 and LK080 showed significant cell cycle arrest 
(Figure 42). Overall, these data suggest DAS induces cell cycle arrest in T-ALL cells 
which resembles LCK knockdown effects. 
 
Figure 42. G0/G1 arrest after DAS treatment in T-ALL cell lines and PDXs. T-ALL 
cell lines and PDXs were treated with 2 μM or 1 μM DAS for 24 hours respectively. 
Cell cycle status was determined and shown in flow plots (red control; blue DAS-
treated, x-axis represents Hoechst distribution (DNA content), y-axis shows events 
(cell counts)) and bar plots (x-axis shows different samples with or without DAS 
treatment, y axis represents cell cycle phase (%), blue G0/G1 phase; orange S phase; 
and grey G2/M phase). Statistical analysis were performed on G0/G1 phase (n = 3, * p 





4.3.2 DAS Induces an G0 Cell Cycle Arrest in T-ALL Cell Lines 
To further evaluate DAS effect on cell cycle arrest, a method to differentiate the G0 
and the G1 phase was performed in Jurkat, SUPT1 and MOLT4 cells. Hoechst 33342 
was used for DNA content measurement while Pyronin intercalate into RNA allowing 
to separate G0 and G1 phases. Cells in G0 phase are often identified by low RNA 
content, therefore, this method could distinguish G0 and G1 phase.  
As little as 200 nM DAS treatment for 24 hours effectively induced G0 cell cycle arrest 
in Jurkat (from 2.9% to 17.6%) and SUPT1 cells (from 8.7% to 18.4%). With increasing 
concentration of DAS treatment, the degree of G0/G1 arrest did not further accumulate. 
Similar findings were observed in MOLT4 cells where DAS increased the G0 
population from 9.5% to 21.1%. 
 
Figure 43. DAS induces a G0 cell cycle arrest. T-ALL cells Jurkat (n = 2), SUPT1 (n 
= 2) and MOLT4 (n = 1) were treated with DAS for 24 hours. Increased concentration 
of DAS was applied to Jurkat and SUPT1 with 200 nM, 1 μM and 5 μM. MOLT4 was 
treated with 1 μM DAS only. Cells were stained with Hoechst and Pyronin and 
analysed by flow cytometry. X-axis, Pyronin staining demonstrates RNA content, Y-





4.4 DAS Sensitivity of T-ALL Cell Lines Correlates with LCK Activation 
Cytotoxic assays in nine T-ALL cell lines were performed to determine DAS sensitivity. 
The IC50 of DAS was determined by repeated independent experiments. HSB-2 and 
KOPT-K1 were very sensitive to DAS with an IC50 of 5 nM and 20 nM. SUPT1, CUTLL1 
and MOLT4 showed an intermediate response to DAS with an IC50 of approximately 
2 - 5 μM, whilst HPB-ALL, CCRF-CEM, DU528 and MOLT16 were more resistant to 
DAS with IC50 values of approximately 15 μM (Figure 44). At the same time, PhosFlow 
was used in all cell lines to determine the degree of LCK activation (p-Y394LCK) and 
expression (LCK). HSB-2 had much higher p-Y394LCK compared with other T-ALL cell 
lines as it carries a t(1;7)(p34;q34) LCK-TCRB translocation and its survival and 
proliferation was shown to heavily dependent on LCK (Wright et al., 1994). KOPT-K1 
had an intermediate p-Y394LCK/LCK ratio but showed much higher levels of p-Y394LCK 
by western blotting. Cell lines that expressed the lowest p-Y394LCK/LCK ratio were 
CCRF-CEM, DU528 and MOLT16. When correlating these two data sets, there was a 
significant negative linear correlation between DAS IC50 and p-Y394LCK/LCK (R2 = 
0.778, p = 0.004; Figure 44). This indicates that T-ALL cell line response to DAS is 
dependent on LCK activation, suggesting that at least in T-ALL cell lines, the primary 
target of DAS is LCK. 
 
Figure 44. DAS sensitivity correlates with p-Y394LCK/LCK in T-ALL cell lines. The 
IC50 of T-ALL cell lines was plotted on the y-axis (red: hypersensitive cell lines; blue: 
sensitive cell lines; and purple: resistant cells lines). PhosFlow determined the p-
Y394LCK/LCK ratio. The linear correlation analysis was performed in SPSS (R2=0.778, 
p=0.004). HSB2 was excluded from this analysis, as the extreme sensitivity to 
dasatinib was caused by the presence of a unique translocation absent in all other 





PDX samples were also used for evaluation of DAS sensitivity. Notably, PDX cells 
directly used after thawing failed to respond to DAS. As previously shown, DAS acts 
on cell proliferation by inhibiting cell cycle of T-ALL cells, PDX cells straight from 
thawing were almost all in G0/G1 phase; therefore, the failure in DAS sensitivity was 
expected. To restore cell cycle progression, PDXs were co-cultured with OP9-DL1 
feeder cells in vitro for at least one week. For DAS sensitivity assessment, PDX cells 
were washed and separated from feeder cells through multiple transfers to fresh 
plates. In general, DAS had clear cytostatic effects with a GI50 between 23.8 nM to 
6.36 μM on T-ALL PDXs. However, these values did not correlate with pSRC/LCK in 
PDXs which were analysed in parallel at the day of treatment. 
 
Figure 45. No significant correlation between the DAS GI50 and pSRC/LCK was 
identified in PDXs. Left, the table shows pSRC/LCK, GI50, and maximal inhibition 
(lowest viability) of PDXs. Right, correlation analysis of pSRC/LCK and GI50. R2 = 0.02, 
p = 0.81. 
 
In this setting, only six PDX samples were evaluated. LK287 was hypersensitive to 
DAS as this sample has a kinase activating genetic lesion (FIP1L1-PDFGRA). More 
investigations will be needed to be done to understand genetic aberrations of these 
PDX samples. Moreover expanding the PDX cohort will be necessary to assess the 






4.5 LCK Downstream Signalling Regulates Cell Cycle Progression 
4.5.1 Reverse Phase Protein Array (RPPA) Reveals Downstream Signalling of 
LCK in CUTLL1 Cells 
TCR signalling is known to regulate NFAT, AKT, ERK and NFκB signalling in healthy 
T cells, but which downstream signalling are more relevant for T-ALL cell proliferation 
remains less characterised. To address this question, protein lysates from shLCK#3, 
shZAP70#1 and shCtrl transduced CUTLL1 cells were collected and sent to the 
protein/antibody microarray facility of the University of Edinburgh for RPPA analysis. 
In total, 94 antibodies covering TCR signalling, JAK-STAT signalling, MAPK signalling, 
apoptosis, cell cycle, WNT signalling, P53 signalling and chemokine signalling 
pathways were used. As expected, the protein expression profiles after LCK 
knockdown and ZAP70 knockdown were significantly correlated (R2 = 0.23; p < 
0.0001). In shZAP70#1 transduced cells, 50% loss of ZAP70 was observed while no 
changes in ZAP70 expression were seen after shLCK#3 and shCtrl transduction as 
expected. Unfortunately, LCK antibody was not in the antibody panel, however, 
shLCK#3 induced the knockdown of pSRC by 60%. Around half of the proteins that 
were included in this array were significantly downregulated by both LCK knockdown 
and ZAP70 knockdown (p < 0.01). Among these proteins, p-AKTSer473, p-AKTThr308, p-
ERK1Thr202/204, p-ERK2Thr185/187, and p-MEK1/2Ser217/221 were dramatically 
downregulated after LCK knockdown (54%, 43%, 62% and 55% respectively) (Figure 
46). Similar effects were observed after ZAP70 knockdown but to a lesser extent. This 
study demonstrates that in the T-ALL cell line CUTLL1, LCK and ZAP70 knockdown 
leads to downregulation of the AKT and ERK signalling pathways, both situated 






Figure 46. RPPA analysis after LCK and ZAP70 knockdown in CUTLL1 cells. The 
top 50 downregulated protein targets after LCK and ZAP70 knockdown. Light grey (0 
to -0.5): no change to 30% downregulation; dark grey (-0.5 to -1.0 to more): 





4.5.2 G0/G1 Arrest of shLCK Might Be Due to the Reduction of AKT and/or ERK 
Signalling 
RPPA data suggest that downregulation of AKT and ERK signalling pathways might 
contribute to cell cycle arrest after LCK knockdown. To verify this hypothesis, the AKT 
inhibitor MK2206 and the ERK inhibitor SCH772984 were used on T-ALL cell lines. 
Same amounts of inhibitors were applied to T-ALL cell lines for 24 hours to compare 
the effect of DAS, MK2206 and SCH772984. After PI staining and cell cycle analysis, 
a more pronounced cell cycle arrest was observed in DAS treated cells compared with 
AKT and ERK inhibitor-treated cells. In CUTLL1, Jurkat and MOLT4, both MK2206 
and SCH772984 induced G0/G1 arrest. But only the AKT inhibitor induced cell cycle 
arrest in SUPT1 cells. No effect on cell cycle after ERK inhibition was observed at 
least at this concentration (Figure 47). Cytotoxic assays demonstrated varying 
responses to the AKT inhibitor MK2206 on T-ALL cell lines, yet a cell cycle arrest was 
observed in all four cell lines. Consistent with the fact that there is no effect of 
SCH772984 on the cell cycle of SUPT1 cells, SUPT1 cells are highly resistant to this 
ERK inhibitor in toxicity studies (Figure 47). These data suggest that T-ALL cell cycle 
progression is controlled by LCK via at least two downstream signalling pathways, i.e. 






Figure 47. Cell cycle and cytotoxicity analysis of T-ALL cells after LCK, AKT and 
ERK inhibition. CUTLL1, Jurkat, MOLT4 and SUPT1 were treated with DAS (1.5 μM), 
MK2206 (1.5 μM) and SCH772984 (1.5 μM) for 24 hours (n = 1). Cell cycle profiles of 
the vehicle (red) and inhibitor-treated cells (blue) were overlayed. The y-axis 
represents PI distribution (DNA content), the x-axis represents events (cell counts). 
The cytotoxicity curves of these four T-ALL cell lines (black, MOLT4; blue, CUTLL1; 
red, SUPT1; and purple, Jurkat) were determined using a resazurin assay. The y-axis 
represents the cell viability (%), the x-axis represents the concentration of the AKT 



















Dasatinib and Dexamethasone Offer a Novel Therapeutic 











DAS leads to cell cycle arrest in T-ALL cell lines and PDX cells indicating that DAS 
treatment of T-ALL has a cytostatic, rather than cytotoxic effect. In practice, effective 
eradication of ALL requires combinatorial treatment. We thus investigated potential 
synergy between DAS and the glucocorticoid dexamethasone (DEX), which is a core 
component of the first-line multi-agent chemotherapy in treating paediatric ALL. 
However, 20% of T-ALL patients experience relapse, which is often DEX-resistant. In 
T-ALL, inhibition of IL-7R signalling or AKT function has been shown to enhance DEX-
induced cell death (Li et al., 2016; Piovan et al., 2013). 
Acute leukaemia PDX samples can be used in a phase II-like mouse trial that mimics 
human randomised clinical trials. Such an experiment can reveal drug efficacy and 
generate biomarkers in both treatment-naïve and relapsed/refractory disease. The 
benefit of phase II-like clinical trials in mice is to make the comparison between 
treatment arms very comparable to a human phase-II study since multiple PDXs will 
be assessed in parallel and any significant data will be more meaningful. It also allows 
for studying a wide range of heterogeneous biological samples to identify potential 
drug response biomarkers. In another relevant study, pilot drug studies were designed 
using an MDM2 inhibitor CGM097 in B-ALL to compare three-versus-three (three mice 
per treatment arm) and one-versus-one (one mouse per treatment arm) trial settings. 
Similar results were observed between the two formats indicating the one-mouse-
cohort study was sufficient for mouse clinical trials (Townsend et al., 2016). 
Leukaemia infiltration into the CNS remains a clinical challenge in curing ALL patients. 
Most optimal levels of chemotherapy drugs are reduced after the blood-brain barrier; 
therefore, CNS provides a protected niche for leukaemia cells. Mechanically, ZAP70 
has been shown to correlate with CNS in B-ALL while CNS positive T-ALL patients 
express higher CCR7/CXCR4 (Alsadeq et al., 2017). In UKALL2003, 12% of T-ALL 
patients develop CNS disease, while only 5% of B-ALL patients show CNS disease. 
Therefore, to develop a novel drug combination that could reverse DEX-resistance 







5.2 LCK Knockdown Cells Are Re-sensitised to DEX 
After silencing LCK by shLCK#1 and shLCK#3 in SUPT1 and CUTLL1 cells, the cell 
viability was measured in the presence of increasing concentrations of DEX (0 - 1699 
nM). Wildtype cells (Mock, grey) and control shRNA transduced cells (shCtrl, black) 
were resistant to DEX while LCK knockdown cells (shLCK#1 in red and shLCK#3 in 
blue) were sensitive to DEX (Figure 48). In SUPT1 cells, a more pronounced 
knockdown by shLCK#3, compared with shLCK#1 (Figure 30), led to a more 
significant effect of re-sensitisation of cells to DEX. These data indicated that LCK 
inhibition could reverse DEX resistance. 
 
Figure 48. Knockdown of LCK re-sensitises SUPT1 and CUTLL1 to DEX. T-ALL 
cell lines SUPT1 and CUTLL1 were transduced with shLCK#1, shLCK#3 and shNTC. 
Cytotoxic assays of DEX were performed in knockdown cells (blue: shLCK#3; red: 
shLCK#1) and control cells (black: shNTC; grey: mock (wildtype) cells). The x-axis 
represents DEX concentration (0 - 1699 nM), the y-axis shows cell viability of 




5.3 Drug Matrix Analysis of DAS and DEX Reveals Synergy in T-ALLs 
To further evaluate the relationship between LCK inhibition and DEX response, drug 
matrix analyses were performed. For each matrix, T-ALL cells were seeded into three 
96-well plates. DAS and DEX were titrated in two dimensions. Cell viability was 
measured by CCK-8 after 72-hour treatment. 
 
5.3.1 Drug Matrix of T-ALL Cell Lines 
Ten T-ALL cell lines were used to examine drug interactions of DAS and DEX. DEX 
was titrated from 0.09 nM – 600 nM in all matrixes. However, DAS was titrated 
differently according to cell line sensitivity: 0.08 μM – 50 μM for SUPT1 and Jurkat; 
0.37 μM – 30 μM for CUTLL1, CCRF-CEM, MOLT16, HPB-ALL and MOLT4; 0.005 
nM to 50 nM for HSB2, KOPTK1 and ALL-SIL. These concentration ranges were 
chosen based on cytotoxicity studies of dasatinib in these cell lines, however, the 
highest concentration of DAS (30-50 μM) might have potential off-targets in T-ALL 
cells. 
The cell viability of SUPT1 exposed to DEX decreased in the presence of DAS in a 
concentration-dependent manner. Data were generated in triplicates and imported into 
Combenefit (Di Veroli et al., 2016) to interrogate drug interaction. This software gave 
drug synergy (blue) or antagonism (red) based on the Loewe model (Loewe, 1926). 
There were several synergistic combinations of DEX and DAS in SUPT1 cells 
indicated by dark blue colour. In order to analyse the significance of the data generated 
of all ten T-ALL cell lines, a scatterplot was generated indicating significant enrichment 
of drug synergy in the area (shaded box) of loge(DEX concentration) from 2.7 to 4.7 (8 
- 110 nM) and loge(DAS concentration) from -1.5 to 1.5 (0.223 - 4.5 μM) (Figure 49). 
This concentration ranges included the clinically applicable Cmax of DAS (264 nM) 
(Liston and Davis, 2017) and DEX (100 nM) (Yang et al., 2008). Thus, DEX and DAS 







Figure 49. Drug matrix analysis in T-ALL cells demonstrates significant drug 
synergy, including Cmax of DAS and DEX. Matrix was plotted in cytotoxicity curves 
of DEX in the presence of different levels of DAS and the synergy plot from 
Combenefit. (Left) The cell viability of SUPT1 cells after exposure to DEX (0 - 600 nM) 
and DAS (black: 0 μM; blue: 0.08 μM; and red: 2 μM) as derived from the drug matrix 
analysis. (Middle) Drug synergy plot as drawn by Combenefit using DAS (0 - 50 μM) 
and DEX (0 - 600 nM) on SUPT1 cells. (Right) Combined statistical analysis (by Dr 
Amir Enshaei) of all drug matrices derived from 10 T-ALL cell lines was performed in 
RStudio (area of the circles indicate synergy levels; red colour shading: the darker, the 
higher the cell viability). The x-axis represents the DEX concentration ((loge(DEX)= -3 
– 7; 0 - 600 nM) and the y-axis represents the DAS concentration (loge(DAS)= -13 – 
4; 0.005 nM – 50 μM). The size of the circle represents the level of synergy observed. 
The shaded grey square highlights drug concentrations resulting in statistically 
significant drug synergy and loss of cell viability. This grey shaded area includes 




5.3.2 Drug Matrix of T-ALL PDXs 
Similar studies were performed in T-ALL PDXs. The PDX cells were thawed and co-
cultured on OP9-DL1 cells for one week (L903, LK214, and LK809) or several weeks 
(LK080, L963 and LK203). As no cytotoxic assays of single drug DAS or DEX were 
performed previously on these PDXs in our laboratory, the range of drug 
concentrations used in cell lines was applied in the PDX drug matrices. After co-
culture, PDX cells were separated from feeder cells by multiple transfers. PDX cells 
were counted and seeded in three 96-well plates for one drug matrix analysis. DAS 
and DEX were added in the plates on the same day. Three days later, plates were 
developed by CCK-8. Data were normalised relative to the control well (0 nM DEX and 
0 μM DAS). Combenefit gives both the viability and the degree of synergy as shown 
in Figure 39. Overall, synergy was observed in all six PDXs, though at variable 
concentrations of DAS and DEX (Figure 50). 
 
Figure 50. Drug matrix analysis of PDXs. DEX and DAS were titrated in two 
dimensions in a range of 0 - 600 nM and 0 - 50 μM respectively. CCK-8 measured 
cell viability after 72-h drug treatments. Data points were analysed by Combenefit and 
generated synergy plots (blue: synergy; red, antagonism). Viability plots (shaded 





5.3.3 DAS and DEX Induce Apoptosis 
Based on drug matrix assays, DAS and DEX in combination led to a decrease in cell 
viability, however, whether this was dependent on apoptosis remained an open 
question. To address this, Annexin V/viability (Live-Dead aqua) staining was 
conducted in Jurkat cells treated with 2 μM DAS and/or 100 nM DEX after 24 h and 
48 h. 
Since Jurkat is a DEX-resistant cell line, 100 nM DEX did not induce any cell death. 
On the contrary, 2 μM DAS induced 6.1% early apoptosis. Furthermore, DAS in 
combination with DEX led to 14.6% early apoptosis (AnnexinV+/Live-Dead aqua-) 
without affecting the percentage of dead cells (Live-Dead aqua+; Figure 51). After 
incubation of cells for another 24 hours, Annexin V staining identified more dead cells 
in DAS (30.5%), and combination (52.2%) treated samples compared with the control 
sample (18.0%) (Figure 51). Taken together, this data suggests that the DAS and DEX 
combination induces increased apoptosis-induced cell death compared to no 





Figure 51. Drug combination of DAS and DEX induces greater apoptosis-
induced cell death in Jurkat cells. Jurkat cells were treated with DAS (2 μM) and 
DEX (100 nM) for 24 hours and 48 hours, respectively (n = 1). Annexin V and 
Live/Dead Aqua separated the live cells (bottom left, Annexin V- Aqua-), apoptotic cells 
(bottom right, Annexin V+ Aqua-) and dead cells (top right, Annexin V+ Aqua+). The bar 
graph shows the proportion of live cells (blue, AnnexinV- Aqua-), early apoptotic cells 
(grey, Annexin V+ Aqua-) and dead cells (orange, Annexin V+ Aqua+) under drug 
treatment as determined by flow cytometry and indicated in dot plots. 
 
5.4 A Phase II-like Trial in Mice Confirms the Synergy between DAS and DEX 
5.4.1 Toxicity Study of the Combination of DAS and DEX in vivo 
Our lab has previously used DEX in in vivo mouse models. Based on these 
experiments, the appropriate dosing of DEX in NSG mice was established as 1 mg/kg. 
At this concentration, it will reach a mouse plasma level of 100 nM which is similar to 
the Cmax in patients (Yang et al., 2008). However, for DAS, several pieces of literature 
have published on DAS doses in vivo where they applied from 5 mg/kg to 50 mg/kg. 
This however did not help to predict the suitable dosing for drug combinations of DAS 
and DEX. 
Therefore, a pilot toxicity study was performed in a small number of NSG mice to 
explore the maximal tolerated dosing of DAS in combination with 1 mg/kg DEX. Six 
healthy NSG mice (three males and three females) were dosed daily (Monday to 
Friday) with one single combined dose of 1 mg/kg DEX and DAS by intraperitoneal 
(IP) injection. Mice were examined and weighed daily. The starting dose of DAS was 
5 mg/kg. The dose was increased to 10 mg/kg, 20mg/kg and 35mg/kg in the following 
weeks. While this experiment was ongoing, a study was published showing 
combination dosing of DEX (5 mg/kg) and DAS (35 mg/kg) in vivo (Serafin et al., 2017). 
Thus, the DAS dosing was set according to this study and evaluated how many weeks 
the mice would tolerate this drug regimen. Using DEX 1 mg/kg and DAS 35 mg/kg 
mice lost weight during drug treatment within the accepted range of 10%. On the 3rd 
week, all six mice lost around 10 - 15% of weight indicating that they could not tolerate 
this dose any longer. In particular, NN (m) reached 15.3% weight loss, thus dosing 
was stopped on that day. It regained weight and the dosing was restarted. Weight 
monitoring was continued for more than 10 days after dosing finished. Overall, mice 




weight around 12 days later. Mouse NN (f) had to be euthanised as it showed 15% 
weight loss for three consecutive days (Figure 52). In summary, our pilot study 
indicated that the maximum tolerated dosing for NSG mice is 35 mg/kg DAS with 1 
mg/kg DEX for in total three weeks. 
 
Figure 52. The weight monitoring and dosing timeline of six healthy mice in the 
toxicity study. Mice weights (f: female; m: male) were monitored daily for seven days 
before the toxicity study commenced. Both drugs, DEX and DAS, were were 
resuspended in distilled water and injected intraperitonealy. DEX was applied daily at 
1 mg/kg throughout the study. DAS was dosed daily at 5 mg/kg for the 1st week, 10 
mg/kg for the 2nd week, and 20 mg/kg for the 3rd week, and kept at 35 mg/kg for the 
following three weeks. Dosing was stopped after 6 weeks because significant weight 
loss was observed. The weights were monitored for another 10 days after stopping of 
the treatment in order to evaluate whether observed toxicity was reversible. 
 
5.4.2 Study Design of a Murine phase-II-like Trial 
To evaluate the efficacy of combination treatment, we used 10 T-ALL PDXs for a 
phase II-like trail in mice. All 10 PDXs were generated from NSG mice which had been 
injected with primary patient T-ALL samples previously. The survival time of those 
primary engrafted mice varied from 48 - 216 days (Appendix 4). For the murine phase-
II like study, each PDX was intrafemorally injected into 4 NSG mice (40 mice in total). 
T-ALL engraftment was monitored weekly by tail bleeds (20 μl blood/mouse) and 
peripheral blood staining for hCD7, hCD45 and mCD45. The 4 mice derived from each 
PDX were randomised to receive the vehicle, DAS alone (35 mg/kg), DEX alone (1 
mg/kg) or the combination treatment (35 mg/kg DAS plus 1 mg/kg DEX) by 




blood hCD45+ cells). Mice were dosed once daily from Monday to Friday. Treatment 
was given for two or three weeks depending on the rate of engraftment and 
progression. In cases where the PDXs engrafted very quickly, the mice were not kept 
alive for another weeks’ dosing. In the end, mice of the same PDX were sacrificed at 
the same time to assess leukaemia progression and combination treatment efficacy 
(Figure 53). For analyses, mice blood, spleen, bone marrow, liver and CNS infiltration 
were harvested and tumour infiltration was determined by flow cytometry. 
 
Figure 53. Schematic representation of the phase II-like clinical trial in mice. Ten 
T-ALL PDX samples were injected into 40 NSG mice (4 mice each PDX). Leukaemia 
engraftment was monitored by tail bleeds every week. Mice were randomised to 
receive control vehicle, DAS (35 mg/kg), DEX (1 mg/kg) or drug combination (DAS 35 
mg/kg + DEX 1 mg/kg). The peripheral blood monitoring was continued during the 
dosing. Treatment was given for 2 or 3 weeks. When any of the four mice derived from 
1 single PDX showed clinical symptoms, all four mice were killed and spleens, bone 





5.4.3 Peripheral Blood Monitoring for Disease Progression and Treatment 
Effects 
For peripheral blood engraftment monitoring, 20 μl of blood drawn from the mouse tail 
vein was stained weekly for hCD7, hCD45 and mCD45. Human leukaemia blast 
engraftment was shown by hCD45 or hCD7 cells in mouse blood. The dosing was 
commenced once > 1% (except L903 was started > 0.5%) peripheral blood 
engraftment was observed. The engraftment rate varied for different PDXs; LK080 and 
LK287 were dosed starting on the 3rd week after injection; L963 and LK203 were dosed 
starting on the 4th week after injection; L970 were dosed starting on the 6th week and 
L809, L903, LK290 and L907 were dosed starting on the 7th week. The dosing time 
was determined by clinical symptoms as observed in the mice. In order to determine 
the final peripheral blood engraftment, we collected mice blood right after euthanizing 
out of the eyeball after removing (Figure 54). 
 
Figure 54. Peripheral blood monitoring in 35 mice derived from nine PDXs. 
Mouse tail vein blood was taken every week to monitor leukaemia engraftment in vivo. 
The four mice of each PDX was allocated to different treatment groups randomly: 




window was shown with dotted lines. Time (days after injection of leukaemia cells) 
was shown on the X-axis while the percentage of human cells (hCD45+ or hCD7+) in 
mouse blood was shown on the Y-axis. 
 
5.4.4 Drug Efficacy in Mouse Bone Marrow, Spleen, and Liver Engraftment 
It was very challenging to determine when to euthanise the mice for such an elaborate 
experiment. In most of the cases, such as LK080, L809, L963, LK287, LK203 and 
L970, the mice were harvested because the control vehicle mouse had high 
engraftment (> 70% hCD7+/hCD45+ cells) as established by peripheral blood staining. 
In the case of L903, the mice were harvested due to sickness of the mouse receiving 
the combinatorial treatment. For L907, the four mice were harvested because of high 
engraftment in the peripheral blood in the DAS treated mouse, which might have been 
due to higher engraftment rate prior to commencing dosing. For LK290, since the 
engraftment in the peripheral blood fluctuated (maximal 55% and 60%) in mice 
injected with the primary patient sample (n = 2), these mice were harvested when the 
control vehicle mouse reached 51% engraftment in peripheral blood. LK214 was 
excluded from the whole analysis because of experiment failure; this PDX samples 
engrafted so quickly that the mice had to be euthanised before treatment was 
commenced. At the end of the experiment, mice’s peripheral blood, spleen, bone 
marrow and liver were analysed for 35 mice (the DAS mouse of LK080 died before the 
experiment commenced). 
For the spleen samples, only PDXs that engrafted in the spleen as determined by 
enlarged spleens were taken into consideration for the analysis. Therefore, spleens 
derived from L903 and LK290 were excluded from the analysis. Spleen weights were 
recorded, and spleen sizes of 5 PDXs were captured in photos. Among the same PDX, 
the combination treated mouse displayed the smallest spleens compared to the control 
mouse or DEX/DAS single arm treated mice. Taken all the weights in statistical 
analysis, it turns out that control and single drug-treated mice had significantly more 






Figure 55. Spleen weights and size of spleens in the phase II-like murine trial. 
Mouse spleens of 5 PDXs were imaged at the same scale. Spleen weights are 
indicated. The dot plot shows spleen weights of all seven PDXs on the Y-axis with 
treatment arms on the X-axis. Statistical analysis was performed in R Studio by the 
linear mix model (Ctrl vs Combo, p = 0.00296; DAS vs Combo, p = 0.006699; DEX vs 





After homogenising material through a cell strainer with PBS, spleen and liver samples 
were stained with mCD45, hCD45 and hCD7. The end-point peripheral blood and 
bone marrow samples were also incubated with the same staining antibody cocktail. 
After (FSC/SSC) gating of singlets, doublets exclusion and exclusion of dead cells, 
flow cytometry dot plots were generated showing degree of PDX engraftment (mCD45 
vs hCD7 or mCD45 vs hCD45; Figure 56). 
 
Figure 56. Gating strategy of flow cytometry data to assess human leukaemia 
cell engraftment in mouse spleens. Flowjo analysis was performed after acquiring 
samples on a BD FACSCanto II. Each sample was (i) gated according to their 
appearance in FSC vs SSC to exclude any debris, (ii) cleaned of doublets by FSC-A 
vs FSC-H and (iii) pruned of any dead cells by gating out Live/Dead Aqua positive 
cells. hCD45 or hCD7 positive cells in the live cell population were considered  human 
leukaemia cells. In this example of L970, the leukaemia engraftment in the 
combination treatment mouse and the control mouse was 45% and 99% respectively. 
 
Of nine T-ALL peripheral blood samples (round dots), the combination treatment group 
had significantly less engraftment judged by hCD7+ cells compared to control (p = 
0.000001393), DAS (p = 0.00593), or DEX-treated mice (p = 0.0003794).  Seven 
PDXs were included in spleen engraftment analysis (squares). Also in spleen 
leukaemia progression was significantly impaired when combination treatment was 
applied. DAS and DEX in combination was substantially more effective than vehicle (p 
= 0.0009869) or single drug treatment (p = 0.01104 when compared with DAS and p 




injection. Bone marrow samples were harvested from both left and right femurs. In the 
final analysis (triangles) of 9 PDXs, the combination treatment significantly reduced 
leukaemia burden in bone marrow compared with control (p = 0.0000557), DAS (p = 
0.008554) and DEX treatment (p = 0.00684). Initially, liver samples were not 
considered for analysis. However, it was observed that leukemia cells inflitrated to 
mouse livers, therefore liver samples had been also assessed, though no liver 
samples were collected from the first three PDXs. The remaining 6 PDXs were used 
to analyse liver engraftment. Consistent with the previous analyses in other organs, 
the combination treated mice had least liver engraftment among four treatment arms 
(Figure 57). 
 
Figure 57. End-point analysis of human leukaemia engraftment (hCD7+) in NSG 
mice. Human leukaemia engraftment was determined by hCD7+ expression in 
peripheral blood (n = 9), spleen (n = 7), bone marrow (n = 9) and liver (n = 6) samples 
were plotted (black, control vehicle; blue, DAS; green, DEX; red, DEX in combination 






Similar analyses were performed using hCD45+ cells as marker of human leukaemia 
engraftment. Seven out of nine PDXs expressed similar amounts of hCD45 and hCD7. 
LK290 had lower hCD45+ expression than hCD7+, while L970 had lower median 
expression of hCD45 compared with hCD7. However, overall the results of leukaemia 
engraftment remained similar, using either hCD45 or hCD7 as marker. In peripheral 
blood (n = 9), spleen (n = 6), bone marrow (n = 9) and liver (n = 6) samples, the 
combination treatment was significantly better than control or single drug treatments 
in impairing leukaemia engraftment (p values indicated in the graph) (Figure 58). 
 
Figure 58. End-point analysis of human leukaemia engraftment (hCD45+) in NSG 
mice. Samples examined in Figure 46 were assessed at the same time also for their 
hCD45 expression. Peripheral blood (n = 9), spleen (n = 6), bone marrow (n = 8) and 
liver (n = 6) samples were plotted (black, control vehicle; blue, DAS; green, DEX; red, 






All statistical analysis above were carried out with RStudio (Team, 2017) using a linear 
mixed effects model (Bates, 2014) with a varying intercept of PDX, and a fixed effect 
of drug treatments. P-values were obtained by likelihood ratio tests of the full model 
with the effect of PDX IDs against the model without the PDX IDs. 
Although, in general, all mice included in this trial responded very similar according to 
their treatment arms, there were some outliers. The mice derived from PDX LK080 
and L907 and treated with combination treatment had high leukaemia engraftment (the 
top two red dots of Figure 57 and Figure 58) in some organs similar to those of their 
control treated mice. There are several explanations for these observations: 1) LK080 
derived mice were harvested three weeks after finishing drug treatments. Without 
being treated the leukaemia progressed very rapidly in these three weeks as shown 
by peripheral blood monitoring resulting in enlarged spleens (Ctrl 0.76 g, DEX 0.75 g, 
Combination 0.57 g) which were heavily infiltrated with leukaemia cells (Figure 54), 2) 
During the three week treatment window, PDX L907 had the least response to 
combination treatment compared with other T-ALLs. For example, after the complete 
dosing schedule the engraftment of the combination treated mouse versus the control 
treated mouse of L963 was 1.4% versus 79.7%, of LK287 was 28.7% versus 82.2%, 
of LK080 was 7.0% versus 30.2%, of L970 was 2.0% versus 75.8%, of L809 was 
0.92% versus 80.9%, but for L907 it was 58.5% versus 73.4%. Although there was a 
difference in spleen weights of the combination treated mouse (0.15 g) versus the 
control mouse (0.38 g), no substantial difference in spleen engraftment was observed 
(Figure 54, Figure 57 and Figure 58). In addition, the DAS treated mouse of L907 had 
the quickest engraftment in the peripheral blood and most prominent spleen size 
among the four mice. This was possibly due to either higher engraftment at the 





5.4.5 Drug Efficacy in Mouse CNS 
The CNS infiltration is common in T-ALL which makes the eradication of leukaemia 
from CNS is crucial for cure. To investigate how DEX+DAS affects the CNS leukaemia 
burden, whole brain-skull preparations from mice in the murine phase ‖-like trial were 
made. The evaluation for CNS leukaemia engraftment was performed in collaboration 
of Dr Christina Halsey in University of Glasgow. Notably, PDX samples displayed 
considerable heterogeneity in overall CNS infiltration as indicated by the infiltration of 
control animals. In 7 out of 9 PDXs, DEX alone produced a reduction in CNS 
leukaemia infiltration while DAS alone affected 4 out of 8 PDXs. Notably, the 
DEX+DAS therapy was particularly effective, with complete removal of measurable 
CNS leukaemia engraftment in 5 PDXs and less engraftment in 3 out of 4 remaining 
PDXs. Statistical analysis of the cohort of 9 PDX samples, a significant reduction of 
leukaemia infiltration in CNS was shown only in DEX+DAS group (Figure 59).  This 
demonstrates that on the one hand the high efficacy of DEX+DAS might overcome 
CNS engraftment of T-ALL, on the other hand, the maximum effect of DEX+DAS group 
might be simply due to the least leukaemia engraftment overall in NSG mice as 






Figure 59. CNS engraftment in the murine phase ‖-like trial.  Top, the average 
depth of CNS engraftment across 5 coronal sections per mouse analysed by paired t-
test, significance level * p < 0.05. Means of the 5 individual measurements of the depth 
of each mouse are shown in the table. Bottom, Photomicrographs of whole brain-skull 
sections stained with hematoxylin and eosin from PDX L809, left panel – low power 
scout view of whole brain with an area shown in all other images is marked by a black 
box; centre and right panels – high power view (x 20 objective) of meninges around 
the central venous sinus, red arrows mark the leukemic infiltration. Scale bar marks 1 
mm on scout view and 100 μm on high power images. These analysis have been 





5.4.6 DAS Inhibits LCK Activity in vivo 
To investigate whether DAS could inhibit LCK in vivo, PDX L809 cells isolated from 
mouse spleens after three weeks of drug treatment in the phase II-like murine trial 
were harvested and examined by Western Blot analysis. DAS and DAS+DEX 
combination completely abolished LCK phosphorylation at Y394 and Y505. Also, total 
LCK was decreased substantially after three weeks of treatment compared to the 
control cells, treated with the vehicle alone (Figure 60). This data demonstrates that 
DAS, in presence or absence of DEX, affects both overall LCK levels and LCK 
activation phosphorylation resulting in an efficient inhibition of LCK in vivo. 
 
Figure 60. DAS diminishes LCK levels in L809 in vivo. L809 human leukaemia cells 
derived from the spleen of mice treated in the phase II-like murine trial were examined 
by western blotting of whole cell lysates for p-Y394LCK, p-Y505LCK, total LCK and 
GAPDH. 
 
As shown previously in vitro short exposure to DAS for 24 hours led to p-Y394LCK and 
p-Y505LCK reduction, but no apparent change in total LCK in L809 (Figure 40). 
However, long term treatment of DAS or DAS+DEX combination for three weeks in 
vivo, also total LCK protein expression was substantially reduced (Figure 60). These 
results suggest that in the short exposure to DAS, its occupancy of the nucleotide-
binding site of LCK abrogates the kinase activity without affecting total protein levels. 





5.5 Potential Mechanisms Underlying DAS and DEX Synergy 
5.5.1 LCK Inhibition Enhances GILZ Expression after DEX Exposure 
One gene target of GR signalling – Glucocorticoid-induced leucine zipper (GILZ, also 
known as TSC22D3) was used to evaluate drug synergy mechanisms of DAS and 
DEX. After knockdown of LCK, 100 nM DEX was applied to Jurkat cells (DEX-
resistant). RNA samples were collected after 24-hour treatment, and GILZ expression 
was interrogated by qRT-PCR. In this experiment, the LCK knockdown level achieved 
was 72%. Whereas DEX treatment induced 27 fold induction of GILZ in control cells 
with normal LCK levels, knockdown of LCK induced an 80 fold increase of GILZ mRNA 
expression (Figure 61). This result suggests that LCK knockdown cells might be at 
least 3 fold more sensitive to DEX compared with control cells, indicating that LCK 
levels and/or activity supports DEX resistance at least in Jurkat cells. 
 
Figure 61. LCK depletion re-sensitises Jurkat cells to DEX. Jurkat cells were 
transduced with shNTC or shLCK#3 expression constructs. Stable knockdown cells 
were treated with DEX (100 nM) for 24 hours and analysed by qRT-PCR for GILZ 
expression levels, relative to GAPDH and normalised to shNTC control vehicle 








LCK depletion-mediated re-sensitisation of cells to DEX was further assessed by using 
DAS. To evaluate this effect to a broader extent, six T-ALL cell lines that showed a 
strong synergistic effect of DEX+DAS in drug matrix analysis and five T-ALL PDXs 
were used in this experiment. 
T-ALL cell lines were treated with 2 μM DAS and/or 100 nM DEX for 24 hours. RNA 
samples were collected, and GILZ expression was measured by qRT-PCR. Similar to 
LCK knockdown results, DAS alone could only induce 2 - 4 fold GILZ induction. DEX 
treatment led to 7 - 74 fold (CCRF-CEM 28 fold; CUTLL1 13 fold; Jurkat 7 fold; SUPT1 
44 fold; MOLT16 23 fold; MOLT4 74 fold) induction of GILZ expression compared with 
the control sample. Strikingly, all T-ALL cell lines showed a substantial increase of 
GILZ expression after DEX and DAS combination treatment (CCRF-CEM 84 fold; 
CUTLL1 154 fold; Jurkat 216 fold; SUPT1 221 fold; MOLT16 293 fold;  MOLT4 364 
fold) (Figure 62). Taken together, in T-ALL cell lines, DAS and DEX synergistically 
induce substantial GILZ expression which might also apply to other DEX-targeted 
genes. Further investigations addressing DAS enhancing DEX-targeted genes will be 
performed in the future. 
 
Figure 62. Heatmap demonstrating GILZ induction after DEX and/or DAS 
treatment in T-ALL cell lines and PDX cells. Six T-ALL cell lines (CCRF-CEM, 
CUTLL1, Jurkat, SUPT1, MOLT16 and MOLT4) were treated with 100 nM DEX and/or 
2 μM DAS for 24 hours. GILZ expression (normalised to GAPDH expression) was 
determined by qRT-PCR (scale varying between 0 - 400 fold changes). Five T-ALL 
PDXs (L970, L809, LK080, L907 and LK203) were treated with 100 nM DEX and/or 1 
μM DAS for 24 hours. GILZ expression (normalised to GAPDH expression) was 





T-ALL PDXs (L970, L809, LK080, L907 and LK203) after in vitro expansion were 
treated with 1 μM DAS and/or 100 nM DEX. After 24 hour treatment, RNA samples 
were collected. GILZ expression levels were examined by qRT-PCR. Consistently with 
T-ALL cell lines, DAS alone induced a 2 fold increase of GILZ expression, indicating 
that LCK inhibition itself did not alter GILZ expression substantially.  
Regarding DEX+DAS effect, PDX samples showed varied effects of DAS and DEX 
combination. PDX LK080, L907 and LK203 showed a similar response to T-ALL cell 
lines. DEX treatment alone induced GILZ expression by 49, 167 and 162 fold, whilst 
DEX in combination with DAS induced GILZ by 105, 217 and 240 fold, respectively 
(Figure 62), however, PDX L809 treated with DEX+DAS showed a smaller increase in 
GILZ expression of 39 fold, which was similar to DEX only treatment (31 fold).  
L970 was the only PDX that showed less GILZ induction after combination of DEX 
with DAS (Figure 62). Further investigation showed that DEX treatment induced a 70% 
reduction of LCK on mRNA expression levels. DEX+DAS sample had more than 90% 
reduction of LCK and even less GILZ induction compared with the DEX-treated sample 
(Figure 63). The decrease of LCK by DEX was only observed in L970 but no other T-
ALL cells (Discussion chapter 6.2.5). These data indicate that LCK inhibition re-
sensitises cells to DEX as shown by a substantial increase of DEX-targeted gene 
GILZ. 
 
Figure 63. Transcriptional expression levels of GILZ and LCK in PDX L970 after 
drug treatment. L970 cells were treated with control vehicle (ctrl), DAS (1 μM), DEX 
(100 nM) and combination drugs for 24 hours. GILZ (left) and LCK (right) mRNA 




5.5.2 The ERK Pathway Might Play a Role in DAS/DEX Synergy 
To have more understanding of the mechanism underlying the observed drug synergy 
between DAS and DEX, the downstream signalling pathways of LCK were 
interrogated. Our previous RPPA analysis identified the ERK and AKT pathways as 
the predominant signalling pathways activated downstream of LCK in the T-ALL cell 
line CUTLL1. AKT has been shown to trap GR in the cytoplasm by regulating GR 
phosphorylation at Ser132 resulting in glucocorticoid resistance in T-ALL (Piovan et 
al., 2013). RAS mutations led to less sensitivity to prednisone in a cohort of 109 infant 
ALLs (Driessen et al., 2013). Also, steroid-resistant relapse might be conferred from a 
subpopulation of diagnostic samples with KRAS mutations (Irving et al., 2014). 
The AKT inhibitor MK2206 and ERK1/2 inhibitor SCH772984 were used to examine if 
these pathways were involved in re-sensitising cells to DEX. In the presence of an 
inhibitor to LCK, AKT or ERK, there was minimal induction of GILZ mRNA expression 
in T-ALL cells. DEX-induced expression of GILZ was further increased when combined 
with DAS, MK2206, SCH772984, or both MK2206 and SCH772984 inhibitors. Notably, 
the combined effect of DEX with both the AKT and ERK inhibitors (DEX+AKTi+ERKi) 
induced more GILZ expression than using DEX+AKTi or DEX+ERKi, but this effect 
was still less pronounced when compared with the combination of DEX+DAS (Figure 
64). LCK represents a proximal signalling node in the TCR signalling pathway. This 
observation might suggest that there might be signalling pathways downstream of 








Figure 64. Heatmap of GILZ mRNA induction in T-ALL cell lines after the 
treatment with different drugs and drug combinations. The relative mRNA 
expression of GILZ was obtained by qRT-qPCR. T-ALL cell line CUTLL1, Jurkat, 
MOLT4 and SUPT1 were treated with the IC75 concentration of DAS, MK2206, 
SCH772984 (CUTLL1, 2.8 µM, 0.4 µM, 12.6 µM; Jurkat, 1.1 µM, 0.6 µM, 11 µM; 
MOLT4, 2.6 µM, 0.2 µM, 7.3 µM; SUPT1 0.3 µM, 3.6 µM, 18.7 µM), with or without 
DEX (100 nM) (combinations of DEX + DAS, DEX + MK2206, DEX + SCH772984, or 
DEX + MK2206 + SCH772984). The expression of GILZ was normalised to GAPDH 
and the non-treated control sample (Ctrl). The blue gradient bar graph on the right 
























The event-free survival rate of paediatric T-ALL has exceeded 85%, but comes at a 
cost due to the use of high-dose, multi-agent chemotherapy, which is often 
accompanied by acute and chronic side effects. Also, there is virtually no cure for 
relapsed or refractory T-ALL (Bhojwani and Pui, 2013). These patients thus represent 
an unmet medical need. DEX is a core component of the intensive chemotherapy 
resulting in apoptosis. However, DEX-resistance has been associated with an 
increased risk of relapse and poor clinical outcome (Inaba and Pui, 2010). It is thus 
imperative to discover novel drug targets for T-ALL treatment and new strategies to 
overcome steroid resistance. T-ALL cells arise from the transformation of thymocyte 
progenitors to T-cell malignancies (Durinck et al., 2015). Development checkpoints 
are provided by the pTCR during β-selection and TCR in positive/negative selection 
(Li and Rudensky, 2016). To investigate the roles of pTCR/TCR complex components 
in T-ALL, a functional shRNA screen targeting pTCR/TCR signalling was performed in 
T-ALL cell lines and PDXs. We hypothesised that pathway components could provide 
new drug targets. 
 
6.1 Targeted shRNA Screens Discovered a Role for LCK in Controlling T-ALL 
Growth 
Our functional genomics approach identified LCK, an essential kinase in the 
pTCR/TCR signalling pathway, as a critical gene involved in T-ALL proliferation and 
maintenance. LCK is a central molecule in pTCR/TCR signalling transduction and has 
been shown to enhance tumourigenic BCR signalling in other lymphoid malignancies, 
namely CLL (Harr et al., 2010).  
The screen library contained shRNAs targeting pTCR/TCR components (PTCRA, 
LCK, FYN, ZAP70, LAT and CD3E), ribosomal proteins (RPL9 and RPS29), PTEN, 
and negative controls (NTC, RUNX1/ETO). The in vitro shRNA screens were carried 
out in four T-ALL cell lines (SUPT1, CUTLL1, MOLT4 and HPB-ALL). In general, the 
screening was successful because the performance of control shRNAs was consistent 
with our expectation; the negative controls were not depleted or enriched, knockdown 
of essential ribosomal proteins led to depletion, and cells with PTEN shRNAs were 
enriched as predicted. The screen identified crucial roles for LCK, ZAP70 or PTCRA 




depleted in all four cell lines with the highest significance, suggesting its essentiality 
for T-ALL maintenance. 
 
6.1.1 In vitro Validation Demonstrated the Essentiality of LCK, but Not FYN 
In vitro validation of the roles of pTCRα, LCK, and ZAP70 in T-ALL cell lines by 
competitive assays demonstrated the essentiality of the pTCR/TCR signalling complex 
in cell proliferation. LCK and ZAP70 showed the capacity to steer cell proliferation in 
5 out of 6 cell lines that were tested (except for HPB-ALL) (Figure 31). Cell lines that 
only express pTCR (SUPT1 and MOLT4) are dependent on pTCRα. However, it is 
dispensable for pTCR+/TCR+ cell line CUTLL1 due to the possible redundant role of 
TCR to replace pTCR function. Remarkably, the impact of LCK on leukaemia 
propagation is further confirmed in vivo as demonstrated by the observation that 
shNTC cells outcompeted shLCK cells in MOLT4 transplanted mice. This effect was 
consistently observed in spleen, bone marrow and liver (Figure 34). 
Interestingly, the other T-cell specific SFK (FYN) appeared to be non-essential for T-
ALL cell proliferation or survival. No significant depletion or enrichment was observed 
in the targeted shRNA screens in SUPT1, MOLT4 and CUTLL1. In vitro depletion of 
LCK induced significant G0/G1 cell cycle arrest rather than apoptosis; however, 
knockdown (50% KD) of FYN by three shRNAs all failed to affect cell growth in MOLT4 
and CUTLL1 for up to 40 days (Figure 29). Previous studies have shown that both Fyn 
and Lck are crucial for cell survival, but only Lck regulates cell proliferation in 
peripheral T cells (Seddon et al., 2000; Seddon and Zamoyska, 2002a). In these 
studies, it seemed that both LCK and FYN were dispensable for T-ALL cell survival. 
The regulation of cell survival by LCK and FYN in healthy T cells might be disturbed 
by the genetic lesions in T-ALL. Leukaemia cells are broadly considered immature T 
cells, which are usually more dependent on Lck rather than Fyn (Molina et al., 1998; 
Stein et al., 1992). Our data support the notion that LCK, rather than FYN, is imperative 
for T-ALL proliferation. 
HPB-ALL is an unusal cell line in this project, as it behaved differently than all other 
cell lines tested. Both shLCK#1, #2, #3 and shFYN#1, #2 were significantly depleted 
in the targeted shRNA screen indicating its proliferation or survival is dependent on 




follow up examinations. In the competitive assays, where we used shRNA constructs 
with GFP expression, several control shRNAs including shNTC and shRUNX1/ETO, 
were gradually lost at a similar speed as shLCK, shFYN, shPTCRA and shZAP70. It 
seems that HPB-ALL cannot retain GFP expression in general, which means that 
probably the un-transduced cells outcompeted GFP-transduced cells due to GFP 
toxicity. A similar phenomenon was observed in the repetition experiment. Other 
fluorescent proteins, such as RFP657 or dTomato, have not been tested. Perhaps 
using shRNA constructs with other fluorescent tags would work to evaluate the screen 
data. But no further investigations were carried out in HPB-ALL cells in this study.                            
 
6.1.2 Limited Screen in PDX L963 and LK080 in vivo 
Followed by the success of targeted shRNA screens in vitro, a similar approach was 
expanded to PDX cells to address the importance of LCK in vivo. L963 and LK080 
were chosen to perform this study.  
In PDX L963, shLCK#3 was significantly depleted in spleen and bone marrow samples 
(Figure 28). Unlike T-ALL cell line data where shLCK#1 was also significantly 
depleted, shLCK#1 failed to reach the significance in L963 since it was lost in mouse 
2, 4 and 5, but not the other three mice. Thus, shLCK#1 effect was discordant among 
different mice. Also, knockdown experiments performed in vitro in MOLT4 and 
CUTLL1 demonstrated shLCK#1 caused less reduction in LCK expression compared 
with shLCK#3, which makes it a less robust candidate for the depletion in vivo. 
The relapsed sample LK080 showed clonal expansion in the in vivo shRNA screen 
with loss of library coverage. This made it difficult to interpret the functional role of 
individual shRNAs in this primary sample. However, LK080 was tested in vitro with the 
LCK inhibitor DAS. DAS abolished the activation of LCK and resulted in G0/G1 arrest 
in LK080, indicating its dependency on LCK (Figure 42). Also, a strong drug synergy 
was observed in LK080 drug matrix analyses in vitro, and it responded well to the 
DEX/DAS combination in the murine trial within the treatment window (Figure 54). 
LK080 is a GC-resistant sample both in vitro and in vivo, which could be used in the 
future to investigate how LCK inhibition improves DEX response. At the end-point 
analysis, there was little difference in leukaemia engraftment of the LK080 control 




weeks after completing treatment. It is possible that continued dosing would have 
resulted in a significant impairment in leukaemia progression. Alternatively, this 
observation raised the assumption that DEX+DAS cannot eradicate leukaemia, at 
least in this primary sample. Further investigations into the mechanisms of DEX+DAS 
resistance might result in the development of a triple drug combination and enforce 
the application of targeted therapies. 
 
6.2 LCK Regulation in T-ALL 
6.2.1 Possible Mechanisms of LCK Activation in T-ALL 
LCK in T-ALL exhibits non-oncogene addiction regulating cell proliferation in vitro and 
propagation in vivo. The cell growth of the HSB-2 cell line is dependent on LCK as it 
has a t(1; 7)(p34; q34) translocation, which places LCK under the control of the TCRB 
promoter (Wright et al., 1994). However, in T-ALL patients, it is infrequent to have 
mutations or translocations of the LCK locus. This raises the question of how LCK is 
(ab)normally activated or upregulated in T-ALL cells. Four scenarios might provide an 
explanation: 
1. The most likely situation is that there is no abnormal activation or upregulation of 
LCK in T-ALL. Because LCK, and its activation, play a critical role in T-cell 
maintenance/tonic signalling (Li and Rudensky, 2016), it is present in levels that can 
be targeted/inhibited in T-ALL. To address this, comparisons of the expression and 
activation of LCK in healthy individuals and T-ALL patients are needed. 
2. LCK might be activated because of genetic alterations upstream of pTCR/TCR, 
such as activation of the Notch pathway, which directly binds and upregulates PTCRA 
expression (Bene et al., 1995). Moreover, in T-ALL cell line Jurkat, LCK has been 
shown to interact with ICN and PI3K, which is necessary for ICN induced expression 
of anti-apoptotic proteins, such as BCL2, BCL-xL, and IAP-2. Enforced expression of 
ICN upregulates p-LCK in this cell line (Sade et al., 2004). Moreover, mouse studies 
on TCR reprogramming and engineering have demonstrated the oncogenic role of 
TCR signalling in T-cell malignancies. Firstly, in a mouse model in which mice were 
derived from a reprogrammed T-cell, half of the mice developed T-cell lymphomas. 
These lymphomas were dependent on TCR signalling as inhibition of TCR signalling, 




al., 2010). In another mouse study which assessed engineered Sur-TCR-Tg (survivin-
TCR-transgenic) in thymocytes, murine T-ALL occurred of 100% in cases in this 
model, which was dependent on TCR signalling resulting from the interaction of Sur-
TCR-Tg and antigens (peptide 20-28 of survivin) (Cui et al., 2015).  
3. Another possibility might be that LCK activation is aberrantly triggered either by the 
phosphorylation of Y394 or the dephosphorylation of Y505. Notably, alterations in the 
phosphatase CD45, which controls pY505LCK, have been found in association with 
leukaemia. Particularly, mutations in the gene PTPRC, which encodes for CD45, has 
been found in T-ALL cell lines and patient samples concurrent with gene lesions in the 
IL-7R signalling pathway (Porcu et al., 2012). For example, the G863R mutant of 
PTPRC was found in combination with the TCRB-LCK translocation in HSB-2 cells. 
The R751* mutation was associated with JAK1 Y652H gain of function in a T-ALL 
patient, while the W764* mutation co-occurred with an insertion in IL-7R in the DND-
41 cell line (Porcu et al., 2012). Also, it has been demonstrated that low or 
undetectable CD45 expression occurs in 3.7% of patients with childhood T-ALL (Ratei 
et al., 1998). In our cohort of ten PDXs, L970 and LK290 showed low CD45 expression 
on the cell surface. Future work will be carried out to investigate whether CD45 is 
downregulated by PTPRC mutations (or other mechanisms) and drives LCK activation 
in T-ALL cells. 
4. Perhaps LCK expression is regulated by oncogenic super-enhancers recruiting core 
components of a major leukaemogenic transcriptional complex that contains for 
example TAL1, MYB, RUNX1 and GATA3 (Ferrando et al., 2002). In order to identify 
these super-enhancers, CRISPRa (Clustered Regularly Interspaced Short 
Palindromic Repeats activation) screens provide a robust tool to interrogate the 
enhancers that upregulate LCK in T-ALL. It has previously been used to identify IL-2R 
regulatory enhancers in T cells previously (Simeonov et al., 2017).  
 
6.2.2 Dasatinib Inhibits LCK in T-ALL Cells 
6.2.2.1 LCK as the Primary Target of DAS in T-ALL Cells 
The dual ABL/SFKs inhibitor DAS has been approved for the treatment of CML and 
Ph+ ALL (Squibb, 2009). In T-ALL, DAS eradicates LCK kinase activity as shown by 




DAS significantly correlates with pY394LCK/LCK in T-ALL cell lines (IC50 from 23.8 nM 
to 19.7 µM) (Figure 44), which at least in part demonstrates the main target of DAS in 
T-ALL cells is LCK. This is in line with a previous study which showed that among 20 
possible targets of DAS including ABL1, KIT, MAPAK5, EPHB2, EPHB4, SRC, YES, 
FGR, HCK, PDGFRα and PDGFRβ, LCK is the most abundantly expressed gene in 
T-ALL cell lines (Laukkanen et al., 2017). To further address the question around the 
main drug target of DAS, a more specific LCK inhibitor (Lowenberg et al., 2005) other 
than DAS could be used to confirm the role of LCK in T-ALL cell lines. The response 
of T-ALL to the SRC inhibitor KX2-391 correlates with DAS response, suggesting DAS 
acts via inhibiting the SRC pathway (Frismantas et al., 2017). A mutation of threonine 
(T) to methionine (M) at the gatekeeper residue T316 of LCK conferred resistance to 
DAS in T-cells (Lee et al., 2010). Overexpression of LCKT316M in a LCK null 
background or the use of CRISPR/Cas9 to knock-in T316M into the human T-ALL 
genome, would allow us to address this notion elaborately and confirm that LCK is the 
likely primary target of DAS in T-ALL cells. 
One of the limitations of this study was that there was no correlation between 
pY394LCK/LCK and DAS response in primary samples (Figure 45). The high sensitivity 
to DAS (IC50 < 100 nM) in 30% of T-ALL patient samples (with the absence of ABL 
class mutations) was shown in an in vitro drug response profiling platform (Frismantas 
et al., 2017). In our study, 2 out of 6 PDXs (LK287 and L903) were highly sensitive to 
DAS with GI50 less than 100 nM, while the others showed GI50 > 1 µM. LK287 had a 
FIP1L1-PDGFRA fusion, which explained the high sensitivity to DAS. However, no 
known recurrent genetic abnormality could be identified in L903 to link with its high 
sensitivity to DAS. Only six PDXs were evaluated for pY394LCK/LCK and DAS 
response in this study, which hinders the discovery of any correlations between them. 
Also, primary cells generally had problems with cell proliferation in vitro. Although we 
tried to co-culture PDXs with feeder cells for at least a week to support their 
proliferation before applying any drugs, the drug assays were performed without 
feeder cells, which would affect the evaluation of DAS response. In the future, 
developing a platform in which drug assays could be performed on PDXs co-cultured 






6.2.2.2 DAS Reduces LCK Protein Expression in Some T-ALL Samples 
DAS reduced LCK total protein levels in some cell lines and PDXs. For example, total 
LCK decreased after 24 h-treatment of DAS in SUPT1, MOLT4, CUTLL1, L907 and 
L963. But no substantial difference in LCK protein was shown in Jurkat, LK203, L970, 
L809 and LK080 (Figure 40). This variability is in line with their sensitivity to DAS based 
on IC50 and GI50 values observed in our study. Therefore, the reduction in LCK levels 
might differ according to the DAS dose or treatment duration employed. Another piece 
of evidence supporting this notion is the complete loss of LCK expression after long-
term DAS treatment in L809 engrafted mice, which were exposed to DAS or DEX/DAS 
in vivo for three weeks. Further evaluations of the dosing and treatment duration 
effects of DAS on LCK are needed.  
Interestingly, the transcriptional level of LCK in various T-ALLs remained unchanged 
after 24 h-DAS treatment. It is thus more likely that the half-life of LCK protein is 
affected by DAS. The RING finger E3 ubiquitin ligase CBL negatively regulated LCK 
function by ubiquitination and degradation through proteasome. Also, without 
phosphorylation at Y505, LCK was more susceptible to CBL-dependent ubiquitination 
and degradation (Rao et al., 2002). DAS inhibits the phosphorylation at Y394 and 
Y505 which might have an impact on ubiquitination of LCK. This question needs to be 
addressed in the future. 
 
6.2.2.3 Comparison of LCK Knockdown and DAS Treatment 
In general, DAS treatment and LCK KD produced similar effects, namely the induction 
of G0/G1 arrest in a panel of T-ALL cells and mild apoptosis induction in MOLT4 after 
shLCK and Jurkat after DAS treatment. The direct comparison of the degrees of cell 
cycle arrest or apoptosis generated by DAS inhibition and LCK knockdown is not 
straightforward. Because the maximal knockdown level of shLCK is around 70% in T-
ALL cells which limited the LCK knockdown effects, however, presumably higher 
concentrations of DAS would induce more substantial effects. In line with this thought, 
the cell cycle arrest induced by DAS appeared slightly more pronounced than LCK 
knockdown. Alternatively, if DAS leads to increased G0/G1 arrest, this could be 
explained by the non-specific target inhibition of DAS. A more valid comparison would 




6.2.3 The Comparison of LCK Deficiency Induced Cell Cycle Arrest in Normal 
and Malignant T cells 
One study reported that a murine LCK deficient T helper 2 (Th2) cell line increased 
expression of cyclin A, cyclin B, cdc2, accompanied by G2/M cell cycle arrest 
compared with its parental cells. The upregulated cdc2 was highly phosphorylated, 
resulting in defects in cdc2 kinase activity (al-Ramadi et al., 1998). In contrast, in our 
study, knockdown or inhibition of LCK led to G0/G1, not G2/M cell cycle arrest in human 
malignant T cells. RPPA data of the CUTLL1 cell line demonstrated that both CDK1 
(also known as CDC2) and pY15CDK1 were downregulated after LCK knockdown. 
Furthermore, RNA-seq data derived after 24 h DAS treatment in LK203 and LK080 
showed a 30% reduction of CDK1 expression. These data suggest that the cell cycle 
progression controlled by LCK differs between murine and human cells, or between 
normal and malignant T cells.  
 
6.2.4 LCK Might Regulate Cell Survival or Proliferation in Different Subgroups 
of T-ALL 
Knockdown of LCK leads to significant G0/G1 cell cycle arrest in MOLT4, SUPT1, 
Jurkat and CUTLL1. However, a mild apoptotic response was only observed in MOLT4 
cells. This might illustrate that regulatory networks governed by LCK vary between T-
ALL cell lines.  
Based on my observation, DAS response profiling revealed three sub-groups of T-ALL 
cell lines. One group (DAS-hypersensitive) contained the hypersensitive cell lines with 
the IC50 in nM range, including HSB-2, KOPT-K1 and ALL-SIL; a second group (DAS-
sensitive) was represented by the sensitive cell lines (IC50 < 10 μM) such as CUTLL1, 
MOLT4, and Jurkat, with a third one (DAS-resistant) consisting of the resistant cell 
lines (IC50 > 10 μM, e.g. CCRF-CEM and MOLT16).  
I observed that single electroporation with LCK siRNA instantly induced apoptosis and 
G0/G1 arrest in HSB-2 (DAS-hypersensitive) cells, but no apoptosis nor cell cycle 
arrest was observed in MOLT4 (DAS-sensitive) and CCRF-CEM (DAS-resistant) cells. 
In my opinion, the transient knockdown of LCK is not sufficient to induce cell cycle 
arrest in DAS-sensitive and DAS-resistant cell lines. In line with this observation, 




hypersensitive) led to substantial apoptosis and reduced proliferation while this was 
not seen in Jurkat (DAS-sensitive) and SUPT1 (DAS-sensitive) after single 
electroporation of siLCK (De Keersmaecker et al., 2014). Both HSB-2 and ALL-SIL 
are hypersensitive to dasatinib because of the presence of activated kinases and 
responded to the transient LCK knockdown by siRNA. However, the role of LCK in T-
ALL cell cycle progression might be underestimated by the transient knockdown 
method itself. Based on our data, the essentiality of LCK for modulating cell 
proliferation and cell cycle progression was well characterised in DEX-sensitive cell 
lines, such as SUPT1, MOLT4, Jurkat and CUTLL1. This was achieved using a shRNA 
and lentiviral transduction approach, which generated stable cell lines with LCK 
knockdown for the long term. In this way, we discovered that LCK indeed modulates 
T-ALL cell cycle progression not only in DAS-hypersensitive group but also in DAS-
sensitive group (Figure 37). 
We have also shown that LCK is vital for cell cycle progression in vitro in co-cultured 
PDX L963 and LK203 cells. Knockdown of LCK by shRNA in L963 and LK203 induced 
G0/G1 cell cycle arrest. Moreover, cell proliferation assays of L963 with control or LCK 
shRNA after a two-week co-culture with feeder cells demonstrated that shLCK delayed 
cell division compared with shNTC cells (Figure 38). Notably, the GI50 of DAS in L963 
and LK203 was 4 μM and 1 μM respectively, which was similar to the IC50 of DAS-
sensitive cell lines. Consistent with the cell line data, single electroporation of siLCK 
did not induce G0/G1 arrest in L963 and LK203. However, cell cycle arrest appeared 
after the 2nd electroporation of siLCK and was further enhanced after the 3rd 
electroporation (Figure 39).  
Collectively, these findings support the notion that LCK regulates different signalling 
networks in DAS-hypersensitive and DAS-sensitive cell lines by controlling cell 
proliferation and survival in DAS-hypersensitive group, while only regulating cell 
proliferation in DAS-sensitive T-ALL cell lines. The divergence needs to be further 
investigated. 
 
6.2.5 DEX Downregulates LCK mRNA Expression in DEX-sensitive Cells 
In practice, treatment of leukaemia needs a combination of drugs. In this study, DAS 




reported that DEX downregulates LCK mRNA expression in DEX-sensitive cells such 
as thymocytes (S49.A2) and the murine T-lymphoma cells (WEHI7.2) (Harr et al., 
2010). The mechanism underlying this response is currently unknown. Consistent with 
the literature, I found that PDX L970 was sensitive to DEX, and the mRNA expression 
of LCK was 60% downregulated upon DEX treatment (100 nM) (Figure 63). On the 
contrary, LCK downregulation was not observed in DEX-resistant T-ALL PDXs and 
cell lines.  
However, this does not seem to affect DEX+DAS response. PDX L970 was included 
in the phase II-like murine trail. DEX treatment effectively reduced about 50% 
leukaemia engraftment in spleen and bone marrow. Although DAS treatment alone 
did not lead to substantial engraftment reduction, the DEX+DAS mouse had the most 
significant reduction in leukaemia blasts and this response was thus more effective 
than treatment with DEX alone.  
 
6.3 A Phase II-like Murine Trial Demonstrates High Efficacy of DAS+DEX in vivo 
The drug combination of DEX and DAS decreased the proliferation of physiological 
CD3+ and virus-specific CD8+ T cells without affecting cytokine production and cell 
viability (Nerreter et al., 2013). However, in malignant T cells, DAS synergises with 
DEX to induce more significant cell death in both DEX-sensitive and DEX-resistant 
patient samples (Figure 50). Significant enrichment of drug synergy can be observed 
at clinical-relevant Cmax concentrations of DEX and DAS (Figure 49). 
To evaluate the drug combination efficacy of DEX+DAS in vitro, a phase II-like murine 
trial was performed with ten primary samples. Each PDX was injected into four mice 
of the same gender and similar age. All four mice were randomised to the treatment 
of vehicle, DAS, DEX or DAS+DEX upon human leukaemia engraftment in the 
peripheral blood above 0.5%. Overall, DAS+DEX significantly reduced leukaemia 
engraftment in spleen (n=7), bone marrow (n=9), peripheral blood (n=9) and liver (n=6) 
samples (Figure 57).  
The phase II-like clinical trials in mice allow not only fair comparison between 
treatment arms as the four mice receiving the same PDX, but also reflecting early 
phase clinical trials in humans as it includes heterogeneous biological samples. 




these PDXs was different, causing the complication of determining when to start and 
when to stop the treatment. In line with other studies (Girardi et al., 2017; Jing et al., 
2015), we decided to monitor peripheral blood engraftment weekly and commence 
dosing when the hCD45+ cell count reached 1% (apart from L903 whose treatment 
started when engraftment > 0.5%). Secondly, the heterogeneity of different PDX 
samples made the final statistical analysis complicated. The general student t-test 
does not apply in this study, as four treatment arms were not independent. The drug 
efficiency comparison had to consider additional variables, for example PDX IDs. 
Therefore, a linear mixed effects model (Bates et al., 2015) was used with a varying 
intercept of PDX and a fixed effect of drug treatments and the p-values were obtained 
by likelihood ratio tests. 
 
6.3.1 Exclusion of LK214 in the Final Analysis of the Murine Trial 
PDX LK214 (n = 4 female mice) was excluded from the final analysis because of its 
rapid engraftment before the onset of treatment. Similar to other primary samples, 
treatment of LK214 was commenced after signs of engraftment in the peripheral blood. 
However, three out of four mice were unexpectedly found sudden death during the 1st 
week of treatment. Autopsy of these mice demonstrated heavy leukaemia burden with 
enlarged spleens (0.5 g), suggesting that these PDXs did not show peripheral blood 
engraftment although lymphoid organs had already heavily engrafted. A second 
attempt using LK214 was carried out in four male mice. This time dosing was 
commenced blindly without weekly tail bleed monitoring. Instead, treatment initiation 
(the 2nd week after injection of PDX cells) and duration (two-week dosing to avoid 
unexpected sudden death) were dictated by our previous experience with LK214. This 
time however, neither enlarged spleen (0.02 g) nor bone marrow or liver engraftment 
was detected when harvested on the 4th week after injection. Thus, LK214 was 
excluded from the final analysis of the phase II-like murine trial. 
 
6.3.2 DEX+DAS Significantly Affected CNS Engraftment in the Murine Trial 
CNS infiltration is frequently seen in T-ALL patients; therefore, novel therapies should 
aim for eradication of leukaemia cells from this sanctuary site. In our phase ‖-like 




while DAS alone affected 4 PDXs. Notably, a significant decrease in leukaemia 
infiltration in the CNS was shown in the DEX+DAS group of the cohort of 9 PDX 
samples (Figure 59), indicating that DEX+DAS might overcome CNS engraftment of 
T-ALL. It is also possible that the DEX+DAS group had the least leukaemia 
engraftment overall (spleen, bone marrow and liver) resulting in the least CNS 
engraftment. To address this, further experiments, including the evaluation of CNS 
infiltration prior to treatment initiation, would be useful. With regards to the mechanism 
underlying reduction in CNS infiltration, it has previously been shown that reduction in 
ZAP70, a downstream target of LCK, impairs leukaemic infiltration of the CNS 
(Alsadeq et al., 2017).  
 
6.3.3 One Case of DEX+DAS Toxicity in the Murine Trial 
The synergistic effect of DEX+DAS was evaluated in the phase ‖-like trial in mice with 
ten PDXs. The DEX+DAS combination significantly reduced leukaemia burden 
compared with control or single-drug treated mice. The leukaemic engraftment in NSG 
mice was substantially impaired in the tissue of the spleen, bone marrow, liver and 
CNS. However, the potential toxicity of this drug combination was observed in one 
PDX sample L903. The four mice of L903 were harvested three days after completion 
of dosing (2 weeks) due to signs of illness of the DEX+DAS mouse. It was pale and 
reluctant to move; therefore, all four mice had to be collected. This PDX overall showed 
little engraftment in the spleen (about 4% hCD7+ cells with the weights of 0.04 - 0.06 
g) suggesting an early stage of leukaemia engraftment. Although the DEX+DAS 
mouse had the least engraftment in the blood, bone marrow and liver among all four 
arms of treatment, it showed general weakness, which might be due to the potential 
toxicity of this drug combination. In the case of human clinical trials, DAS was shown 
to be well tolerated in paediatric CML patients (McCafferty et al., 2018). However, 
some minor AEs (adverse events) were identified such as arthralgia, diarrhoea, and 
fatigue, haemorrhage, rash and vomiting. Interestingly, the DAS-treated mouse did not 
show any sickness signs. It might be that the combinatorial effect of DEX+DAS leads 
to toxicity in this particular sample. It is possible that DAS increased the plasma level 
of DEX and thus caused toxicity. Further investigation such as establishing the 




As shown in a previous study, the Cmax of mice dosed with 1 mg/kg DEX is 
approximately 100 nM which is similar to the Cmax achieved in patients’ serum (Yang 
et al., 2008). However, the blood concentrations of DAS and DEX after 35 mg/kg DAS 
and DEX+DAS administration remain unknown. Investigations will be carried out to 
identify the Cmax of DAS and DEX and explore a dose which has the least toxicity but 
still synergises with DEX.  
6.3.4 Identification of the Response Biomarker of DEX+DAS 
Last year a paper described that pharmacological inhibition of LCK by DAS could 
reverse GC-resistance in PPR (prednisone-poor responders) patients with T-ALL 
(Serafin et al., 2017). When examining LCK phosphorylation status in 87 patient 
samples by phosphoproteomics, they identified high p-Y416SRC and low p-Y505LCK in 
PPR patients compared with PGR (prednisone-good responders) patients. However, 
I could not confirm the correlation between LCK activity and DEX response in our 
panel of T-ALL cell lines and PDXs in this study. Although my results suggest that LCK 
plays a role in DEX-resistance, it would be premature to conclude at this stage that 
DEX-resistance is caused by high LCK activation. The synergy between DAS and DEX 
is preserved in DEX-sensitive T-ALLs as well. However, it is possible that this 
inconsistency is due to the small sample size of PDXs in my study. Expanding the 
PDX sample size and understanding the LCK association with GC-resistance would 
be a primary focus in future research. 
It is imperative to identify the biomarker of DEX+DAS response to stratify patients to 
receive this treatment in the clinic. One of the aims of conducting a phase ‖-like murine 
trial was to identify a possible biomarker for DEX+DAS combination responsiveness. 
At least 7 out of 9 PDXs revealed an excellent response to DEX+DAS treatment in the 
murine trial, as shown by more than two-fold reduction in leukaemia engraftment in 
peripheral blood, spleen and bone marrow. Although this is an exciting observation, it 
makes it difficult to establish a response biomarker. 
The therapeutic advantage of DEX+DAS was seen in LK080 during the treatment 
window as demonstrated by peripheral blood engraftment over time; however, this 
advantage was lost after the completion of the treatment because the DAS+DEX 
mouse had the same engraftment rates in spleen and bone marrow compared with its 




The least response to DEX+DAS was seen in L907 in the spleen, bone marrow and 
liver (4% - 40% reduction in leukaemia engraftment compared with the control mouse). 
Interestingly, DAS treatment alone did not provide benefit for this PDX sample, 
suggesting the little response to DEX+DAS might have been partially due to resistance 
to DAS. Up to now, this study has inadequate evidence to conclude on the 
identification of a biomarker for DEX+DAS response. DNA and RNA sequencing are 
ongoing to reveal the full mutational and transcriptomic landscape of these samples. 
These will be correlated with in vitro and in vivo treatment response in a further attempt 
to establish a response biomarker. In the future, this murine trial will be expanded to 
include relapsed T-ALL PDXs. Multivariate biomarker analysis will be performed to 
interrogate any association between differentiation stage, gene expression, mutational 
profiles, phosphoprotein profiles (including LCK) and treatment response. 
 
6.4 Future Perspectives 
6.4.1 Hypothesis for DEX+DAS Synergy 
Our growing appreciation that LCK inhibition synergises with DEX response and the 
combined therapy DEX+DAS significantly improves leukaemia treatment in vivo has 
fuelled our interest in understanding the mechanism of DAS and DEX interaction. 
Several hypotheses could be formulated. 
 
6.4.1.1 Pharmacokinetics of DEX and DAS 
Pharmacokinetic (PK) studies of either DAS or DEX alone have been established 
(Liston and Davis, 2017; Yang et al., 2008). However, there is no investigation on the 
PK of either DAS or DEX when they are given together. It is possible that one drug 
somehow affects the metabolism or stability of the other drug in vivo, which augments 
its function. The normal phase HPLC (High-Performance Liquid Chromatography) 
assay for DEX (Samtani and Jusko, 2005) is well-established in the Drug Discovery 
group in NICR, while the HPLC-MS assay to quantify DAS levels needs to be 
developed (De Francia et al., 2009). In order to facilitate the development and 
optimisation of such an assay, a PK study incorporating numerous blood samples will 
be collected in healthy BALB/c mice treated with 35 mg/kg DAS and/or 1 mg/kg DEX 





6.4.1.2 The ERK Pathway May Be Involved in DEX Resistance 
Since LCK and GCs are molecules in signalling networks that interact and play various 
biological functions, it is likely that the interplays of downstream signalling play a 
crucial role in DEX+DAS synergy. It has been shown that DAS could facilitate DEX-
induced BIM induction, which is a pro-apoptotic protein (Scherr et al., 2018). Another 
possibility could be that LCK downstream signalling pathways, such as ERK signalling, 
play a role in DEX-resistance (Polak et al., 2016). The combination of DEX and 
Selumetinib (MEK inhibitor) has been shown to synergise in the RAS pathway mutated 
ALL (Matheson et al., 2019). This combination is currently tested in an early phase 
clinical trial (UK, 2018). It is conceivable that DAS inhibits LCK and its downstream 
ERK signalling, thereby sensitising cells to DEX. Our preliminary data have 
demonstrated that an ERK inhibitor could substantially augment DEX-induced GILZ 
gene expression in CUTLL1 and Jurkat (Figure 64), suggesting that the ERK pathway 
is implicated in DEX-resistance. 
 
6.4.1.3 LCK and GC Interaction 
The interplay between TCR and GR has been shown in healthy T cells, and GR 
translocation is not directly affected by TCR in healthy T cells (Zacharchuk et al., 
1990). However, the effect of TCR activity on GR localisation remains an open 
question and needs to be interrogated in T-ALL cells. There is the possibility that LCK 
knockdown enhances DEX-induced GR translocation in malignant T cells, as has been 
shown in a similar fashion for AKT inhibition (Piovan et al., 2013). GR is a part of a 
multiprotein complex linked with TCR which contains LCK and HSP90. The binding of 
GC to the GR leads to rapid disassociation of LCK and FYN from this complex; 
therefore attenuating TCR signalling (Lowenberg et al., 2006). One hypothesis to 
explain the mechanism underlying DEX-resistance would be that in DEX-resistant T-
ALL cells, the GR is tightly associated with this complex, which forbids GR 
disassociation and subsequently translocation into the nucleus after GC stimulus. 
Inhibition or knockdown of LCK would facilitate the release of GR and augment GR 
induced apoptosis. To address this question, I plan to perform co-immunoprecipitation 
of GR and LCK and assess the translocation of GR from the cytoplasm to nucleus 
after DEX+DAS treatment. A more comprehensive understanding could be achieved 




when comparing this interactome in healthy T-cells versus malignant T-cells, as well 
as in DEX-resistant T-ALLs versus DEX-sensitive T-ALLs. 
 
6.4.2 The Rationale of Performing Functional Genomic Studies for DEX+DAS 
Synergy and Resistance 
As I mentioned before, it looks like we can explore the observed drug synergy 
mechanism from many angles. However, the number of essential genes involved in 
regulating DEX+DAS synergy is easily underestimated. I propose to perform a 
genome-wide CRISPR/Cas9 screen under selection pressure from four different arms 
of treatment (Ctrl, DAS, DEX, DEX+DAS) to facilitate the identification of genes that 
are essential in leukaemia survival vulnerability, drug synergy and therapy resistance 
in a systematic manner. DAS sensitises DEX in multiple T-ALL cell lines and PDXs, 
which represent different genetic subtypes, leukemogenic stages and differentiation 
stages. Performing this genome-wide screen in a large and diverse panel of cell 
lines/PDXs would increase the chance to find universal mechanisms of drug synergy 
and resistance relevant to T-ALL.  
 
6.4.2.1 Identification of DAS-target Genes and DEX-resistance Associated Genes 
In a first analysis, differentially expressed sgRNAs in single drug-treated samples, 
compared to control cells, could answer several questions:  
1) Differentially enriched sgRNAs in DAS-treated cells demonstrate DAS targeted 
genes. After knockout of these genes, cells become resistant to DAS and have high 
abundance in the pool. By analysing these genes, we could cross-reference whether 
these genes are DAS targets or LCK-signalling associated genes.  
2) Differentially depleted sgRNAs in DEX-treated cells, but not in control samples, 
point towards genes related to GC-resistance, as these knockout cells are only 
depleted when treated with DEX. Identification of these genes allows us to gain a 
comprehensive insight into understanding steroid-resistance in T-ALL, which might be 










Figure 65. Principle of genome-wide CRISPR/Cas9 screening analysis. After 
lentiviral library transduction, cells will be treated with control vehicle (CTRL), DAS, 
DEX and DEX+DAS arms. CTRL samples will be compared with baselines to identify 
genes that suppress or promote leukaemia cell proliferation/survival, such as 
enrichment of sgPTEN and depletion of sgMYC. The DAS (DEX) treated arm will be 
compared with CTRL arm to identify differentially expressed sgRNAs. DAS impairs 
cell proliferation via inhibiting LCK; thus, sgLCK is expected to be enriched in DAS-
treated arm. DEX induces apoptosis via activating NR3C1, thus knockout of NR3C1 
(sgNR3C1) is expected to cause DEX resistance. AKT has been shown to antagonise 
DEX response. Therefore, sgAKT will sensitise cells to DEX response, which will be 
depleted in the DEX-treated arm. Similar principles apply to DEX+DAS arm. sgRNAs 
that are differentially enriched in DEX+DAS treated cells demonstrating DEX+DAS 
synergy-related genes. On the contrary, differentially depleted sgRNAs in DEX+DAS 
samples are genes that cause DEX+DAS resistance. For example, loss of function of 
ERK would sensitise cells to DEX+DAS treatment leading to the reduction of this 
sgERK clone. This will facilitate to develop more powerful multi-drug combination to 










6.4.2.2 Identification of Genes for DEX+DAS Synergy 
The integrated analysis of DAS-targeted genes and DEX-resistance related genes 
would facilitate the discovery of possible mechanisms underlying DAS sensitising the 
DEX response in T-ALL. More importantly, these genes can be further examined in 
cells receiving the combined DEX+DAS treatment arm. 
The discovery of sgRNAs that are only differentially expressed in the DEX+DAS-
treated cells, but not control or single treatment samples, would enable us to identify 
genes involved in both synergy with DEX+DAS and resistance to DEX+DAS. 3) 
sgRNAs that are enriched explicitly in DEX+DAS group suggest these genes 
contribute to drug synergy. Such essentiality might point to novel cytoplasm-nucleus 
transporters that affect GR translocation, chaperones involved in GR-LCK interaction, 
phosphatases regulating LCK signalling, transcription factors or cofactors differentially 
associated with GR, as well as BH3 proteins with pro-apoptotic or anti-apoptotic roles. 
Overall, the global vision of DEX+DAS synergy-related genes would allow us to 
identify novel mechanisms of how LCK or TCR signalling modulates DEX response.  
 
6.4.2.3 Discovery of Genes for DEX+DAS Resistance 
4) In the murine phase ‖-like clinical trial, the engraftment of leukaemia cells of PDX 
LK080 was impaired during the three-week dosing with DEX+DAS. Peripheral blood 
monitor revealed a substantial reduction of leukaemia engraftment in the DEX+DAS 
mouse. However, as soon as the treatment was completed, the leukaemia progressed 
and eventually reached similar engraftment levels as observed in the control mouse, 
suggesting potential resistant mechanisms to the combination of DEX+DAS. 
Any differentially depleted sgRNAs in the DEX+DAS treatment group would provide 
potential drug targets to synergise with DEX+DAS. Perhaps other activated kinases 
causing resistance to the DEX+DAS treatment will be identified. If so, it would be 
sensible to explore other kinase inhibitors and design more efficient combinatorial 
therapies. More intriguingly, the genes underlying DEX+DAS resistance might be 
metabolic regulators, cytokines, as well as surface receptors that can be targeted. In 
this case, it would be feasible to combine a metabolism inhibitor, antibody therapy, or 
immunotherapy with DEX+DAS. Once the resistance genes are identified, validation 
can be done by investigation of these genes in cell lines that do not show synergy with 




lines. Another approach is to manipulate these newly identified genes to drive cells to 
DEX+DAS resistance. The ultimate aim of identifying drug resistance mechanisms is 
to develop novel triple/quadruple drug combinations to assess the efficacy in vitro and 
in vivo against T-ALL. 
Using a whole-genome screen approach to investigate DEX+DAS synergy and 
resistance mechanisms would offer a global view of genes and pathways interacting 
or cooperating with LCK and GC regulated networks, to aid the development of a more 
robust drug combination to eradicate leukaemia cells and improve patient outcomes 
completely.  
 
6.4.3 RNA-Seq to Identify Auxiliary Survival Pathways  
We have received the RNA-seq data for two PDX samples (LK203 and LK080) treated 
with Ctrl, DAS, DEX and DEX/DAS in vitro for 24 hours. These data will provide insight 
into biological processes induced by DEX+DAS treatment and hint towards the 
activation of potential auxiliary survival pathways. Shortly, more samples of PDXs 
treated in vivo in murine phase ‖-like clinical trials will be sent for RNA sequencing to 
increase this data set. Analysis and interpretation of this dataset would provide some 






6.4.4 Perform Phase II-like Trial with Novel Multi-Drug Combination Leading to 
Early Phase Clinical Trial  
Once DEX+DAS resistance mechanisms had been identified, a novel triple/quadruple 
drug combination could be designed. Depending on the type of mediator, a kinase 
inhibitor, metabolism inhibitor, chemotherapy drug, or immunotherapy could be used 
to explore the combinatorial drug efficacy in vitro. For in vivo evaluation, the maximal 
tolerated dose and pharmacokinetics of this drug combination will be assessed. In 
order to increase the success rate of translation of preclinical trials into the clinical 
setting, the novel triple/quadruple drug combination will be validated in randomised 
phase II-like murine trials whose principle and methodology will be similar to what we 
have done in this study.  
To summarise, this study I have identified a novel drug target in T-ALL, namely LCK, 
which universally modulates cell cycle progression, moreover, I have developed an 
efficient drug combination of DEX/DAS that could substantially reduce leukaemia 
burden in a murine phase II-like clinical trial. Future work will focus on unravelling the 
synergy and DEX/DAS resistance mechanisms to develop a robust multi-drug 




















In summary, we hypothesised that the pTCR/TCR signalling pathway has an essential 
function in promoting cell proliferation and survival in T-ALL cells. The in vitro targeted 
shRNA screen identified LCK, ZAP70 and PTCRA as crucial genes for cell proliferation 
in T-ALL cell lines. These data have been validated in vitro by shRNA-mediated gene 
silencing and in vivo using a competitive assay with MOLT4 cells, in which the shNTC 
population outcompeted LCK knockdown cells demonstrating LCK is required for 
leukaemia propagation. Notably, the in vivo screening of PDX L963 in which all six 
mice showed significant depletion of shLCK#3 in both spleen and bone marrow 
samples, further confirms the essentiality of LCK in T-ALL cell maintenance.  
Phenotypically, knockdown of LCK primarily induced G0/G1 arrest and reduced the 
rate of cell division. The dual ABL/SFKs inhibitor DAS effectively inhibited LCK kinase 
activity, as demonstrated by the abolishment of p-Y394LCK and p-Y783PLCγ1. Treatment 
of DAS caused substantial cell cycle arrest in cell lines and PDXs. Moreover, the 
sensitivity of T-ALL cell lines to DAS was significantly correlated with p-Y394LCK/LCK. 
The broad impact of DEX on the induction of apoptosis in lymphoid malignancies 
suggests a rationale to explore its efficacy in LCK knockdown cells. Excitingly, SUPT1 
and CUTLL1 cells were re-sensitised to DEX after LCK depletion. Pharmacological 
inhibition of LCK by DAS synergised with DEX to induce greater cell death in both DEX 
sensitive and resistant T-ALLs in vitro. Bioinformatics analysis of integrated drug 
matrix data revealed significant enrichment of drug synergy around the clinically-
relevant concentrations of DAS and DEX. 
Evidence is emerging that murine trials using acute leukaemia PDXs, that mimic 
human randomised clinical trials, can assess drug efficacy. We first determined the 
maximum tolerated doses of the DEX/DAS combination, and then performed a phase 
‖-like clinical trial in mice with ten T-ALL PDXs. Collectively, the DEX/DAS combination 
proved to be an efficient leukaemia treatment and significantly delayed the 
engraftment of primary patient samples in bone marrow, spleen, and liver compared 
with control mice and single-drug treatment groups. DEX/DAS also considerably 
reduced or delayed the CNS infiltration of leukaemia cells, which was achieved less 
effectively by DEX or DAS alone. 
The presented evidence endeavours to highlight the crucial role of LCK in T-ALL cell 




re-sensitise leukaemia cells to DEX. The synergistic effects and the high efficacy of 
DAS and DEX in triggering apoptosis in vivo might provide a novel treatment strategy 
for T-ALL patients, particularly for the refractory and relapsed T-ALL cases. 
 
Figure 66. The proposed model of LCK modulating cell cycle progression and 
steroid resistance in leukemic cells.  LCK is constitutively activated in T cells 
resulting in tonic TCR signalling that promotes cell cycle progression. DAS effectively 
inhibits LCK kinase activity and induces cell cycle arrest. DEX activates GR upon 
binding, and GR subsequently translocates to the nucleus to induce apoptosis. The 
interplay between TCR and GR signalling is affected by LCK depletion or DAS 
treatment, which could sensitise cells to DEX-induced cell death. In this way, DAS and 










Table 6. Barcoding reverse primers used in the targeted shRNA screen. 
Name Sequences Primer Seq Read 
1 CAAGCAGAAGACGGCATACGAGATCGTGATATTTATACCATTTTAATTCAGCTTTGT CGTGAT ATCACG 
2 CAAGCAGAAGACGGCATACGAGATACATCGATTTATACCATTTTAATTCAGCTTTGT ACATCG CGATGT 
3 CAAGCAGAAGACGGCATACGAGATGCCTAAATTTATACCATTTTAATTCAGCTTTGT GCCTAA TTAGGC 
4 CAAGCAGAAGACGGCATACGAGATTGGTCAATTTATACCATTTTAATTCAGCTTTGT TGGTCA TGACCA 
5 CAAGCAGAAGACGGCATACGAGATCACTGTATTTATACCATTTTAATTCAGCTTTGT CACTGT ACAGTG 
6 CAAGCAGAAGACGGCATACGAGATATTGGCATTTATACCATTTTAATTCAGCTTTGT ATTGGC GCCAAT 
7 CAAGCAGAAGACGGCATACGAGATGATCTGATTTATACCATTTTAATTCAGCTTTGT GATCTG CAGATC 
8 CAAGCAGAAGACGGCATACGAGATTCAAGTATTTATACCATTTTAATTCAGCTTTGT TCAAGT ACTTGA 
9 CAAGCAGAAGACGGCATACGAGATCTGATCATTTATACCATTTTAATTCAGCTTTGT CTGATC GATCAG 
10 CAAGCAGAAGACGGCATACGAGATAAGCTAATTTATACCATTTTAATTCAGCTTTGT AAGCTA TAGCTT 
11 CAAGCAGAAGACGGCATACGAGATGTAGCCATTTATACCATTTTAATTCAGCTTTGT GTAGCC GGCTAC 
12 CAAGCAGAAGACGGCATACGAGATTACAAGATTTATACCATTTTAATTCAGCTTTGT TACAAG CTTGTA 
13 CAAGCAGAAGACGGCATACGAGATTTGACTATTTATACCATTTTAATTCAGCTTTGT TTGACT AGTCAA 
14 CAAGCAGAAGACGGCATACGAGATGGAACTATTTATACCATTTTAATTCAGCTTTGT GGAACT AGTTCC 
15 CAAGCAGAAGACGGCATACGAGATTGACATATTTATACCATTTTAATTCAGCTTTGT TGACAT ATGTCA 




17 CAAGCAGAAGACGGCATACGAGATCTCTACATTTATACCATTTTAATTCAGCTTTGT CTCTAC GTAGAG 
18 CAAGCAGAAGACGGCATACGAGATGCGGACATTTATACCATTTTAATTCAGCTTTGT GCGGAC GTCCGC 
19 CAAGCAGAAGACGGCATACGAGATTTTCACATTTATACCATTTTAATTCAGCTTTGT TTTCAC GTGAAA 
20 CAAGCAGAAGACGGCATACGAGATGTGGCCATTTATACCATTTTAATTCAGCTTTGT GTGGCC GTGGCC 
21 CAAGCAGAAGACGGCATACGAGATCGAAACATTTATACCATTTTAATTCAGCTTTGT CGAAAC GTTTCG 
22 CAAGCAGAAGACGGCATACGAGATCGTACGATTTATACCATTTTAATTCAGCTTTGT CGTACG CGTACG 
23 CAAGCAGAAGACGGCATACGAGATCCACTCATTTATACCATTTTAATTCAGCTTTGT CCACTC GAGTGG 
24 CAAGCAGAAGACGGCATACGAGATGCTACCATTTATACCATTTTAATTCAGCTTTGT GCTACC GGTAGC 
25 CAAGCAGAAGACGGCATACGAGATATCAGTATTTATACCATTTTAATTCAGCTTTGT ATCAGT ACTGAT 
26 CAAGCAGAAGACGGCATACGAGATGCTCATATTTATACCATTTTAATTCAGCTTTGT GCTCAT ATGAGC 
27 CAAGCAGAAGACGGCATACGAGATAGGAATATTTATACCATTTTAATTCAGCTTTGT AGGAAT ATTCCT 
28 CAAGCAGAAGACGGCATACGAGATCTTTTGATTTATACCATTTTAATTCAGCTTTGT CTTTTG CAAAAG 
29 CAAGCAGAAGACGGCATACGAGATTAGTTGATTTATACCATTTTAATTCAGCTTTGT TAGTTG CAACTA 
30 CAAGCAGAAGACGGCATACGAGATCCGGTGATTTATACCATTTTAATTCAGCTTTGT CCGGTG CACCGG 
31 CAAGCAGAAGACGGCATACGAGATATCGTGATTTATACCATTTTAATTCAGCTTTGT ATCGTG CACGAT 
32 CAAGCAGAAGACGGCATACGAGATTGAGTGATTTATACCATTTTAATTCAGCTTTGT TGAGTG CACTCA 
33 CAAGCAGAAGACGGCATACGAGATGCGGACATTTATACCATTTTAATTCAGCTTTGT GCGGAC GCGGAC 
 * same with No. 18, not used in this study   
34 CAAGCAGAAGACGGCATACGAGATGCCATGATTTATACCATTTTAATTCAGCTTTGT GCCATG CATGGC 
35 CAAGCAGAAGACGGCATACGAGATAAAATGATTTATACCATTTTAATTCAGCTTTGT AAAATG CATTTT 




37 CAAGCAGAAGACGGCATACGAGATATTCCGATTTATACCATTTTAATTCAGCTTTGT ATTCCG CGGAAT 
38 CAAGCAGAAGACGGCATACGAGATAGCTAGATTTATACCATTTTAATTCAGCTTTGT AGCTAG CTAGCT 
39 CAAGCAGAAGACGGCATACGAGATGTATAGATTTATACCATTTTAATTCAGCTTTGT GTATAG CTATAC 
40 CAAGCAGAAGACGGCATACGAGATTCTGAGATTTATACCATTTTAATTCAGCTTTGT TCTGAG CTCAGA 
41 CAAGCAGAAGACGGCATACGAGATGTCGTCATTTATACCATTTTAATTCAGCTTTGT GTCGTC GACGAC 
42 CAAGCAGAAGACGGCATACGAGATCGATTAATTTATACCATTTTAATTCAGCTTTGT CGATTA TAATCG 
43 CAAGCAGAAGACGGCATACGAGATGCTGTAATTTATACCATTTTAATTCAGCTTTGT GCTGTA TACAGC 
44 CAAGCAGAAGACGGCATACGAGATATTATAATTTATACCATTTTAATTCAGCTTTGT ATTATA TATAAT 
45 CAAGCAGAAGACGGCATACGAGATGAATGAATTTATACCATTTTAATTCAGCTTTGT GAATGA TCATTC 
46 CAAGCAGAAGACGGCATACGAGATTCGGGAATTTATACCATTTTAATTCAGCTTTGT TCGGGA TCCCGA 
47 CAAGCAGAAGACGGCATACGAGATCTTCGAATTTATACCATTTTAATTCAGCTTTGT CTTCGA TCGAAG 
48 CAAGCAGAAGACGGCATACGAGATTGCCGAATTTATACCATTTTAATTCAGCTTTGT TGCCGA TCGGCA 
49 CAAGCAGAAGACGGCATACGAGATTAGCGCATTTATACCATTTTAATTCAGCTTTGT TAGCGC GCGCTA 
50 CAAGCAGAAGACGGCATACGAGATGTGTTTATTTATACCATTTTAATTCAGCTTTGT GTGTTT AAACAC 
51 CAAGCAGAAGACGGCATACGAGATCCTTCAATTTATACCATTTTAATTCAGCTTTGT CCTTCA TGAAGG 
52 CAAGCAGAAGACGGCATACGAGATTATGTTATTTATACCATTTTAATTCAGCTTTGT TATGTT AACATA 
53 CAAGCAGAAGACGGCATACGAGATGACGCGATTTATACCATTTTAATTCAGCTTTGT GACGCG CGCGTC 
54 CAAGCAGAAGACGGCATACGAGATTGTATCATTTATACCATTTTAATTCAGCTTTGT TGTATC GATACA 
55 CAAGCAGAAGACGGCATACGAGATCACACCATTTATACCATTTTAATTCAGCTTTGT CACACC GGTGTG 
56 CAAGCAGAAGACGGCATACGAGATTTCTTAATTTATACCATTTTAATTCAGCTTTGT TTCTTA TAAGAA 




58 CAAGCAGAAGACGGCATACGAGATTAACCGATTTATACCATTTTAATTCAGCTTTGT TAACCG CGGTTA 
59 CAAGCAGAAGACGGCATACGAGATAAAGCTATTTATACCATTTTAATTCAGCTTTGT AAAGCT AGCTTT 
60 CAAGCAGAAGACGGCATACGAGATAGACCAATTTATACCATTTTAATTCAGCTTTGT AGACCA TGGTCT 
61 CAAGCAGAAGACGGCATACGAGATGGGATAATTTATACCATTTTAATTCAGCTTTGT GGGATA TATCCC 
62 CAAGCAGAAGACGGCATACGAGATACGACAATTTATACCATTTTAATTCAGCTTTGT ACGACA TGTCGT 
63 CAAGCAGAAGACGGCATACGAGATGTGGGGATTTATACCATTTTAATTCAGCTTTGT GTGGGG CCCCAC 
64 CAAGCAGAAGACGGCATACGAGATTCGTATATTTATACCATTTTAATTCAGCTTTGT TCGTAT ATACGA 
65 CAAGCAGAAGACGGCATACGAGATCAAGGGATTTATACCATTTTAATTCAGCTTTGT CAAGGG CCCTTG 
66 CAAGCAGAAGACGGCATACGAGATGCCGGTATTTATACCATTTTAATTCAGCTTTGT GCCGGT ACCGGC 
67 CAAGCAGAAGACGGCATACGAGATCAGTAAATTTATACCATTTTAATTCAGCTTTGT CAGTAA TTACTG 
68 CAAGCAGAAGACGGCATACGAGATAGTTCCATTTATACCATTTTAATTCAGCTTTGT AGTTCC GGAACT 
69 CAAGCAGAAGACGGCATACGAGATAATAACATTTATACCATTTTAATTCAGCTTTGT AATAAC GTTATT 
70 CAAGCAGAAGACGGCATACGAGATACTTTTATTTATACCATTTTAATTCAGCTTTGT ACTTTT AAAAGT 
71 CAAGCAGAAGACGGCATACGAGATTCCCTTATTTATACCATTTTAATTCAGCTTTGT TCCCTT AAGGGA 
72 CAAGCAGAAGACGGCATACGAGATATACTTATTTATACCATTTTAATTCAGCTTTGT ATACTT AAGTAT 
73 CAAGCAGAAGACGGCATACGAGATAGATGTATTTATACCATTTTAATTCAGCTTTGT AGATGT ACATCT 
74 CAAGCAGAAGACGGCATACGAGATAATCGTATTTATACCATTTTAATTCAGCTTTGT AATCGT ACGATT 
75 CAAGCAGAAGACGGCATACGAGATCGGCGTATTTATACCATTTTAATTCAGCTTTGT CGGCGT ACGCCG 
76 CAAGCAGAAGACGGCATACGAGATGAGAGTATTTATACCATTTTAATTCAGCTTTGT GAGAGT ACTCTC 
77 CAAGCAGAAGACGGCATACGAGATGATTCTATTTATACCATTTTAATTCAGCTTTGT GATTCT AGAATC 




79 CAAGCAGAAGACGGCATACGAGATACGCGGATTTATACCATTTTAATTCAGCTTTGT ACGCGG CCGCGT 
80 CAAGCAGAAGACGGCATACGAGATAGGGCGATTTATACCATTTTAATTCAGCTTTGT AGGGCG CGCCCT 
81 CAAGCAGAAGACGGCATACGAGATCTGCAGATTTATACCATTTTAATTCAGCTTTGT CTGCAG CTGCAG 
82 CAAGCAGAAGACGGCATACGAGATAACTTCATTTATACCATTTTAATTCAGCTTTGT AACTTC GAAGTT 
83 CAAGCAGAAGACGGCATACGAGATGGGTGCATTTATACCATTTTAATTCAGCTTTGT GGGTGC GCACCC 
84 CAAGCAGAAGACGGCATACGAGATTCCTGCATTTATACCATTTTAATTCAGCTTTGT TCCTGC GCAGGA 
85 CAAGCAGAAGACGGCATACGAGATCGCGGCATTTATACCATTTTAATTCAGCTTTGT CGCGGC GCCGCG 
86 CAAGCAGAAGACGGCATACGAGATACCGCCATTTATACCATTTTAATTCAGCTTTGT ACCGCC GGCGGT 
87 CAAGCAGAAGACGGCATACGAGATTAATACATTTATACCATTTTAATTCAGCTTTGT TAATAC GTATTA 
88 CAAGCAGAAGACGGCATACGAGATCACGTAATTTATACCATTTTAATTCAGCTTTGT CACGTA TACGTG 
89 CAAGCAGAAGACGGCATACGAGATATGTGAATTTATACCATTTTAATTCAGCTTTGT ATGTGA TCACAT 






















Table 7. The sample annotation and quantification of the targeted shRNA screen. 
No. Barcode Sample ng/ul 
1 1 Spleen T-ALL9 2411 LN L963 13.6 
2 2 Spleen T-ALL9 2411 RN L963 3.24 
3 3 Spleen T-ALL9 2411 NN L963 8.25 
4 4 Spleen T-ALL9 2410 LN L963 6.58 
5 5 Spleen T-ALL9 2413 LN L963 12.5 
6 6 Spleen T-ALL9 2413 NN L963 6.6 
7 7 Bone marrow T-ALL9 2411 LN L963 4.12 
8 8 Bone marrow T-ALL9 2411 RN L963 7.56 
9 9 Bone marrow T-ALL9 2411 NN L963 7.16 
10 10 Bone marrow T-ALL9 2410 LN L963 7.44 
11 11 Bone marrow T-ALL9 2413 LN L963 10.9 
12 12 Bone marrow T-ALL9 2413 NN L963 7.36 
13 13 Spleen T-ALL13 2544 NN LK080 25.6 
14 14 Spleen T-ALL13 2544 LN LK080 14 
15 15 Spleen T-ALL13 2544 RN LK080 3.54 
16 16 Spleen T-ALL13 2543 NN LK080 8.88 
18 18 Spleen T-ALL13 2543 RN LK080 38.8 
19 19 Bone marrow T-ALL13 2544 NN LK080 34.8 
20 20 Bone marrow T-ALL13 2544 LN LK080 27.8 
21 21 Bone marrow T-ALL13 2544 RN LK080 42.8 
22 22 Bone marrow T-ALL13 2543 NN LK080 7.92 
23 23 Bone marrow T-ALL13 2543 LN LK080 25.6 
24 24 Bone marrow T-ALL13 2543 RN LK080 23.8 
25 25 Spleen T-ALL3 3343 LN LK203 11.5 
26 26 Spleen T-ALL3 3343 RN LK203 5.72 
27 27 Spleen T-ALL3 3343 NN LK203 10.8 
28 88 Spleen T-ALL3 3343 BN LK203 7.12 
29 29 Spleen T-ALL3 3343 2LN LK203 10.3 
30 30 Spleen T-ALL3 3343 2RN LK203 7.32 
31 31 Bone marrow T-ALL3 3343 LN LK203 23 
32 32 Bone marrow T-ALL3 3343 RN LK203 12.8 
33 83 Bone marrow T-ALL3 3343 NN LK203 12.4 
34 34 Bone marrow T-ALL3 3343 BN LK203 7.4 
35 35 Bone marrow T-ALL3 3343 2LN LK203 8.98 
36 36 Bone marrow T-ALL3 3343 2RN LK203 18.9 
37 37 
 
T-ALL13 d16 in vitro LK080 10.8 
38 38 
 
T-ALL13 d30 in vitro LK080 7.18 
39 39 
 
T-ALL3 d16 in vitro LK203 17.2 
40 40 
 
T-ALL3 d30 -MSC LK203 10.9 
41 41 
 
T-ALL3 d30 +MSC LK203 11.3 
42 42 
 







T-ALL9 L963 baseline 27 
44 44 
 
T-ALL9 L963 baseline 24.2 
45 45 
 
T-ALL13 LK080 baseline 27 
46 46 
 
T-ALL13 LK080 baseline 25.8 
47 47 
 
T-ALL13 LK080 baseline 25.8 
48 48 
 
T-ALL3 LK203 baseline 31.2 
49 49 
 
T-ALL3 LK203 baseline 21.8 
50 50 
 
T-ALL3 LK203 baseline 26.6 
51 51 
 
SUPT1 Lib 1 d16 12.5 
52 52 
 
SUPT1 Lib 2 d16 30.6 
53 53 
 
SUPT1 Lib 1 d30 16 
54 54 
 
SUPT1 Lib 2 d30 25.2 
55 55 
 
SUPT1 Lib 1 d40 15.3 
56 56 
 
SUPT1 Lib 2 d40 25 
57 57 
 
CUTLL1 Lib 1 d16 20.2 
58 58 
 
CUTLL1 Lib 2 d16 30.2 
59 59 
 
CUTLL1 Lib 1 d30 18.5 
60 60 
 
CUTLL1 Lib 2 d30 27.4 
61 61 
 
CUTLL1 Lib 1 d40 22 
62 62 
 
CUTLL1 Lib 2 d40 32.4 
63 63 
 
MOLT4 Lib 1 d16 23.2 
64 64 
 
MOLT4 Lib 2 d16 28 
65 65 
 
MOLT4 Lib 1 d30 20.6 
66 66 
 
MOLT4 Lib 2 d30 19.9 
67 67 
 
MOLT4 Lib 1 d40 18.6 
68 68 
 
MOLT4 Lib 2 d40 18.5 
69 69 
 
HPB-ALL Lib 1 d16 17.2 
70 70 
 
HPB-ALL Lib 2 d16 26 
71 71 
 
HPB-ALL Lib1 d30 12 
72 72 
 
HPB-ALL Lib2 d30 25.8 
73 73 
 
HPB-ALL Lib 1 d40 23.2 
74 74 
 
HPB-ALL Lib 2 d40 25.4 
75 75 
 
SUPT1 Lib 1 baseline 19.3 
76 76 
 
SUPT1 Lib 2 baseline 30 
77 77 
 
CUTLL1 Lib 1 baseline 24 
78 78 
 
CUTLL1 Lib 2 baseline 40.4 
79 79 
 
MOLT4 Lib 1 baseline 24.2 
80 80 
 
MOLT4 Lib 2 baseline 12.4 
81 81 
 
HPB-ALL Lib 1 baseline 16 
82 82 
 






Table 8. The raw data of shRNA screens. 
 
SUPT1  
shRNA gene slope logCPM LR PValue FDR 
shRPS29#1 RPS29 -0.53123 14.29437 72.14488 2.00E-17 7.20E-16 
shRPL9#1 RPL9 -0.55786 13.85047 67.01331 2.70E-16 4.85E-15 
shLCK#3 LCK -0.61735 13.94143 52.16641 5.10E-13 6.12E-12 
shPTCRA#2 PTCRA -0.54271 13.57462 46.17613 1.08E-11 9.73E-11 
shPTEN#2 PTEN 0.282258 15.35395 35.02909 3.25E-09 2.34E-08 
shPTEN#3 PTEN 0.424263 15.38662 32.73342 1.06E-08 6.34E-08 
shZAP70#1 ZAP70 -0.37416 13.77377 31.02042 2.55E-08 1.31E-07 
shLCK#1 LCK -0.34628 14.26935 25.45437 4.53E-07 2.04E-06 
shPTEN#1 PTEN 0.289544 15.57128 20.91663 4.80E-06 1.92E-05 
shCD3e#1 CD3e -0.24225 14.39331 19.64187 9.34E-06 3.36E-05 
shLAT#2 LAT 0.273 14.31746 14.00058 0.000183 0.000598 
shRPL9#2 RPL9 -0.18126 14.89238 12.83435 0.00034 0.001021 
shTRPM7#2 TRPM7 -0.19066 14.65694 12.51527 0.000404 0.001118 
shPTCRA#3 PTCRA -0.35518 14.13973 12.15597 0.000489 0.001258 
shRPS29#2 RPS29 0.628086 12.66522 8.708742 0.003167 0.007601 
shKLHL7 KLHL7 0.162163 15.11518 8.211222 0.004163 0.009367 
shCD3e#2 CD3e -0.14202 14.55194 6.734616 0.009456 0.020024 
shCD19#2 CD19 0.12862 14.4973 5.898472 0.015154 0.030308 
shSESN2 SESN2 0.129881 14.83796 5.430274 0.019791 0.037498 
shCD3e#3 CD3e -0.09928 14.71464 3.841146 0.050009 0.090017 
shZAP70#3 ZAP70 0.121387 14.66767 3.03661 0.081406 0.139553 
shFYN#3 FYN 0.08937 14.62285 2.836867 0.092124 0.150748 
shDDB2 DDB2 0.08035 15.58186 2.732132 0.098348 0.153936 
shFYN#1 FYN -0.07978 14.72385 2.471572 0.115922 0.173883 
shERGIC3 ERGIC3 0.065503 14.82244 1.627733 0.202017 0.28986 
shLCK#2 LCK -0.06171 15.14572 1.575962 0.209343 0.28986 
shNTC NTC 0.062558 15.05358 1.325919 0.249533 0.33271 
shCD19#1 CD19 -0.04584 14.65114 0.636513 0.424976 0.546398 
shLAT#3 LAT -0.04232 14.63143 0.364078 0.54625 0.678104 
shFYN#2 FYN 0.027577 15.02277 0.293038 0.58828 0.705936 
shPTCRA#1 PTCRA -0.07778 12.83142 0.260297 0.609916 0.70829 
shFLG FLG 0.018123 15.83752 0.129273 0.719188 0.809086 
shZAP70#2 ZAP70 0.02048 15.15053 0.069517 0.792042 0.842413 
shRUNX1/ETO Run1 0.012942 15.29902 0.067097 0.795612 0.842413 
shLAT#1 LAT -0.01131 14.34605 0.043935 0.833974 0.857802 







shRNA gene slope logCPM LR PValue FDR 
shLCK#3 LCK -0.49393 14.57817 37.60301 8.67E-10 3.12E-08 
shRPS29#1 RPS29 -0.32417 14.50428 13.0007 0.000311 0.005605 
shPTCRA#2 PTCRA -0.19116 14.18089 7.283953 0.006957 0.083488 
shERGIC3 ERGIC3 0.1602 14.77733 5.377864 0.020394 0.183544 
shKLHL7 KLHL7 0.130125 14.88374 4.360828 0.036774 0.231921 
shLCK#1 LCK -0.13122 14.76446 4.085409 0.043255 0.231921 
shPTEN#2 PTEN 0.109527 14.80355 4.015054 0.045096 0.231921 
shZAP70#2 ZAP70 0.136615 15.01813 3.505103 0.06118 0.27531 
shLCK#2 LCK -0.16797 15.34151 3.129431 0.076891 0.275791 
shZAP70#3 ZAP70 0.347658 14.31406 3.121749 0.077254 0.275791 
shNTC NTC 0.214847 14.77209 2.980575 0.084269 0.275791 
shFYN#3 FYN 0.104816 14.56482 2.537008 0.111205 0.310058 
shCD19#2 CD19 0.304433 14.16582 2.526258 0.111965 0.310058 
shLAT#2 LAT 0.420649 13.73192 2.350098 0.125275 0.316841 
shSESN2 SESN2 0.119695 14.52444 2.268625 0.132017 0.316841 
shFYN#2 FYN -0.11644 15.07516 1.8726 0.171178 0.38515 
shCD3e#3 CD3e 0.097748 14.92095 1.407473 0.235476 0.484078 
shCD19#1 CD19 0.076676 14.63632 1.36868 0.242039 0.484078 
shZAP70#1 ZAP70 -0.06882 14.24169 1.04734 0.30612 0.580018 
shTRPM7#2 TRPM7 0.073465 14.78222 0.850954 0.356283 0.641309 
shLAT#3 LAT -0.0557 14.45989 0.731144 0.392513 0.654138 
shLAT#1 LAT -0.05618 14.38549 0.709075 0.399751 0.654138 
shRPS29#2 RPS29 0.455703 11.59586 0.554487 0.45649 0.714506 
shPTEN#3 PTEN 0.037494 14.68379 0.428577 0.512688 0.734676 
shTRPM7#1 TRPM7 -0.04328 15.18369 0.357437 0.549933 0.734676 
shRUNX1/ETO Run1 -0.04558 15.46496 0.32547 0.568339 0.734676 
shPTEN#1 PTEN 0.030015 15.12332 0.320785 0.571136 0.734676 
shCD3e#1 CD3e 0.053084 14.7422 0.320321 0.571415 0.734676 
shPTCRA#3 PTCRA -0.03215 14.61697 0.239374 0.624659 0.775439 
shPTCRA#1 PTCRA 0.267687 12.7532 0.208158 0.648215 0.777858 
shDDB2 DDB2 -0.01769 15.59403 0.083688 0.77236 0.896935 
shRPL9#1 RPL9 -0.01118 14.45504 0.023847 0.877274 0.948472 
shFYN#1 FYN 0.007742 14.81366 0.018907 0.890633 0.948472 
shRPL9#2 RPL9 0.007072 15.13202 0.01716 0.895779 0.948472 
shFLG FLG 0.003909 15.84047 0.005994 0.938291 0.965099 









shRNA gene slope logCPM LR PValue FDR 
shLCK#3 LCK -0.35675 14.29463 132.3253 1.27E-30 4.57E-29 
shPTEN#3 PTEN 0.270945 14.94674 89.43219 3.17E-21 5.71E-20 
shTRPM7#2 TRPM7 -0.24783 14.66783 74.99375 4.72E-18 5.67E-17 
shPTEN#1 PTEN 0.233804 15.29035 71.80669 2.37E-17 2.14E-16 
shRPS29#2 RPS29 0.287987 13.31127 41.1585 1.40E-10 1.01E-09 
shZAP70#1 ZAP70 -0.14383 14.17178 19.57463 9.67E-06 5.80E-05 
shTRPM7#1 TRPM7 -0.13288 14.8739 18.39057 1.80E-05 9.25E-05 
shPTCRA#1 PTCRA 0.144236 14.12509 14.74569 0.000123 0.000554 
shPTEN#2 PTEN 0.10558 14.9605 12.22175 0.000472 0.001889 
shSESN2 SESN2 0.080821 14.62455 7.360335 0.006668 0.024004 
shRPL9#2 RPL9 -0.06889 15.13805 5.806092 0.015971 0.052268 
shLCK#1 LCK -0.05504 14.65581 3.562372 0.059103 0.173345 
shZAP70#2 ZAP70 -0.05783 15.04069 3.467211 0.062597 0.173345 
shPTCRA#2 PTCRA 0.04774 14.35548 2.492345 0.114401 0.286763 
shRPS29#1 RPS29 -0.04414 14.94927 2.424066 0.119484 0.286763 
shLAT#2 LAT 0.049563 14.24421 2.267049 0.132151 0.29734 
shFYN#2 FYN -0.03946 14.81744 1.948541 0.162744 0.344635 
shRPL9#1 RPL9 -0.03939 14.58448 1.841226 0.174807 0.349615 
shFYN#1 FYN -0.03403 14.6642 1.363196 0.242984 0.460391 
shNTC NTC 0.026824 14.92501 0.916581 0.338374 0.609074 
shFYN#3 FYN 0.021791 14.52647 0.547283 0.45943 0.787594 
shLCK#2 LCK -0.01924 15.03996 0.410081 0.521928 0.787689 
shCD3e#3 CD3e 0.017933 14.88124 0.403658 0.525206 0.787689 
shFLG FLG -0.01381 15.7347 0.258837 0.61092 0.787689 
shKLHL7 KLHL7 0.014446 14.82185 0.258797 0.610948 0.787689 
shCD19#2 CD19 0.01455 14.51295 0.233252 0.629123 0.787689 
shCD19#1 CD19 -0.01426 14.71381 0.229565 0.631846 0.787689 
shERGIC3 ERGIC3 -0.01392 14.61057 0.229422 0.631952 0.787689 
shCD3e#2 CD3e -0.01372 14.76283 0.225394 0.63496 0.787689 
shZAP70#3 ZAP70 0.01156 14.50116 0.149549 0.698967 0.787689 
shLAT#1 LAT 0.012082 14.28583 0.142321 0.705985 0.787689 
shLAT#3 LAT 0.011454 14.41083 0.137908 0.71037 0.787689 
shRUNX1/ETO Run1 0.009921 15.20024 0.126539 0.722048 0.787689 
shCD3e#1 CD3e -0.00759 14.72741 0.066942 0.795843 0.842657 
shPTCRA#3 PTCRA -0.00638 14.61162 0.044858 0.832265 0.856044 









shRNA gene slope logCPM LR PValue FDR 
shRPS29#2 RPS29 1.390155 11.19096 116.9687 2.92E-27 1.05E-25 
shPTCRA#1 PTCRA 1.162686 12.44823 97.1251 6.51E-23 1.17E-21 
shRPL9#1 RPL9 -1.21206 13.30871 93.49248 4.08E-22 4.89E-21 
shLAT#2 LAT 0.448203 13.41074 82.51448 1.05E-19 9.44E-19 
shLCK#3 LCK -0.30854 14.80821 71.77447 2.41E-17 1.74E-16 
shPTEN#3 PTEN 0.324605 15.09946 68.71281 1.14E-16 6.83E-16 
shPTEN#2 PTEN 0.360431 15.34098 60.10506 8.99E-15 4.62E-14 
shRPL9#2 RPL9 -0.54714 14.65503 57.88878 2.77E-14 1.25E-13 
shZAP70#3 ZAP70 0.307299 14.0987 40.39811 2.07E-10 8.29E-10 
shPTEN#1 PTEN 0.192277 15.38286 23.49149 1.25E-06 4.52E-06 
shLCK#2 LCK -0.16964 15.37185 20.91965 4.79E-06 1.57E-05 
shNTC NTC 0.142722 14.67407 16.20187 5.69E-05 0.000171 
shCD19#2 CD19 0.322201 14.00891 15.24878 9.42E-05 0.000261 
shZAP70#1 ZAP70 -0.14588 14.20112 12.15537 0.000489 0.001231 
shRPS29#1 RPS29 -0.1659 15.04966 12.06883 0.000513 0.001231 
shLCK#1 LCK -0.12064 14.80174 10.8718 0.000976 0.002181 
shFYN#2 FYN -0.1498 15.14792 10.77279 0.00103 0.002181 
shFYN#1 FYN -0.1067 14.72682 8.761949 0.003076 0.00609 
shERGIC3 ERGIC3 0.149835 14.66639 8.681668 0.003214 0.00609 
shCD3e#3 CD3e 0.110724 14.81066 5.815661 0.015884 0.028591 
shPTCRA#2 PTCRA -0.09302 14.33642 5.450512 0.019563 0.033536 
shDDB2 DDB2 -0.07671 15.54087 4.91949 0.026555 0.043454 
shTRPM7#1 TRPM7 -0.07996 15.19215 4.631726 0.031386 0.04911 
shLAT#1 LAT -0.07844 14.33617 4.559337 0.03274 0.04911 
shKLHL7 KLHL7 0.094138 14.73021 3.918114 0.047768 0.068787 
shLAT#3 LAT -0.08526 14.49881 3.410346 0.064789 0.089708 
shRUNX1/ETO Run1 -0.05371 15.45031 2.394155 0.12179 0.162386 
shFYN#3 FYN 0.052444 14.53822 1.91671 0.16622 0.213711 
shZAP70#2 ZAP70 0.060226 15.03983 1.719252 0.189789 0.235601 
shPTCRA#3 PTCRA 0.045001 14.68605 1.3185 0.250862 0.301034 
shFLG FLG -0.03314 15.809 0.840896 0.359141 0.417067 
shCD3e#1 CD3e 0.074454 14.68732 0.737249 0.390543 0.438663 
shSESN2 SESN2 0.05198 14.32832 0.702013 0.402108 0.438663 
shCD3e#2 CD3e -0.02839 14.99087 0.530497 0.466398 0.493833 
shCD19#1 CD19 -0.02494 14.61324 0.360766 0.548081 0.563741 








LK203 in vitro 
shRNA logFC logCPM LR PValue FDR 
shRPL9#2 -2.34442 14.34755 57.47394 3.42E-14 1.23E-12 
shRPS29#1 -3.28914 13.91702 18.12502 2.07E-05 0.0003 
shSESN2 1.058582 14.68708 17.23154 3.31E-05 0.0003 
shERGIC3 1.769788 15.65966 17.22071 3.33E-05 0.0003 
shPTEN#3 0.97378 15.07812 15.42601 8.58E-05 0.000618 
shLCK#1 -0.77115 14.55244 10.42664 0.001242 0.007453 
shLAT#1 -0.79255 14.38541 10.03618 1.53E-03 0.007894 
shZAP70#3 0.913031 14.12767 8.893602 0.002862 0.012878 
shLCK#2 -0.67921 15.12368 7.527476 0.006076 0.022739 
shLAT#3 -0.81492 14.37636 7.457751 0.006316 0.022739 
shRPL9#1 -1.72479 13.97955 5.985659 0.014423 0.047201 
shLCK#3 -0.65503 15.0903 5.812054 0.015917 0.04775 
shPTEN#2 0.577326 15.27768 4.590465 0.03215 0.086249 
shTRPM7#2 -0.69319 14.87496 4.517927 0.033541 0.086249 
shCD19#2 0.563898 14.21015 3.744642 0.052977 0.122818 
shPTEN#1 0.513298 14.97789 3.6947 0.054586 0.122818 
shTRPM7#1 0.619672 15.45041 3.558532 0.05924 0.12545 
shPTCRA#3 -0.53497 14.5679 3.154093 0.075737 0.151474 
shNTC 0.43134 14.77022 2.861392 0.090729 0.171907 
shFYN#1 -0.45909 14.66029 2.5511 0.110218 0.198392 
shPTCRA#2 -0.94997 14.01477 2.396064 0.121641 0.208527 
shCD3E#3 0.350878 14.81547 2.265706 0.132266 0.216245 
shFYN#2 -0.36781 15.08274 2.198372 0.138157 0.216245 
shCD3E#2 0.363319 15.12521 1.809009 0.178627 0.267941 
shPTCRA#1 0.764157 13.1688 1.504773 2.20E-01 0.316711 
shCD3E#1 0.284976 14.5903 1.312212 0.251995 0.343891 
shRPS29#2 0.792341 10.99167 1.273523 2.59E-01 3.44E-01 
shKLHL7 0.278821 14.20479 1.229674 2.67E-01 0.343891 
shRUNX1/ETO -0.26394 15.47563 1.101449 0.293948 0.364901 
shDDB2 -0.24191 15.4647 0.99148 0.319381 0.383257 
shZAP70#1 -0.2403 14.2102 0.766361 3.81E-01 0.442853 
shCD19#1 0.151835 14.9887 0.447914 0.503327 0.566243 
shFYN#3 0.134089 14.51175 0.32771 0.567011 0.618557 
shLAT#2 0.173499 13.50733 0.187032 0.665398 0.704539 
shFLG 0.026086 15.75399 0.011679 0.913942 0.9148 








L963 in vivo spleen 
shRNA logFC logCPM LR PValue FDR 
shLCK#3 -8.03321 12.38082 31.3336 2.17E-08 7.82E-07 
shRPL9#1 -6.10375 11.56515 10.30905 0.001324 0.023828 
shCD19#2 -3.204 12.52308 5.983788 0.014438 0.173256 
shFYN#1 -1.84535 13.22957 3.100858 0.078251 0.70426 
shPTEN#3 -2.03758 12.77494 2.452733 0.11732 0.844707 
shERGIC3 2.276879 16.74306 2.167813 0.140927 0.845559 
shPTEN#1 -1.68258 16.29354 1.21885 0.269586 0.97833 
shZAP70#1 -1.7052 13.5309 1.21095 0.271144 0.97833 
shRUNX1/ETO -1.24494 13.95386 1.073682 0.300115 0.97833 
shSESN2 -1.19801 14.09281 0.952131 0.329178 0.97833 
shLAT#3 -1.22223 13.02144 0.900891 0.342543 0.97833 
shPTCRA#2 1.322231 16.3038 0.800911 0.370821 0.97833 
shKLHL7 -1.08219 14.4175 0.763621 0.382198 0.97833 
shCD3E#2 -1.11341 13.91845 0.727283 0.393765 0.97833 
shLAT#1 1.335508 15.05768 0.68568 0.407638 0.97833 
shLAT#2 -0.97306 12.92357 0.572829 0.449137 0.983201 
shCD19#1 1.115446 15.03059 0.441655 0.506325 0.983201 
shCD3E#3 -0.60982 14.28719 0.219188 0.63966 0.983201 
shDDB2 0.588038 16.93928 0.207383 0.648827 0.983201 
shFYN#3 0.565636 14.69092 0.16716 0.682649 0.983201 
shNTC 0.412178 14.50807 0.165008 0.684587 0.983201 
shLCK#1 -0.76202 14.11903 0.157834 0.691159 0.983201 
shCD3E#1 -0.43304 15.02011 0.143895 0.704439 0.983201 
shFYN#2 -0.49307 14.25891 0.119843 0.729204 0.983201 
shFLG -0.38268 15.06153 0.093593 0.759658 0.983201 
shPTCRA#1 -0.34852 12.41615 0.050705 0.821841 0.983201 
shTRPM7#1 0.316594 16.76503 0.044782 0.832406 0.983201 
shPTCRA#3 -0.23218 13.87086 0.042135 0.837362 0.983201 
shZAP70#2 0.20482 14.9653 0.0318 0.858466 0.983201 
shTRPM7#2 -0.15276 14.70756 0.012512 0.910937 0.983201 
shPTEN#2 0.157617 14.2727 0.011548 0.914423 0.983201 
shLCK#2 0.12677 15.19829 0.010496 0.918399 0.983201 
shRPL9#2 -0.12975 14.19795 0.008017 0.928657 0.983201 
shZAP70#3 0.053671 14.20344 0.001976 0.964547 0.983201 
shRPS29#1 0.037446 14.52556 0.000707 0.978787 0.983201 








L963 in vivo bone marrow 
shRNA logFC logCPM LR PValue FDR 
shLCK#3 -8.57718 12.38082 26.24361 3.01E-07 1.08E-05 
shRPL9#1 -6.49117 11.56515 9.817988 0.001728 0.031106 
shCD19#2 -3.25763 12.52308 6.059984 0.013828 0.160969 
shERGIC3 4.058343 16.74306 5.607333 0.017885 0.160969 
shPTEN#1 -2.94281 16.29354 3.816812 0.050741 0.365333 
shPTEN#3 -2.59947 12.77494 3.110715 0.077779 0.390707 
shLAT#3 -2.39486 13.02144 3.075171 0.079496 0.390707 
shLAT#2 -1.92967 12.92357 2.9323 0.086824 0.390707 
shPTCRA#2 1.95272 16.3038 1.774488 0.182828 0.731311 
shKLHL7 -1.47015 14.4175 1.514979 0.218381 0.762553 
shFYN#1 -1.3497 13.22957 1.422439 0.233002 0.762553 
shDDB2 1.461431 16.93928 1.028954 0.310405 0.906671 
shCD3E#2 -1.28722 13.91845 0.959119 0.327409 0.906671 
shCD3E#3 -1.04132 14.28719 0.636985 0.424805 0.922599 
shZAP70#3 1.02018 14.20344 0.618771 0.431504 0.922599 
shSESN2 -0.82483 14.09281 0.494419 0.481963 0.922599 
shLCK#2 0.795998 15.19829 0.363831 0.546386 0.922599 
shRUNX1/ETO -0.78189 13.95386 0.338049 5.61E-01 9.23E-01 
shZAP70#2 -0.53391 14.9653 0.236764 0.626553 0.922599 
shTRPM7#1 -0.6809 16.76503 0.20726 0.648923 0.922599 
shNTC 0.408758 14.50807 0.155089 0.693718 0.922599 
shLCK#1 0.737421 14.11903 0.153269 0.695431 0.922599 
shCD19#1 0.678317 15.03059 0.145387 0.702983 0.922599 
shZAP70#1 -0.68116 13.5309 0.126603 0.721981 0.922599 
shFYN#3 0.510772 14.69092 0.11697 0.732345 0.922599 
shRPS29#1 -0.44438 14.52556 0.095859 0.756857 0.922599 
shRPL9#2 0.47237 14.19795 0.091172 0.762693 0.922599 
shFLG -0.37716 15.06153 0.081228 0.775641 0.922599 
shFYN#2 -0.41495 14.25891 0.079526 0.777941 0.922599 
shLAT#1 0.35956 15.05768 0.050328 0.822494 0.922599 
shPTCRA#3 -0.26426 13.87086 0.047526 0.827426 0.922599 
shTRPM7#2 -0.26199 14.70756 0.03781 0.845825 0.922599 
shPTEN#2 -0.24905 14.2727 0.027004 0.869473 0.922599 
shPTCRA#1 -0.2584 12.41615 0.026229 0.871343 0.922599 
shCD3E#1 0.050404 15.02011 0.001907 0.965171 0.965706 








Table 9. The average life span of mice engrafted with T-ALL PDXs. 
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AN ESSENTIAL ROLE OF LCK IN T-ALL CELL PROLIFERATION AND SURVIVAL 
Yuzhe Shi*1, Melanie Beckett1, Helen Blair1, Olaf Heidenreich1, Anja Krippner-
Heidenreich1, Frederik van Delft1 
1Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, 
Newcastle University, Newcastle upon Tyne, United Kingdom  
Background: T-cell Acute Lymphoblastic Leukemia (T-ALL) is caused by malignant 
transformation of T cells showing differentiation arrest and uncontrolled proliferation. 
The checkpoints during T-cell development are dominated by pre-T-cell receptor 
(pTCR) for β-selection and T-cell receptor (TCR) for positive/negative selection. Gene 
lesions with proximity to these checkpoints are found in T-ALL such as NOTCH, 
FBXW7, PTEN and NRAS. As shown in B-cell Precursor Leukemia, kinases of the pre-
B-cell receptor signaling complex (SYK and BTK) have been validated as drug targets, 
but whether critical components of the pTCR/TCR signaling such as LCK or ZAP70 
play a similar role in T-ALL remains unclear. LCK (lymphocyte-specific kinase) is a 
central molecule in pTCR/TCR signaling transduction. The important role for LCK has 
been shown in Chronic Lymphoblastic Leukemia, however, the role of LCK in T-ALL 
has not been studied. 
Aims: To investigate the importance of pTCR/TCR complex for T-ALL cell proliferation 
and survival.  
Methods: We performed limited screens targeting six components of the pTCR/TCR 
signaling complex in vitro and in vivo in 4 TALL cell lines and 2 T-ALL patient-derived 
xenografts (PDXs). To validate the screening results we conducted gene knockdown 
experiments in T-ALL cell lines using GFP-expressing lentiviral shRNA vectors and 
evaluated cell proliferation by competitive assays in vitro and in vivo. The activation 
and expression of LCK were determined in 11 T-ALL cell lines and 10 PDXs by qPCR, 
western blotting and Phosflow. The kinase activity of LCK was abrogated using 
Dasatinib. Synergism between Dexamethasone and Dasatinib was evaluated by drug 
matrix assays. The ex-vivo expansion of PDXs was achieved by co-culture with OP9-





Results: A targeted in vitro and in vivo shRNA screen targeting central components of 
the pTCR/TCR signalling complex (PTCRA, CD3ε, LCK, FYN, ZAP70 and LAT) in T-
ALL cell lines and PDXs identified LCK to be crucial for T-ALL maintenance and 
engraftment. Knockdown of LCK in SUP-T1, CUTLL1 and MOLT4 cells revealed a 
significant loss of at least 50% of GFP+/LCK shRNA transduced cells over a time period 
of 2-3 weeks. This was also confirmed in vivo in competitive assays with MOLT4 cells 
showing a growth advantage of control shNTC cells over LCK knockdown cells in bone 
marrow, spleen and liver. Mechanistic analyses indicate that knockdown or inhibition 
of LCK by Dasatinib impairs cell proliferation by inducing G1/G0 arrest in both TALL 
cell lines and PDXs, but has little effect on the induction of cell death. The sensitivity 
of T-ALL cell lines towards Dasatinib seems to correlate positively with activated LCK 
(LCK p-Y394). Moreover, LCK knockdown significantly sensitizes T-ALL cells to 
Dexamethasone (Dex) and strong synergistic lethal effects between Dex and Dasatinib 
have been observed in various T-ALL cell lines and PDXs. Importantly, both Dex-
sensitive and Dex-resistant T-ALLs are highly sensitive to Dex/Dasatinib combination 
treatment. To evaluate this further we currently perform a randomized phase-‖ like 
mini-trial in NSG mice with 10 PDXs comparing four treatment arms including control, 
Dex, Dasatinib and combination. 
Summary/Conclusion: Overall, our data demonstrate that LCK plays a critical role in 
T-ALL cell proliferation and engraftment. 
LCK inhibition with Dasatinib, in conjunction with Dex, reverses glucocorticoid 
resistance and induces cell death. The Dex/Dasatinib combination might provide a 
novel treatment strategy for refractory and relapsed T-ALL patients. 
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T-cell Acute Lymphoblastic Leukemia (T-ALL) is frequently characterized by 30 
glucocorticoid (GC) resistance, which is associated with inferior outcomes, thus 31 
highlighting the need for novel therapeutic approaches for GC resistant T-ALL. The 32 
pTCR/TCR signaling pathways play a critical role in cell fate decisions during 33 
physiological thymocyte development, with an interplay between TCR and 34 
glucocorticoid receptor (GR) signaling determining the T-lymphocyte selection 35 
process. We performed an shRNA screen in vitro and in vivo in T-ALL cell lines and 36 
patient derived xenograft (PDX) samples to identify vulnerabilities in the pTCR/TCR 37 
pathway and identified a critical role for the kinase LCK in cell proliferation. LCK 38 
knockdown or inhibition with dasatinib (DAS) caused cell cycle arrest. Combination of 39 
DAS with dexamethasone (DEX) resulted in significant drug synergy leading to cell 40 
death. The efficacy of this drug combination was underscored in a randomized phase 41 
II-like murine trial, recapitulating an early phase human clinical trial. T-ALL expansion 42 
in immunocompromised mice was significantly impaired using this drug combination, 43 
relative to mice receiving control vehicle or single drug treatment, highlighting the 44 
immediate clinical relevance of this drug combination for high risk T-ALL patients. Our 45 
results thus provide a strategy to improve the efficacy of current chemotherapy 46 
platforms and circumvent GC resistance. 47 
 48 
Introduction 49 
Current minimal residual disease (MRD) stratified chemotherapy protocols for patients 50 
with T-ALL result in 5-year event free survival rates of 80% and 50% for pediatric and 51 
adult patients respectively (1, 2). Induction failure, early relapse and isolated central 52 
nervous system involvement are more common in T than B-lineage ALL (3). Moreover, 53 
resistance to conventional chemotherapy including GC is a frequent feature of 54 
relapsed and refractory T-ALL, reducing the second remission rate and long term 55 
outcomes (4). GC are an instrumental component of ALL therapy and induce 56 
apoptosis in lymphoid malignancies (5-7). Resistance to GC is a critical factor 57 
influencing treatment response and outcome (5, 8-11). Amongst ALL subtypes, GC 58 
resistance is more frequently observed in infant ALL and T-ALL (5, 9, 11, 12).  59 
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Endogenous GC can induce apoptosis during the selection process of T-lymphocytes 60 
in the thymus, an effect which can be constrained by crosstalk with T cell receptor 61 
(TCR) signaling (13, 14). Whilst mature T-cell maintenance requires tonic TCR 62 
signaling, inappropriate TCR expression has been shown to give rise to T-cell 63 
malignancies in mouse model systems (15, 16).  64 
The immature pre T-cell receptor (pTCR) consists of a complex of alpha (pTCRα) and 65 
beta (TCRβ) peptide chains complexed with CD3  and CD3  heterodimers. 66 
Activation of this complex occurs through the Src family kinase (SFK) members 67 
Lymphocyte Cell-Specific Protein-Tyrosine Kinase (LCK) and FYN. They are critical 68 
modulators of T-cell development and activation (17). LCK phosphorylates the plasma 69 
membrane associated TCR complex (18) and ZAP70 (19). ZAP70 in turn 70 
phosphorylates the linker for activation of T-cells (LAT) leading to the activation of 71 
downstream signaling cascades. The overall activity of LCK is regulated by the 72 
phosphorylation status of the activating and inhibitory tyrosine residues 394 and 505 73 
respectively (20). LCK activation correlates with SrcY416 phosphorylation, as the latter 74 
overrides the inhibitory effects of Y505 phosphorylation (21). 75 
We hypothesized therefore that T-ALL continues to rely on proliferative and survival 76 
stimuli inherent to the TCR signaling pathway, which, if inhibited, may enhance GC 77 
sensitivity. A targeted shRNA screen directed against components of the TCR 78 
signaling initiation complex identified a crucial role for LCK in T-ALL proliferation, both 79 
in vitro and in vivo. The anti-proliferative effects of LCK knockdown could be replicated 80 
by using the small molecule inhibitor DAS. Drug synergy was observed using DAS in 81 
combination with DEX on patient derived xenograft (PDX) cell survival in vitro. 82 
Mirroring the design of early phase human trials, a murine phase II-like trial 83 
demonstrated significantly impaired leukemia progression in vivo using combination 84 
treatment. Our results present a clear rationale for using DAS in conjunction with DEX 85 
to enhance conventional chemotherapeutic treatment and revert glucocorticoid 86 
resistance in pediatric T-ALL patients. 87 
 88 
Methods 89 
Patient samples 90 
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The patient derived material was collected as part of diagnostic investigations of 91 
patients at the Great North Children’s Hospital, Department of Paediatric Haematology 92 
and Oncology, Newcastle upon Tyne, United Kingdom. The material was collected 93 
and stored with informed consent obtained from all subjects in accordance with the 94 
Declaration of Helsinki.  95 
Samples with explicit written consent for in vivo studies were requested from the 96 
Newcastle Biomedicine Biobank, Newcastle University, United Kingdom and used 97 
according to approvals given by the Newcastle Biomedicine Biobank (NHB application 98 
NHB-008) and the local institutional review board Newcastle & North Tyneside Ethics 99 
Committee (REC reference: 07/H0906/109). 100 
Patient-derived xenografts (PDXs) were harvested from the NOD.Cg-101 
PrkdcscidIl2rgtm1wjl/SzJ (NSG, Charles River labs and bred in-house) mice after the 102 
engraftment of patient samples. PDXs were co-cultured ex vivo with OP9-DL1 in 103 
StemSpan Serum-Free Expansion Medium II (STEMCELL, UK) supplemented with 104 
human IL7 (10 ng/ml) and SCF (100 ng/ml) (both PeproTech, UK). 105 
Drug matrix assays 106 
Dasatinib (9 nM – 30 μM) (DC Chemicals, Shanghai, China) was titrated on T-ALL cell 107 
lines (4 x 104/well) in 96-well plates (Corning, NY, USA). Cell viability was assessed 108 
after 3 days using Cell Counting Kit 8 (NBS Biologicals, Cambridgeshire, UK). The 109 
absorbance was measured at OD450 nm using a POLARstar Omega plate reader 110 
(BMG LABTECH, Bucks, UK). IC50 values were determined by GraphPad Prism. 111 
Assays were performed in triplicate and at least 3 independent repeats were 112 
performed. 113 
For DAS/DEX combination treatments DAS (80 nM – 50 μM) and DEX (0.09 nM – 600 114 
nM) were titrated in 2-dimensions on T-ALL cell lines (4 x 104 cells / 96-well) or ex vivo 115 
expanded PDX cells (8 x 104 cells / 96-well). Ex vivo expansion was achieved after 116 
co-culture with OP9-DL1 for 1 week, after which cells were separated from their 117 
feeders by repetitive transfer and subsequently plated. After 72h of culture, the plates 118 
were developed as above. Drug synergy was determined using Combenefit software 119 
(v2.021) (22).  120 
 121 
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Phase II-like Murine Trial 122 
For each of the 10 patient derived xenograft (PDX) samples, 8 x 106 cells were 123 
intrafemorally (IF) injected into 4 NSG mice (40 mice in total) under isoflurane 124 
anesthesia. The 4 NSG mice derived from one PDX sample were matched for gender 125 
and age. T-ALL engraftment in mouse peripheral blood was monitored weekly by tail 126 
vein bleeds (20 μl blood/mouse). The four mice of each PDX were randomized to 127 
receive control vehicle, DAS (35 mg/kg), DEX (1 mg/kg) or DEX/DAS combination by 128 
intraperitoneal (IP) injection upon engraftment, defined as ≥ 0.5% peripheral blood 129 
hCD45+/hCD7+ cells. The median treatment duration of these mice was 15 days, 130 
depending on the clinical status. When any of the four mice displayed signs of ill health 131 
or weight loss, all four mice derived from this PDX were killed at the same time to 132 
assess leukemia engraftment in bone marrow, blood, spleen, liver and central nervous 133 
system (CNS). Spleen size and weight were recorded. Statistical analyses were 134 
performed using RStudio (MA, USA) with linear mix model. The final analysis excluded 135 
the 4 mice derived from patient sample LK214, as all mice succumbed to T-ALL before 136 
treatment was initiated. 137 
See online supplemental file for further methods. 138 
 139 
Results 140 
A targeted shRNA screen of TCR pathway components identifies an essential 141 
role for LCK in T-ALL cell line and PDX proliferation in vitro 142 
To explore the importance of the pTCR/TCR signaling complex in proliferation and 143 
survival of malignant T-cells, we performed a limited shRNA screen targeting 6 genes 144 
with 3 shRNAs per gene, including LCK, ZAP70, PTCRA, FYN, CD3E and LAT in 4 T-145 
ALL cell lines (HPB-ALL, CUTLL1, MOLT4, SUPT1), and included 18 control shRNAs 146 
(see Supplementary Methods)(Supplementary Table 1). In silico analysis, using the 147 
Cancer Cell Line Encyclopedia (CCLE), demonstrated that these 6 genes are highly 148 
expressed in a panel of T-ALL cell lines (Supplementary Figure 1A). LCK and PTCRA 149 
expression was confirmed by targeted gene expression analysis in T-ALL cell lines 150 
and patient samples (Figure 1B)(Supplementary Figure 1B). The limited shRNA 151 
screen revealed the shLCK#3 construct targeting LCK was the only construct 152 
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significantly depleted in all 4 cell lines, when compared with base line shRNA 153 
integration, underlining an important role for LCK in T-ALL cell line proliferation and/or 154 
survival (Figure 1A)(Supplementary Figure 1C-D). The shLCK#1, shZAP70#1 and 155 
shPTCRA#2 constructs were lost in 3 out of 4 cell lines. Constructs targeting FYN, 156 
CD3E, or LAT were significantly depleted in one cell line only, suggesting that these 157 
molecules do not play an universal role in T-ALL cell proliferation. ShRNAs against 158 
essential ribosomal genes were predictably depleted, whilst all 3 shRNA constructs 159 
targeting the tumor suppressor PTEN were enriched as expected. Repeated sampling 160 
at 16, 30 and 40 days after transduction demonstrated progressive depletion of shRNA 161 
constructs targeting LCK and ZAP70 (Supplementary Figure 1E)(Supplementary 162 
Table 2). PDX LK203 showed good viability (≥75%) and proliferation potential (Td = 163 
2.8 days) in co-culture with human Mesenchymal Stem Cells (hMSC), hence subjected 164 
to shRNA screening. ShRNA sequencing 30 days after transduction confirmed all 165 
constructs targeting LCK were significantly depleted (Figure 1)(Supplementary Figure 166 
1F)(Supplementary Table 3). 167 
 168 
Knockdown of LCK in T-ALL cell lines confirms an essential role for LCK in vitro 169 
propagation. 170 
To confirm the role of LCK and other components of the pTCR/TCR signaling complex 171 
in cell proliferation, competitive outgrowth assays were performed. SUPT1, MOLT4 172 
and CUTLL1 cells were transduced with lentiviral shRNAs targeting LCK, ZAP70, 173 
FYN, PTCRA or non-targeting control shRNAs. Successfully transduced cells 174 
expressing green fluorescence protein (GFP) were seeded in a 1:1 ratio with parental 175 
cells.  176 
Three shRNAs were used to silence LCK, of which shLCK#3 achieved the greatest 177 
degree of knockdown. Lentiviral knockdown with shLCK#3 led to significant reduction 178 
in mRNA in SUPT1 (75%KD), MOLT4 (55% KD) and CUTLL1 (45% KD) cells (Figure 179 
2A). Generally, greater knockdown was associated with more pronounced impairment 180 
of in vitro proliferation (Figure 2B). LCK expression was confirmed at protein level, 181 
demonstrating ubiquitous expression of LCK in cell lines (Supplementary Figure 1G). 182 
In line with mRNA downregulation, knockdown of LCK led to decreased total LCK 183 
protein expression (Figure 2A). Non-transduced cells consistently outcompeted LCK 184 
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knockdown cells resulting in a pronounced loss of over 70% transduced GFP+ cells in 185 
all 3 cell lines, underlining the critical and universal role of LCK in T-ALL cell line 186 
maintenance (Figure 2B)(Supplementary Figure 2A).  187 
A similar, but less significant, observation was made for ZAP70 knockdown in SUPT1, 188 
MOLT4 and CUTLL1 cells. Efficient ZAP70 knockdown correlated with a pronounced 189 
proliferation defect (Supplementary Figure 2A). Knockdown of PTCRA affected 190 
proliferation in pTCRα+ MOLT4 and SUPT1, but not in pTCRa_ CUTLL1 191 
(Supplementary Figure 2A). Moreover, FYN knockdown did not affect proliferation in 192 
any of the cells lines despite efficient knockdown (Supplementary Figure 2B). 193 
 194 
Knockdown of LCK in T-ALL cell lines and PDX samples impairs leukemia 195 
propagation in vivo. 196 
To confirm a functional role for LCK in vivo, PDX L963 cells were transduced with our 197 
shRNA library and transplanted into 6 NSG mice (Figure 3A)(Supplementary Figure 198 
3A). Genomic DNA (gDNA) was extracted from L963 cells isolated from bone marrow 199 
and spleen after mice became symptomatic (week 11). ShRNA sequencing indicated 200 
that shLCK#3 represented the most significantly depleted shRNA construct in vivo 201 
(Figure 3A)(Supplementary Figure 3B)(Supplementary Table 3). 202 
To assess the effect of LCK knockdown on engraftment fitness, MOLT4 cells were 203 
transduced with lentiviral vectors encoding either red fluorescent protein RFP/shNTC 204 
(non-targeting control) or GFP/shLCK#3. Equal proportions of cell populations were 205 
transplanted into NSG mice (n = 5). Leukemia cells were isolated from spleen, bone 206 
marrow and liver once mice were symptomatic (day 26). Flow cytometric analysis of 207 
the leukemic cell population established that cells carrying shNTC had a clear 208 
competitive engraftment advantage over cells with LCK knockdown in all mice tissues 209 
sampled (Figure 3B)(Supplementary Figure 3C). 210 
 211 
Knockdown of LCK leads to cell cycle arrest in T-ALL cell lines and PDX samples 212 
Next we investigated the mechanisms underlying the defect in proliferation, survival 213 
and engraftment observed after LCK knockdown. Jurkat, MOLT4 and SUPT1 cells 214 
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were transduced with shLCK#1/#3 and cell cycle analyses performed. In all cell lines, 215 
we observed significant cell cycle arrest with an increase in G0/G1 phase and decrease 216 
in S phase after LCK knockdown (Figure 4A-C) (Supplementary Figure 4A). 217 
ShLCK#3 led to decreased protein levels of total LCK and activated p-Y416Src in cell 218 
lines, suggesting activation status of LCK is associated with cell cycle arrest. In PDX 219 
L963, LCK knockdown led to a 45% reduction in total LCK expression, as well as 71% 220 
reduction in p-Y416Src as assessed by Phosflow (Figure 4D). This knockdown resulted 221 
in a decrease in S phase over time compared to control (Supplementary Figure 4B). 222 
The proliferative behavior of PDX cells was analyzed after labeling with cell trace violet 223 
(CTV). PDX L963 cells were transduced with shRNA constructs targeting LCK or a 224 
non-targeting control (NTC) and co-cultured with OP9-DL1 feeder cells for 13 days. 225 
The LCK knockdown cells showed restricted proliferation compared to the control cells 226 
(Figure 4E). Confirmatory siRNA knockdown of LCK was undertaken in PDX samples 227 
LK203 and L963. Knockdown of total and activated LCK was confirmed by Phosflow. 228 
Corroborating our earlier findings, cell cycle arrest was observed (Supplementary 229 
Figure 4C-D).  230 
Knockdown of LCK was analyzed for early apoptosis induction in CUTLL1, MOLT4, 231 
SUPT1 and Jurkat. Although a clear increase in Annexin V staining was observed in 232 
MOLT4, suggesting LCK knockdown led to apoptosis, this was not observed in 233 
CUTLL1, Jurkat or SUPT1 (Supplementary Figure 4E). This suggests that cell cycle 234 
arrest, rather than apoptosis induction, is the predominant effect leading to diminished 235 
cell expansion in vitro and reduced propagation in vivo after LCK knockdown. 236 
 237 
The tyrosine kinase inhibitor DAS blocks LCK function and leads to cell cycle 238 
arrest. LCK activation levels predict response to LCK inhibition. 239 
The tyrosine kinase inhibitor DAS is a dual SRC/ABL inhibitor known to effectively 240 
inhibit LCK (21). The effect of DAS on LCK protein expression and activation status 241 
was assessed by Western Blot, after demonstrating near universal LCK activation as 242 
evidenced by tyrosine residue 416 phosphorylation in cell lines (Supplementary Figure 243 
1G). We confirmed that DAS effectively abolished activated p-Y416Src in all 4 T-ALL 244 
cell lines tested, whilst slightly decreasing total LCK protein levels. Furthermore, 245 
dephosphorylation of inhibitory p-Y505LCK was noted, as well as a decrease in p-246 
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Y783PLCγ1 and p-Y493ZAP70, two downstream targets of LCK (Figure 247 
5A)(Supplementary Figure 5A). As knockdown of LCK leads to cell cycle arrest, we 248 
performed cell cycle analyses after administration of DAS.  Cell cycle arrest was 249 
observed in all 6 T-ALL cell lines tested, with a significant increase in G0/G1 and 250 
decrease in S phase (Figure 5A)(Supplementary Figure 5B). In parallel, PDX cells 251 
supported by in vitro co-culture with OP9-DL1 were exposed to DAS. In line with our 252 
cell line data, DAS abolished activated p-Y416Src levels in all 6 PDX samples (Figure 253 
5B)(Supplementary Figure 5C) and cell cycle arrest was observed in all 3 PDX 254 
samples tested (Figure 5B)(Supplementary Figure 5D). 255 
The in vitro sensitivity of a panel of 9 T-ALL cell lines to DAS was determined. The 256 
IC50 observed ranged from 5 nM (HSB2) to 15 µM (MOLT16) (Figure 5C). The cell line 257 
HSB2 not only demonstrated the highest sensitivity to DAS but also the highest p-258 
Y416Src activation level as determined by Phosflow. This observation can be explained 259 
by the presence of a t(1;7)(p34;q34) translocation leading to LCK activation by T cell 260 
receptor beta (TRB) enhancer elements in HSB2 (Figure 5C). We thus hypothesized 261 
that the level of activated LCK might represent a biomarker for DAS responsiveness. 262 
Phosflow was used to quantify and calculate the ratio between p-Y416Src and total 263 
LCK (Figure 5C). A strong and significant correlation was observed between the IC50 264 
for DAS and the ratio of activated Y416Src in T-ALL cell lines (R2=0.778, p=0.004) 265 
(Figure 5C). The sensitivity of PDX cells to DAS ranged from GI50 of 23.8 nM to 19.7 266 
µM (median of 1.2 µM). However, in this setting, no significant correlation between the 267 
GI50 and p-Y416Src/LCK ratio was identified, suggesting that DAS sensitivity of patient-268 
derived cells is dependent on additional factors (Supplementary Figure 5E). 269 
 270 
DAS re-sensitizes DEX resistance in T-ALL cell lines and PDX samples 271 
DAS leads to complete inhibition of p-Y416Src and cell cycle arrest in T-ALL cell lines 272 
and PDX cells, suggesting that DAS treatment of T-ALL has a cytostatic effect. In 273 
clinical practice, effective eradication of T-ALL relies on the application of 274 
combinatorial treatment. LCK inhibition has previously been shown to sensitize chronic 275 
lymphoid leukemia (CLL) to DEX and induce cell death (23). We thus went on to 276 
investigate potential synergy between LCK inhibition and DEX, as DEX is universally 277 
used for treatment of ALL. The cell viability of SUPT1 and CUTLL1, in the presence of 278 
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DEX, was evaluated after knockdown of LCK. Whereas the cell viability of mock 279 
transduced and non-targeting control cells was minimally affected by DEX treatment, 280 
LCK knockdown increased DEX sensitivity suggesting that LCK protein and/or activity 281 
levels play a crucial role in glucocorticoid resistance (Figure 6A)(Supplementary 282 
Figure 6A).  283 
A more detailed analysis of the potency of the combination of DEX and LCK inhibition 284 
was examined by using DAS instead of the LCK knockdown. DEX (0-600 nM) and 285 
DAS (0-50 µM) were titrated along a dose matrix and cell viability was determined. 286 
Synergy for individual drug combinations was determined using Combenefit (22). The 287 
matrix revealed drug synergy at concentrations which are clinically achieved, i.e. 100 288 
nM for DEX and 264 nM for DAS (Figure 6B)(Supplementary Figure 6B) (24, 25). 289 
Bioinformatic analysis of all 10 T-ALL cell lines revealed a statistically significant 290 
enrichment of drug synergy at clinically relevant concentrations. This synergy was 291 
observed at 8-110 nM of DEX and 0.223-4.5 µM of DAS (Supplementary Figure 6C-292 
D).  293 
Subsequently, PDX cells were expanded ex vivo for 1 week and exposed to the same 294 
drug combinations in dose matrices. These assays verified the synergistic action of 295 
DEX+DAS in a wide range of PDX cells, whilst confirming that increased DAS 296 
concentrations and resultant LCK inhibition augmented the response to DEX (Figure 297 
6C)(Supplementary Figure 6E). Combined analysis of all drug matrices with PDX cells 298 
again revealed a statistically significant enrichment of drug synergy at clinically 299 
relevant concentrations (Supplementary Figure 6F). Moreover, the combination of 300 
DEX+DAS induced more cell death compared with control vehicle or single drugs as 301 
revealed by Annexin V/PI staining (Figure 6C). 302 
DEX has a wide range of actions, including genomic and non-genomic effects. 303 
Genomic effects are the result of nuclear translocation of the glucocorticoid receptor 304 
and subsequent transactivation or repression of genes containing a glucocorticoid 305 
response element (GRE), as exemplified by the Glucocorticoid-Induced Leucine 306 
Zipper (GILZ) gene. Accordingly, we observed strong induction of GILZ gene 307 
expression after DEX exposure in the T-ALL cell line Jurkat and 5 PDX samples tested 308 
(Figure 6D)(Supplementary Figure 6G). This response was significantly enhanced 309 
when combining DEX with knockdown of LCK (Figure 6D, left) or DEX+DAS in a range 310 
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of T-ALL cell lines and PDX samples, suggesting that LCK inactivation augments DEX-311 
induced gene transcription and reverses DEX resistance (Figure 6D)(Supplementary 312 
Figure 6G). 313 
 314 
Phase II-like trial in vivo demonstrates significant reduction in leukemia burden 315 
after combination treatment with DEX and DAS  316 
To test the efficacy of DEX and DAS in vivo, we conducted a phase II-like trial in mice 317 
(Figure 7A) (26). Ten PDXs were engrafted in 4 mice each. The 4 mice derived from 318 
1 single patient sample were randomly assigned to treatment arms, namely control 319 
vehicle, DEX (1 mg/kg), DAS (35 mg/kg) or DEX+DAS (1 mg/kg DEX + 35 mg/kg 320 
DAS). After IF injection, mice tail vein blood was monitored weekly for human 321 
CD7/CD45 and murine CD45 expression to monitor peripheral blood engraftment. 322 
Representative PDX L809 commenced treatment 46 days after injection for a total 323 
duration of 3 weeks; the 4 mice were culled 72 days after injection (Figure 7B). L809 324 
cells engrafted in the spleens of the 4 mice showed greatly reduced levels of total LCK 325 
and dephosphorylation of LCK (p-Y416Src and p-Y505) after DAS or DEX+DAS 326 
combination treatment (Figure 7C). Western analysis of positively selected viable 327 
human cells again demonstrated decreased protein expression of LCK and p-Y416Src 328 
after DAS treatment. The number of residual viable human cells after effective 329 
DEX+DAS treatment was not sufficient to categorically confirm reduced protein 330 
expression (Supplementary Figure 7F). One mouse in DAS arm (LK080) developed 331 
uterine prolapse before dosing commenced and the mice derived from PDX LK214 332 
succumbed during first week of treatment. These 5 were excluded from final analysis. 333 
Combining the results of 35 mice derived from 9 patient samples, DEX+DAS treatment 334 
significantly impaired leukemia progression more than single drug DEX, DAS or 335 
control vehicle as measured by hCD45 or hCD7 engraftment in peripheral blood, bone 336 
marrow, spleen and CNS (Figure 7D-F)(Supplementary Figure 7A). Single agent DEX 337 
reduced CNS leukemia burden in 7/9 samples, reflecting its proven efficacy in 338 
reducing CNS relapses (27), whilst DAS showed some reduction in CNS burden in 4/8 339 
samples (Supplementary Figure 7B). Combination therapy was particularly effective, 340 
with complete eradication of measurable CNS leukemia in 5 patient samples and 341 
evidence of an additive effect with DEX in 3 out of 4 of the remaining patient samples 342 
DEX and DAS impair in vivo T-ALL propagation
  Shi Y, et al., 2019 
210 
 
(Supplementary Figure 7B). When considering the cohort of nine patient samples 343 
overall, combination treatment significantly reduced leukemic infiltrates compared to 344 
control (p=0.02). Representative histology images are shown in Figure 7G. Spleen 345 
weight was substantially reduced in mice receiving combination treatment, compared 346 
with the single or control treatment arms (Supplementary Figure 7C-D). DEX+DAS 347 
also significantly reduced hCD45+ or hCD7+ leukemia cell engraftment in liver tissue 348 
of all 6 PDX samples analyzed (Supplementary Figure 7E). The initial therapeutic 349 
advantage of DEX+DAS in mice derived from PDX LK080 was lost at the end of the 350 
experiment, most likely because these mice were kept alive for 3 weeks after 351 
completion of treatment. In the case of L907 however, the benefit of combination 352 
treatment was not observed until the last time point (Supplementary Figure 7G). 353 
  354 
Discussion 355 
Using a phase II-like murine trial, we demonstrate here the efficacy of the drug 356 
combination DEX+DAS in impairing expansion of human T-ALL samples. This effect 357 
is apparent in an unselected, biologically heterogeneous, cohort of PDX samples. This 358 
trial format recapitulates early phase human clinical trials and indicates that this drug 359 
combination could be widely applicable in the treatment of T-ALL. Studies by Serafin 360 
et al first proposed a role for this drug combination (28). Our murine trial extends these 361 
initial observations with an extensive cohort consisting of 9 different PDXs 362 
demonstrating treatment advantage for both DEX sensitive and resistant T-ALL. 363 
Significant superiority of DEX+DAS was demonstrated even after exclusion of mice, 364 
who reached their clinical end points prematurely. These untoward events highlight 365 
the practicalities of performing murine trials.  366 
We propose that the impaired in vivo expansion results from a combination of cell 367 
cycle arrest as well as cell death. Several mechanisms could provide plausible 368 
explanations for the occurrence of cell cycle arrest. DAS is a protein tyrosine kinase 369 
inhibitor which targets Abl and SFK family members. We have confirmed that DAS 370 
effectively inhibits activity of the SFK member LCK by preventing phosphorylation, 371 
leading to G0/G1 arrest. DAS has previously been shown to inhibit cyclin dependent 372 
kinase 1 (CDK1), which plays a central role in G1/S and G2/M transition (29). 373 
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Furthermore, G1 cell cycle arrest, through upregulation of the cyclin-dependent kinase 374 
inhibitors p21CIP1 (CDKN1A) and p27KIP1 (CDKN1B), has been observed after DAS 375 
treatment in AML (30). We propose that LCK is the predominant target of DAS in this 376 
disease setting, as our shRNA screen identified a critical role for LCK in cell 377 
proliferation in cell lines and PDX samples. Moreover, LCK is the proposed DAS target 378 
when blocking T-cell activation (21). Competitive assays confirmed defective 379 
proliferation of T-ALL cells after LCK knockdown in vitro and in vivo. We have shown 380 
that LCK knockdown leads to G0/G1 cell cycle arrest in cell lines and PDXs. This effect 381 
was more pronounced using DAS, a finding which could potentially be explained by 382 
incomplete knockdown of LCK or the wide spectrum of kinases targeted by DAS. 383 
As reported earlier and confirmed in our studies, DAS is cytotoxic to a small subset of 384 
T-ALL samples with IC50 values in the low nanomolar range (31). These observations 385 
were made in T-ALL samples with kinase activating mutations, which are seen very 386 
infrequently in T-ALL. To the best of our knowledge, our cohort includes only one PDX 387 
with such an activating genetic lesion (LK287, FIP1L1-PDGFRA). Cytotoxicity to DAS 388 
is significantly increased upon combination with DEX. Our data indicate drug synergy 389 
between DAS and DEX at clinically relevant concentrations. A previous, mostly in vitro, 390 
study advocated the use of DEX+DAS in GC resistant T-ALL (28). Our extended 391 
studies indicate DEX+DAS act synergistically in the majority of cell lines and PDXs 392 
tested independent of their prior sensitivity to DEX. The potential of DEX+DAS to 393 
revert GC resistance is an exciting observation. GC resistance is frequently observed 394 
in relapsed / refractory T-ALL (4), and DEX+DAS provide a clinically actionable 395 
approach to re-sensitize resistant T-ALL to DEX. 396 
The implementation of DAS into clinical management would benefit from the 397 
identification of a reliable response biomarker. Although LCK activation status (ratio p-398 
Y416Src/LCK) strongly correlates with DAS sensitivity in cell lines, we were unable to 399 
corroborate this observation in PDX cells. Sample size and intricacies of in vitro assays 400 
using PDX cells could provide possible explanations for these inconsistencies. 401 
Nevertheless, in vivo drug synergy was observed in the majority of samples tested. Of 402 
interest, drug response profiling of T-ALL samples suggested SRC pathway activation 403 
may represent a response biomarker (31).  404 
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The mechanism underlying the observed drug synergy remains to be fully elucidated. 405 
T-cell activation can be blocked by using clinically relevant concentrations of the 406 
tyrosine kinase inhibitor DAS, which binds to the ATP-binding pocket of LCK thereby 407 
preventing the phosphorylation of the activating loop of the kinase domain p-Y416 (21, 408 
32). When DEX is combined with DAS, physiological CD3+ T-cell proliferation is 409 
reduced in an additive way (33, 34). Furthermore, it has been previously suggested 410 
that the Calcineurin/NFAT/IL-4 axis is activated in patients exhibiting a prednisone 411 
poor response (28). We have shown here that combination of DEX+DAS significantly 412 
increases GILZ gene expression, reflecting increased transcriptional activity of the GC 413 
receptor. We thus hypothesize that inhibition of LCK disrupts the TCR-GR complex 414 
and established crosstalk between the TCR and GR pathways leading to dissociation 415 
and transcriptional activation of the GR (13).  416 
To conclude, drug resistant T-ALL continues to represent an unmet clinical need. We 417 
provide further support for the inclusion of DAS in the treatment of T-ALL. It has been 418 
reported that DAS in combination with conventional chemotherapy is safe and well 419 
tolerated in children and young adults, although hematologic toxicity was significant 420 
(35). Thus, the DEX+DAS combination should be considered in early phase setting to 421 
evaluate toxicity and efficacy in patients with GC resistant disease with or without 422 
cerebral spinal fluid (CSF) involvement. 423 
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Figure 1. A targeted shRNA screen reveals LCK is essential for in vitro 590 
proliferative potential. (A) T-ALL cell lines (SUPT1, MOLT4, HBP-ALL, CUTLL1) and 591 
PDX LK203 were subjected to a functional screen using a pLKO5-shRNA library 592 
containing 36 constructs targeting selected pTCR/TCR signaling complex components 593 
(PTCRA, CD3E, FYN, ZAP70, LCK, LAT), positive (PTEN, RPS29, RPL9), negative 594 
controls (KLHL7, CD19, DDB2, ERGIC3, FLG, RUNX1-ETO, SESN2, TRPM7) and a 595 
non-targeting control (NTC). Genomic DNA was sampled and barcoded. Enriched and 596 
depleted shRNAs were identified by next generation sequencing (NGS). The heatmap 597 
depicts statistically significant gains (red) or losses (green) of shRNA constructs after 598 
in vitro culture of 4 T-ALL cell lines (40 days) and PDX LK203 (30 days). (B) Relative 599 
gene expression of LCK in 4 cell lines and 12 PDX samples. LCK expression was 600 
determined in 4 T-ALL cell lines, 697 and REH (B-lineage ALL cell lines), TK6 601 
(lymphoblastoid cell line) and 12 PDX samples by real time qPCR. GAPDH served as 602 
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Figure 2.  Knockdown of LCK reduces propagation of T-ALL cell lines in vitro. 610 
SUPT1 (A and B) and MOLT4 (A and C) cells were lentivirally transduced with shNTC 611 
(non-targeting control), shLCK#1, shLCK#2, shLCK#3, shPTCRA#1, or shZAP70#1 612 
expression constructs. (A) Knockdown efficiency of LCK at mRNA level (left) and 613 
protein level (right) after 6 days. Whole cell lysates were probed for total LCK and 614 
GAPDH in Western Blot analysis. (B and C) T-ALL cell lines SUPT1 (B) and MOLT4 615 
(C) transduced with GFP-expressing shLCK (blue), shZAP70 (purple),  shPTCRA 616 
(red) or shNTC (black) constructs were seeded in a 1:1 ratio with non-transduced 617 
parental cells in vitro. Cells were cultured and analyzed repetitively by flow cytometry 618 
for the presence of GFP+ cells over a time period of 30 and 40 days for SUPT1 and 619 
MOLT4, respectively. A relative GFP expression of 1 denotes a mixture of 50% GFP+ 620 
cells with 50% parental cells (ratio 1:1). A value of 0.5 refers to 25% of GFP+ cells and 621 
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Figure 3. Loss of LCK negatively effects propagation potential of the T-ALL cell 630 
line MOLT4 and PDX L963 in vivo. (A) Volcano plot derived from the functional in 631 
vivo screen representing the magnitude of the fold change (log2) in shRNA abundance 632 
derived from leukemia cells isolated from the spleen of PDX L963 on the x-axis. Each 633 
dot represents an individual shRNA construct. The y-axis represents the significance 634 
in enrichment or depletion of shRNA constructs (log10 scale). 3 dots (shLCK#3, 635 
shRPL9#1 and shCD19#2) above the blue line are significantly depleted (p<0.05). Bar 636 
plot of the normalized shLCK#3 sequencing reads (log2) in leukemic cells derived from 637 
the bone marrow (orange) or spleen (blue) of 6 individual mice (M1-6), relative to the 638 
frequency of these reads before transplantation (green, base line B1-3). (B) Schematic 639 
representation of the in vivo competitive outgrowth assay. MOLT4 cells were 640 
lentivirally transduced with shNTC (red fluorescent protein, RFP) or shLCK#3 (GFP) 641 
and intrafemorally injected into 5 NSG mice in a 1:1 ratio. Mice were culled once 642 
symptomatic and the ratio of RFP : GFP positive human leukemic cells in spleen (n=5), 643 
bone marrow (n=3) or liver (n=3) determined by flow cytometry. In all mice the MOLT4 644 
cells carrying shLCK#3 were outcompeted by shNTC cells during engraftment in 645 
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Figure 4. LCK knockdown leads to cell cycle arrest in T-ALL cell lines and PDX 652 
cells. (A - C) Cell cycle status was determined by flow cytometry using Hoechst 33342 653 
in cell lines Jurkat (A and C), MOLT4 (B and C) and SUPT1 (C) 7 days after 654 
transduction with shLCK#3 or shNTC expression vectors. (D) PDX L963 cells were 655 
lentivirally transduced with shLCK#3 or shNTC expression constructs. Phosflow 656 
analysis of total LCK and p-Y416Src was performed 8 days later. (E) shLCK#3 and 657 
shNTC transduced PDX L963 cells were loaded with CTV and cultured for 13 days. 658 
Flow cytometric analysis of CTV incorporation (cell divisions) was performed and 659 
demonstrated progressive reduction in cell number after 4-6 cell divisions after LCK 660 
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Figure 5. DAS inhibits LCK and leads to cell cycle arrest. (A) SUPT1 and MOLT4 669 
cells were treated with vehicle control or DAS (2 µM) for 24 h and expression of total 670 
LCK, activated p-Y416Src, total PLCy1 and activated p-Y783PLCγ1 was assessed in 671 
Western Blot analysis (left) or cells were stained with Hoechst and analyzed for cell 672 
cycle status (middle and right). (B) PDX LK203 and L963 cells were treated for 24 h 673 
with 1 µM of DAS. LCK and PLCγ1 total protein and activating phospho-sites at Y416 674 
and Y783 were assessed in Western Blot analyses or PDXs were stained with Hoechst 675 
and analyzed for cell cycle status. (C) The in vitro sensitivity of a panel of T-ALL cell 676 
lines to DAS was investigated and IC50 calculated. Phosflow was used to determine 677 
the ratio of activated p-Y416Src / total LCK. This ratio was correlated with in vitro 678 
sensitivity to DAS (R2=0.778, p=0.004). Student t-test; *p<0.05, ** p<0.01. NB HSB2 679 
was excluded from this analysis, as the extreme sensitivity to dasatinib was caused 680 
by the presence of a unique translocation absent in all other sensitive cell lines.  681 
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Figure 6. DEX and DAS act synergistically to induce cell death in T-ALL. (A) Cell 683 
viability of parental SUPT1 cells (mock), shCtrl (NTC), shLCK#1 or shLCK#3 684 
transduced SUPT1 cells upon treatment with increasing DEX concentrations (0-1699 685 
nM). (B) Cell viability of SUPT1 with and without DAS (left; black line, no DAS; blue 686 
line, 0.4 µM; red line, 2.0 µM) in combination with increasing concentrations of DEX 687 
(0-600 nM) as derived from the drug matrix with titration of DEX (0-600 nM) and DAS 688 
(0.08-50 uM; right). (Right) Combenefit analysis of drug matrix demonstrates drug 689 
synergy in SUPT1 cells at clinically relevant drug concentrations. (C) (Left) LK203 cells 690 
were expanded ex vivo on OP9-DL1 feeder cells for 1 week prior to treatment with and 691 
without DAS (black line, no DAS; blue line, 0.08 µM; red line, 2.0 µM; orange line, 10 692 
µM) in combination with increasing concentrations of DEX (0-600 nM) as derived from 693 
a drug matrix with DEX (0-600 nM) and DAS (0.08-50 uM)(Supplementary Figure 6E). 694 
(Right) Cell death analysis in LK203 cells exposed to control (Ctrl) conditions, DAS (1 695 
µM), DEX (100 nM) or DAS+DEX combination treatment. (D) (Left) Normalized GILZ 696 
mRNA expression in Jurkat cells after transduction with shNTC or shLCK#3 with or 697 
without DEX exposure (100 nM). (Right) Normalized GILZ mRNA expression in Jurkat 698 
cells after exposure to control (Ctrl) conditions, DAS (2 µM), DEX (100 nM) or 699 
DAS+DEX combination treatment at the same concentrations. Student t-test; *p<0.05, 700 
** p<0.01, *** p<0.005, **** p<0.001. 701 
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Figure 7. DEX + DAS synergize to impair leukemia engraftment in a Phase II-like 703 
murine trial. (A) Layout of the in vivo trial using 10 different PDX samples. PDX 704 
samples were engrafted into 4 mice each and treated with control vehicle (Ctrl), DEX 705 
(1mg/kg), DAS (35mg/kg) or DEX+DAS (1mg/kg DEX + 35mg/kg DAS). Mice were 706 
dosed once daily, 5 times per week, for 2 – 3 weeks depending on clinical status of 707 
the mice. (B) Engraftment of hCD45+ cells (%) was determined weekly in peripheral 708 
blood derived from 4 mice injected with PDX L809. Engraftment levels are shown 709 
starting from day of injection (day 0) in mice receiving control vehicle (Ctrl, black), DAS 710 
(blue), DEX (green) or DEX+DAS (red). The vertical dotted lines indicate the treatment 711 
window (3 weeks) starting on day 46 and completing on day 64. Mice were culled on 712 
day 72 and analyzed for hCD45/hCD7 engraftment. (C) Western blotting of total and 713 
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phosphorylated LCK protein levels of whole cell lysates derived from the spleens of 4 714 
mice injected with PDX L809 under 4 different treatment arms (Ctrl, DAS, DEX or 715 
DEX+DAS) relative to the housekeeper GAPDH. (D - F) Summary of final human 716 
CD7+ engraftment (%) in peripheral blood (D), spleen (E) and bone marrow (F) of mice 717 
treated with Ctrl (black), DAS (blue), DEX (green) or DEX+DAS (red). Significance 718 
levels;*p<0.05, ** p<0.01, *** p<0.001. (G) Photomicrographs of whole brain-skull 719 
sections stained with hematoxylin and eosin from PDX L809. (Left) Low power scout 720 
view of whole brain with area shown in all other images marked by black box. (Centre 721 
and Right) High power view (x20 objective) of meninges around the central venous 722 
sinus in mice receiving Ctrl, DAS, DEX or DEX+DAS treatment. Red arrows mark the 723 
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